<SEC-DOCUMENT>0001104659-20-005985.txt : 20200122
<SEC-HEADER>0001104659-20-005985.hdr.sgml : 20200122
<ACCEPTANCE-DATETIME>20200122173054
ACCESSION NUMBER:		0001104659-20-005985
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20200121
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200122
DATE AS OF CHANGE:		20200122

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adaptimmune Therapeutics PLC
		CENTRAL INDEX KEY:			0001621227
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37368
		FILM NUMBER:		20539717

	BUSINESS ADDRESS:	
		STREET 1:		60 JUBILEE AVENUE
		STREET 2:		MILTON PARK
		CITY:			ABINGDON, OXFORDSHIRE
		STATE:			X0
		ZIP:			OX14 4RX
		BUSINESS PHONE:		44 1235 430000

	MAIL ADDRESS:	
		STREET 1:		60 JUBILEE AVENUE
		STREET 2:		MILTON PARK
		CITY:			ABINGDON, OXFORDSHIRE
		STATE:			X0
		ZIP:			OX14 4RX

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Adaptimmune Ltd
		DATE OF NAME CHANGE:	20141001
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm204193-3_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:adap="http://adaptimmune.com/20200121">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" /></head>
<!-- Field: Set; Name: xdx; ID: xdx_021_US%2DGAAP%2D2019 -->
<!-- Field: Set; Name: xdx; ID: xdx_030_adap_adaptimmune.com_20200121 -->
<!-- Field: Set; Name: xdx; ID: xdx_042_20200120_20200121 -->
<!-- Field: Set; Name: xdx; ID: xdx_054_edei%2D%2DEntityCentralIndexKey_0001621227 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
  <ix:hidden>
    <ix:nonNumeric contextRef="From2020-01-20to2020-01-21" name="dei:EntityCentralIndexKey">0001621227</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-20to2020-01-21" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-20to2020-01-21" id="xdx2ixbrl0014" name="dei:EntityTaxIdentificationNumber">00-0000000</ix:nonNumeric>
    </ix:hidden>
  <ix:references>
    <link:schemaRef xlink:href="adap-20200121.xsd" xlink:type="simple" />
    </ix:references>
  <ix:resources>
    <xbrli:context id="From2020-01-20to2020-01-21">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001621227</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-20</xbrli:startDate>
        <xbrli:endDate>2020-01-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    </ix:resources>
  </ix:header>
</div>


<p style="margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES<br />
SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 18pt"><b>FORM
<span id="xdx_904_edei--DocumentType_c20200120__20200121_z4U3z9O1toGa"><ix:nonNumeric contextRef="From2020-01-20to2020-01-21" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Current Report</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d) of</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>the Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of Report (Date of earliest event
reported):</b> <b><span id="xdx_901_edei--DocumentPeriodEndDate_c20200120__20200121_zyH6f0rKCAz5"><ix:nonNumeric contextRef="From2020-01-20to2020-01-21" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">January 21, 2020</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_904_edei--EntityRegistrantName_c20200120__20200121_z7JPA4XQ0j3j"><ix:nonNumeric contextRef="From2020-01-20to2020-01-21" name="dei:EntityRegistrantName">ADAPTIMMUNE THERAPEUTICS PLC</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Exact name of registrant as specified
in its charter)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90C_edei--EntityIncorporationStateCountryCode_c20200120__20200121_zdpJRLVtMpLc"><ix:nonNumeric contextRef="From2020-01-20to2020-01-21" format="ixt-sec:edgarprovcountryen" name="dei:EntityIncorporationStateCountryCode">England and Wales</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_909_edei--EntityFileNumber_c20200120__20200121_zzaHjx6oQc2"><ix:nonNumeric contextRef="From2020-01-20to2020-01-21" name="dei:EntityFileNumber">1-37368</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span title="::XDX::00-0000000"><span id="xdx_90E_edei--EntityTaxIdentificationNumber_dxL_c20200120__20200121_zEgBd9ZU7urc" title="::XDX::00-0000000"><span style="-sec-ix-hidden: xdx2ixbrl0014">Not Applicable</span></span></span></b></span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(State or other jurisdiction of<br />
incorporation)</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Commission File Number)</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(IRS Employer Identification No.)</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_903_edei--EntityAddressAddressLine1_c20200120__20200121_zXZpv3iZvC59"><ix:nonNumeric contextRef="From2020-01-20to2020-01-21" name="dei:EntityAddressAddressLine1">60 Jubilee Avenue</ix:nonNumeric></span>, <span id="xdx_90A_edei--EntityAddressAddressLine2_c20200120__20200121_zlnVzDKsBMAb"><ix:nonNumeric contextRef="From2020-01-20to2020-01-21" name="dei:EntityAddressAddressLine2">Milton Park</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_903_edei--EntityAddressCityOrTown_c20200120__20200121_zk2LEMjXew4l"><ix:nonNumeric contextRef="From2020-01-20to2020-01-21" name="dei:EntityAddressCityOrTown">Abingdon, Oxfordshire</ix:nonNumeric></span> <span id="xdx_903_edei--EntityAddressPostalZipCode_c20200120__20200121_zZU3LK8cHFIi"><ix:nonNumeric contextRef="From2020-01-20to2020-01-21" name="dei:EntityAddressPostalZipCode">OX14 4RX</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90D_edei--EntityAddressCountry_c20200120__20200121_zvQeFIFE54F"><ix:nonNumeric contextRef="From2020-01-20to2020-01-21" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry">United Kingdom</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices,
including zip code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(<span id="xdx_90B_edei--CityAreaCode_c20200120__20200121_zxLcERoS0Qra"><ix:nonNumeric contextRef="From2020-01-20to2020-01-21" name="dei:CityAreaCode">44</ix:nonNumeric></span>) <span id="xdx_906_edei--LocalPhoneNumber_c20200120__20200121_zx2pNuMeKCUb"><ix:nonNumeric contextRef="From2020-01-20to2020-01-21" name="dei:LocalPhoneNumber">1235 430000</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&#8217;s telephone number, including
area code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Wingdings"><span id="xdx_90F_edei--WrittenCommunications_c20200120__20200121_z8qbwXlOFhz2"><ix:nonNumeric contextRef="From2020-01-20to2020-01-21" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></td><td style="text-align: justify">Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Wingdings"><span id="xdx_90F_edei--SolicitingMaterial_c20200120__20200121_z3nk6vqHBp01"><ix:nonNumeric contextRef="From2020-01-20to2020-01-21" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></td><td style="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Wingdings"><span id="xdx_906_edei--PreCommencementTenderOffer_c20200120__20200121_zSEmmIJ9Q2m9"><ix:nonNumeric contextRef="From2020-01-20to2020-01-21" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></td><td style="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Wingdings"><span id="xdx_904_edei--PreCommencementIssuerTenderOffer_c20200120__20200121_zttFZw8wv3Xk"><ix:nonNumeric contextRef="From2020-01-20to2020-01-21" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></td><td style="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="vertical-align: bottom; width: 35%; text-align: center"><b>Title of each class</b></td>
    <td style="text-align: center; width: 2%; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; width: 26%; text-align: center"><b>Trading Symbol</b></td>
    <td style="text-align: center; width: 2%; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; width: 35%; text-align: center"><b>Name of each exchange on which <br />
registered</b></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><span id="xdx_909_edei--Security12bTitle_c20200120__20200121_zd4J7T86OOTc"><ix:nonNumeric contextRef="From2020-01-20to2020-01-21" name="dei:Security12bTitle">American Depositary Shares, each representing 6 Ordinary Shares, par value &#163;0.001 per share</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_900_edei--TradingSymbol_c20200120__20200121_zxqVJB0R0Mjl"><ix:nonNumeric contextRef="From2020-01-20to2020-01-21" name="dei:TradingSymbol">ADAP</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_909_edei--SecurityExchangeName_c20200120__20200121_zQoFhNkGqB01"><ix:nonNumeric contextRef="From2020-01-20to2020-01-21" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Emerging growth company <span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_90C_edei--EntityEmergingGrowthCompany_c20200120__20200121_ztDlZiLdLGGf"><ix:nonNumeric contextRef="From2020-01-20to2020-01-21" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Wingdings"><span style="font-family: Wingdings">&#168;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1in"><b>Item 1.01</b></td><td><b>Entry into a Material Definitive Agreement.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 22, 2020, Adaptimmune Therapeutics plc (the &#8220;Company&#8221;)
entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with Cowen and Company, LLC, as representative
of the several underwriters named therein (collectively, the &#8220;Underwriters&#8221;), pursuant to which the Company agreed
to issue and sell an aggregate of 21,000,000 of its American Depositary Shares (&#8220;ADSs&#8221;) to the Underwriters (the &#8220;Offering&#8221;).
Each ADS represents six ordinary shares of the Company. The ADSs will be sold at a public offering price of $4.00 per ADS. The
Company expects to receive aggregate net proceeds from the sale of the ADSs of approximately $78.1 million, after deducting underwriting
fees and commissions and estimated offering expenses. Pursuant to the Underwriting Agreement, the Company also granted the Underwriters
a 30-day option to purchase up to 3,150,000 additional ADSs at the public offering price. The Offering is expected to close on
January 24, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Underwriting Agreement contains customary representations,
warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters,
including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions.
The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement
and as of specific dates, were solely for the benefit of the parties to such agreement and may be subject to limitations agreed
upon by the contracting parties. The Company and all of the Company&#8217;s directors and executive officers also agreed to not
sell or transfer any ADSs of the Company for 60 days after January 22, 2020 without first obtaining the consent of Cowen and Company,
LLC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Offering is being made pursuant to the Company&#8217;s effective
shelf registration statement on Form S-3 (Registration No. 333-233557), including the prospectus contained therein, effective September
10, 2019, as the same has been amended and/or supplemented from time to time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A copy of the Underwriting Agreement is attached hereto as Exhibit
1.1 and is incorporated herein by reference. The foregoing description of the terms of the Underwriting Agreement is qualified
in its entirety by reference to such exhibit. A copy of the opinion of Mayer Brown International LLP relating to the legality of
the issuance and the ordinary shares underlying the ADSs in this offering is attached as Exhibit 5.1 hereto and is filed with reference
to, and is hereby incorporated by reference into, the registration statement referred to above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1in"><b>Item 8.01</b></td><td><b>Other Events.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 21, 2020, the Company issued a press release announcing
the commencement of the Offering and issued a subsequent press release on January 22, 2020 announcing the pricing of the Offering.
Copies of these press releases are attached hereto as Exhibits 99.1 and 99.2 hereto, respectively, and are incorporated by reference
herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1in"><b>Item 9.01</b></td><td><b>Financial Statements and Exhibits.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">                                                                                                                                          <tr style="vertical-align: top">
<td style="border-bottom: Black 1pt solid; text-align: center"><b>Exhibit No.</b></td>
    <td style="padding-bottom: 1pt">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: center"><b>Description of Exhibit</b></td></tr>
<tr style="vertical-align: top">
<td style="text-align: center; width: 0.75in"><a href="tm204193d3_ex1-1.htm" style="-sec-extract: exhibit">1.1</a></td>
    <td style="width: 0.1in">&#160;</td><td style="text-align: justify"><a href="tm204193d3_ex1-1.htm" style="-sec-extract: exhibit">Underwriting Agreement, dated January 22, 2020, by and between Adaptimmune Therapeutics plc and Cowen and Company, LLC, as
representative of the several Underwriters named therein.</a></td></tr>
<tr style="vertical-align: top">
<td style="text-align: center">&#160;</td>
    <td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: center"><a href="tm204193d3_ex5-1.htm" style="-sec-extract: exhibit">5.1</a></td>
    <td>&#160;</td><td style="text-align: justify"><a href="tm204193d3_ex5-1.htm" style="-sec-extract: exhibit">Opinion of Mayer Brown International LLP.</a></td></tr>
<tr style="vertical-align: top">
<td style="text-align: center">&#160;</td>
    <td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: center"><a href="tm204193d3_ex5-1.htm" style="-sec-extract: exhibit">23.1</a></td>
    <td>&#160;</td><td style="text-align: justify"><a href="tm204193d3_ex5-1.htm" style="-sec-extract: exhibit">Consent of Mayer Brown International LLP (contained in Exhibit 5.1).</a></td></tr>
<tr style="vertical-align: top">
<td style="text-align: center">&#160;</td>
    <td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: center"><a href="tm204193d3_ex99-1.htm" style="-sec-extract: exhibit">99.1</a></td>
    <td>&#160;</td><td style="text-align: justify"><a href="tm204193d3_ex99-1.htm" style="-sec-extract: exhibit">Press Release dated January 21, 2020.</a></td></tr>
<tr style="vertical-align: top">
<td style="text-align: center">&#160;</td>
    <td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: center"><a href="tm204193d3_ex99-2.htm" style="-sec-extract: exhibit">99.2</a></td>
    <td>&#160;</td><td style="text-align: justify"><a href="tm204193d3_ex99-2.htm" style="-sec-extract: exhibit">Press Release dated January 22, 2020.</a></td></tr>                                                                                                                                                                                                                  <tr style="vertical-align: top">
<td style="text-align: center">&#160;</td>
    <td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: center">104</td>
    <td>&#160;</td><td style="text-align: justify">Cover Page Interactive Date File (embedded within the Inline XBRL document)</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: -58.3pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: -58.3pt"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: -58.3pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Exhibit Index</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">                                                                                                                                          <tr style="vertical-align: top">
<td style="border-bottom: Black 1pt solid; text-align: center"><b>Exhibit No.</b></td>
    <td style="padding-bottom: 1pt">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: center"><b>Description of Exhibit</b></td></tr>
<tr style="vertical-align: top">
<td style="text-align: center; width: 0.75in"><a href="tm204193d3_ex1-1.htm" style="-sec-extract: exhibit">1.1</a></td>
    <td style="width: 0.1in">&#160;</td><td style="text-align: justify"><a href="tm204193d3_ex1-1.htm" style="-sec-extract: exhibit">Underwriting Agreement, dated January 22, 2020, by and between Adaptimmune Therapeutics plc and Cowen and Company, LLC, as
representative of the several Underwriters named therein.</a></td></tr>
<tr style="vertical-align: top">
<td style="text-align: center">&#160;</td>
    <td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: center"><a href="tm204193d3_ex5-1.htm" style="-sec-extract: exhibit">5.1</a></td>
    <td>&#160;</td><td style="text-align: justify"><a href="tm204193d3_ex5-1.htm" style="-sec-extract: exhibit">Opinion of Mayer Brown International LLP.</a></td></tr>
<tr style="vertical-align: top">
<td style="text-align: center">&#160;</td>
    <td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: center"><a href="tm204193d3_ex5-1.htm" style="-sec-extract: exhibit">23.1</a></td>
    <td>&#160;</td><td style="text-align: justify"><a href="tm204193d3_ex5-1.htm" style="-sec-extract: exhibit">Consent of Mayer Brown International LLP (contained in Exhibit 5.1).</a></td></tr>
<tr style="vertical-align: top">
<td style="text-align: center">&#160;</td>
    <td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: center"><a href="tm204193d3_ex99-1.htm" style="-sec-extract: exhibit">99.1</a></td>
    <td>&#160;</td><td style="text-align: justify"><a href="tm204193d3_ex99-1.htm" style="-sec-extract: exhibit">Press Release dated January 21, 2020.</a></td></tr>
<tr style="vertical-align: top">
<td style="text-align: center">&#160;</td>
    <td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: center"><a href="tm204193d3_ex99-2.htm" style="-sec-extract: exhibit">99.2</a></td>
    <td>&#160;</td><td style="text-align: justify"><a href="tm204193d3_ex99-2.htm" style="-sec-extract: exhibit">Press Release dated January 22, 2020.</a></td></tr>
<tr style="vertical-align: top">
<td style="text-align: center">&#160;</td>
    <td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: center">104</td>
    <td>&#160;</td><td style="text-align: justify">Cover Page Interactive Date File (embedded within the Inline XBRL document)</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: -58.3pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: -58.3pt"></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: -58.3pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto
duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
<td>&#160;</td>
<td colspan="3">ADAPTIMMUNE THERAPEUTICS PLC &#160;</td></tr>
<tr style="vertical-align: bottom">
<td>&#160;</td>
<td>&#160;</td>
<td colspan="2">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td><span style="font-size: 10pt">Date: January 22, 2020</span></td>
<td><span style="font-size: 10pt">By:</span>&#160;</td>
<td colspan="2" style="border-bottom: Black 1pt solid"><span style="font-size: 10pt">/s/ Margaret Henry </span></td></tr>
<tr style="vertical-align: bottom">
<td style="width: 50%">&#160;</td>
<td style="width: 3%">&#160;</td>
<td style="width: 4%"><span style="font-size: 10pt">Name:&#160;</span></td>
<td style="width: 43%"><span style="font-size: 10pt">Margaret Henry </span></td></tr>
<tr style="vertical-align: bottom">
<td>&#160;</td>
<td>&#160;</td>
<td><span style="font-size: 10pt">Title:</span>&#160;</td>
<td><span style="font-size: 10pt">Corporate Secretary</span></td></tr>
</table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>



</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KwjAMhZ9g7xB6LbMb/u7SoUOcIkPE27JFKW7NSOvfI/mW1g0xBEJyzpcjxEBktNI1MpwWRQ4HbNpaOYQCz8hoSvSOdL1JwM8CL9o6VsZ16w9MyTPomXEoS3/vnHdtsUpAzobxZBjNQU6T0QT2WxF89ZTMWVdonFY1KFPBnqlljU7xq/9wUE8y1Ly6pCOy1WQSiELZy2+IZRTDju7qQXy1kOepCAZdBSJjurXfmJt11MCyxsZn2R79d/AB5s5JKQ== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>tm204193d3_ex1-1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><FONT STYLE="font-size: 10pt"><B>Exhibit 1.1</B></FONT></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Adaptimmune
Therapeutics plc</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(a public limited company organized under
the laws of England and Wales)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">21,000,000 American Depositary Shares</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Representing an Aggregate of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">126,000,000 Ordinary Shares</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>UNDERWRITING AGREEMENT</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: January 22, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">Adaptimmune
Therapeutics plc</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(a public limited company organized under
the laws of England and Wales)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">21,000,000 American Depositary Shares</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Representing an Aggregate of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">126,000,000 Ordinary Shares</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNDERWRITING AGREEMENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">January 22, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cowen and Company, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">599 Lexington Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-indent: -58.5pt">New York, NY 10022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">as Representative of the several
Underwriters</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Adaptimmune Therapeutics
plc, a public limited company organized under the laws of England and Wales (the &ldquo;Company&rdquo;), confirms its agreement
with Cowen and Company, LLC (&ldquo;Cowen&rdquo;) and each of the other underwriters named in Schedule A hereto (collectively,
the &ldquo;Underwriters,&rdquo; which term shall also include any underwriter substituted as hereinafter provided in Section&nbsp;10
hereof), for whom Cowen is acting as representative (in such capacity, the &ldquo;Representative&rdquo;), with respect to (i) the
issuance and sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers
of American Depositary Shares of the Company (&ldquo;ADSs&rdquo;), each ADS representing 6 new ordinary shares, par value &pound;0.001
per share, of the Company (&ldquo;Ordinary Shares&rdquo;) set forth in Schedule&nbsp;A hereto and (ii) the grant by the Company
to the Underwriters, acting severally and not jointly, of the option described in Section&nbsp;2(b) hereof to purchase all or any
part of 3,150,000 additional ADSs. The aforesaid 21,000,000 ADSs (the &ldquo;Initial Securities&rdquo;) to be purchased by the
Underwriters and all or any part of the 3,150,000 ADSs subject to the option described in Section 2(b) hereof (the &ldquo;Option
Securities&rdquo;) are herein called, collectively, the &ldquo;Securities.&rdquo; The new Ordinary Shares represented by the Securities
are herein called the &ldquo;Shares.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The ADSs will be evidenced by American depositary
receipts (the &ldquo;ADRs&rdquo;) to be issued pursuant to a deposit agreement dated May 11, 2015 by and among the Company, Citibank,
N.A., as depositary (the &ldquo;Depositary&rdquo;), and the holders from time to time of the ADRs evidencing ADSs issued thereunder
(the &ldquo;Deposit Agreement&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company understands that the Underwriters
propose to make a public offering of the Securities as soon as the Representative deems advisable after this agreement (the &ldquo;Agreement&rdquo;)
has been executed and delivered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has filed
with the Securities and Exchange Commission (the &ldquo;Commission&rdquo;) a shelf registration statement on&nbsp;Form S-3&nbsp;(No.
333-233557), covering the public offering and sale of certain securities, including the Securities, under the Securities Act of
1933, as amended (the &ldquo;1933 Act&rdquo;), and the rules and regulations promulgated thereunder (the &ldquo;1933 Act Regulations&rdquo;),
which shelf registration statement has been declared effective by the Commission. Such registration statement, as of any time,
means such registration statement as amended by any post-effective amendments thereto to such time, including the exhibits and
any schedules thereto at such time, the documents incorporated by reference therein at such time pursuant to Item 12 of&nbsp;Form
S-3&nbsp;under the 1933 Act and the documents otherwise deemed to be a part thereof as of such time pursuant to Rule 430B under
the 1933 Act Regulations (&ldquo;Rule 430B&rdquo;), and is referred to herein as the &ldquo;Registration Statement;&rdquo; provided,
however, that the &ldquo;Registration Statement&rdquo; without reference to a time means such registration statement as amended
by any post-effective amendments thereto as of the time of the first contract of sale for the Securities, which time shall be considered
the &ldquo;new effective date&rdquo; of such registration statement with respect to the Securities within the meaning of paragraph
(f)(2) of Rule 430B, including the exhibits and schedules thereto as of such time, the documents incorporated or deemed incorporated
by reference therein at such time pursuant to Item 12 of&nbsp;Form S-3&nbsp;under the 1933 Act and the documents otherwise deemed
to be a part thereof as of such time pursuant to Rule 430B. Each preliminary prospectus used in connection with the offering of
the Securities, including the documents incorporated by reference therein pursuant to Item 12 of&nbsp;Form S-3&nbsp;under the 1933
Act, are collectively referred to herein as a &ldquo;preliminary prospectus.&rdquo; Promptly after execution and delivery of this
Agreement, the Company will prepare and file a final prospectus relating to the Securities in accordance with the provisions of
Rule 424(b) under the 1933 Act Regulations (&ldquo;Rule 424(b)&rdquo;). Any registration statement filed pursuant to Rule 462(b)
of the 1933 Act Regulations is herein called the &ldquo;Rule 462(b) Registration Statement&rdquo; and, after such filing, the term
 &ldquo;Registration Statement&rdquo; shall include the Rule 462(b) Registration Statement. The final prospectus, in the form first
furnished to the Underwriters for use in connection with the offering of the Securities, including the documents incorporated by
reference therein pursuant to Item 12 of&nbsp;Form S-3&nbsp;under the 1933 Act, are collectively referred to herein as the &ldquo;Prospectus.&rdquo;
For purposes of this Agreement, all references to the Registration Statement, any preliminary prospectus, the Prospectus or any
amendment or supplement to any of the foregoing shall be deemed to include the copy filed with the Commission pursuant to its Electronic
Data Gathering, Analysis and Retrieval system (&ldquo;EDGAR&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As used in this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;Applicable
Time&rdquo; means 7:30 A.M., New York City time, on January 22, 2020 or such other time as agreed by the Company and the Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;General
Disclosure Package&rdquo; means any Issuer General Use Free Writing Prospectuses issued at or prior to the Applicable Time, the
most recent preliminary prospectus that is distributed to investors prior to the Applicable Time and the information included on
Schedule B-1 hereto, all considered together.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;Issuer
Free Writing Prospectus&rdquo; means any &ldquo;issuer free writing prospectus,&rdquo; as defined in Rule 433 of the 1933 Act Regulations
(&ldquo;Rule 433&rdquo;), including without limitation any &ldquo;free writing prospectus&rdquo; (as defined in Rule 405 of the
1933 Act Regulations (&ldquo;Rule 405&rdquo;)) relating to the Securities that is (i) required to be filed with the Commission
by the Company, (ii) a &ldquo;road show that is a written communication&rdquo; within the meaning of Rule 433(d)(8)(i), whether
or not required to be filed with the Commission, or (iii) exempt from filing with the Commission pursuant to Rule 433(d)(5)(i)
because it contains a description of the Securities or of the offering that does not reflect the final terms, in each case in the
form filed or required to be filed with the Commission or, if not required to be filed, in the form retained in the Company&rsquo;s
records pursuant to Rule 433(g).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;Issuer
General Use Free Writing Prospectus&rdquo; means any Issuer Free Writing Prospectus that is intended for general distribution to
prospective investors (other than a &ldquo;<I>bona fide</I> electronic road show,&rdquo; as defined in Rule 433 (the &ldquo;Bona
Fide Electronic Road Show&rdquo;)), as evidenced by its being specified in Schedule B-2 hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;Issuer
Limited Use Free Writing Prospectus&rdquo; means any Issuer Free Writing Prospectus that is not an Issuer General Use Free Writing
Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Representations and Warranties</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Representations and Warranties by the Company</I>. The Company represents and warrants to each Underwriter as of the
date hereof, the Applicable Time, the Closing Time (as defined below) and any Date of Delivery (as defined below), and agrees with
each Underwriter, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Registration Statement and Prospectuses</U>. The Company meets the requirements for use of Form S-3 under the 1933 Act.
Each of the Registration Statement and any post-effective amendment thereto has become effective under the 1933 Act. No stop order
suspending the effectiveness of the Registration Statement or any post-effective amendment thereto has been issued under the 1933
Act, no order preventing or suspending the use of any preliminary prospectus or the Prospectus has been issued and no proceedings
for any of those purposes have been instituted or are pending or, to the Company&rsquo;s knowledge, contemplated. The Company has
complied with each request (if any) from the Commission for additional information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Each of the
Registration Statement and any post-effective amendment thereto, at the time of its effectiveness and at each deemed effective
date with respect to the Underwriters pursuant to Rule 430B(f)(2) under the 1933 Act Regulations, complied in all material respects
with the requirements of the 1933 Act and the 1933 Act Regulations. Each preliminary prospectus, the Prospectus and any amendment
or supplement thereto, at the time each was filed with the Commission, complied in all material respects with the requirements
of the 1933 Act and the 1933 Act Regulations. Each preliminary prospectus and the Prospectus delivered to the Underwriters for
use in connection with this offering was or will be identical to the electronically transmitted copies thereof filed with the Commission
pursuant to EDGAR, except to the extent permitted by Regulation S-T.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">The documents
incorporated or deemed to be incorporated by reference in the Registration Statement, any preliminary prospectus and the Prospectus,
when they became effective or at the time they were or hereafter are filed with the Commission, complied and will comply in all
material respects with the requirements of the Securities Exchange Act of 1934, as amended (the &ldquo;1934 Act&rdquo;) and the
rules and regulations of the Commission under the 1934 Act (the &ldquo;1934 Act Regulations&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Accurate
Disclosure</U>. Neither the Registration Statement nor any amendment thereto, at its effective time, at the Closing Time or at
any Date of Delivery, contained, contains or will contain an untrue statement of a material fact or omitted, omits or will omit
to state a material fact required to be stated therein or necessary to make the statements therein not misleading. As of the Applicable
Time, none of (A) the General Disclosure Package and (B) any individual Issuer Limited Use Free Writing Prospectus, when considered
together with the General Disclosure Package, included, includes or will include an untrue statement of a material fact or omitted,
omits or will omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading. Neither the Prospectus nor any amendment or supplement thereto (including any prospectus
wrapper), as of its date, at the time of any filing with the Commission pursuant to Rule 424(b), at the Closing Time or at any
Date of Delivery, included, includes or will include an untrue statement of a material fact or omitted, omits or will omit to
state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were
made, not misleading. The documents incorporated or deemed to be incorporated by reference in the Registration Statement, the
General Disclosure Package and the Prospectus, at the time the Registration Statement became effective or when such documents
incorporated by reference were filed with the Commission, as the case may be, when read together with the other information in
the Registration Statement, the General Disclosure Package or the Prospectus, as the case may be, did not and will not include
an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the
statements therein not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">The representations
and warranties in this subsection shall not apply to statements in or omissions from the Registration Statement (or any amendment
thereto), the General Disclosure Package or the Prospectus (or any amendment or supplement thereto) made in reliance upon and in
conformity with written information furnished to the Company by any Underwriter through the Representative expressly for use therein.
For purposes of this Agreement, the only information so furnished shall be the concession figure appearing in the third paragraph
under the heading &ldquo;Underwriting&mdash;Discounts and Commissions&rdquo; and the statements concerning the Underwriters contained
under the headings &ldquo;Underwriting&mdash;Stabilization&rdquo; and &ldquo;Underwriting&mdash;Passive Market Making&rdquo; (collectively,
the &ldquo;Underwriter Information&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Issuer Free Writing Prospectuses</U>. No Issuer Free Writing Prospectus conflicts or will conflict with the information
contained in the Registration Statement or the Prospectus, including any document incorporated by reference therein, and any preliminary
or other prospectus deemed to be a part thereof that has not been superseded or modified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Form F-6</U>. Registration statements on Form F-6 (File Nos. 333-203642, 333-212714 and 333-233560) with respect to the
ADSs have (A) been prepared by the Company in conformity with the requirements of the 1933 Act and the rules and regulations thereunder,
(B) been filed with the Commission under the 1933 Act, and (C) become effective under the 1933 Act. As used in this Agreement,
 &ldquo;ADS Registration Statements&rdquo; means such registration statements, as amended at the time each became effective under
the 1933 Act, including all exhibits thereto. The Commission has not issued any order suspending the effectiveness of the ADS Registration
Statements, and no proceeding for that purpose has been instituted or, to the Company&rsquo;s knowledge, threatened by the Commission.
The ADS Registration Statements, at the time each became effective under the 1933 Act, (i) conformed in all respects to the requirements
of the 1933 Act and the rules and regulations thereunder and (ii) and did not, as of the applicable effective date, contain an
untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements
therein not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Company
Not Ineligible Issuer</U>. The Company currently is not an &ldquo;ineligible issuer,&rdquo; as defined in Rule 405 of the rules
and regulations of the Commission. The Company agrees to notify the Representative promptly upon the Company becoming an &ldquo;ineligible
issuer.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(vi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Independent
Accountants</U>. The accountants who certified the financial statements and supporting schedules included or incorporated by reference
in the Registration Statement, the General Disclosure Package and the Prospectus are independent public accountants as required
by the 1933 Act, the 1933 Act Regulations, the 1934 Act, the 1934 Act Regulations and the Public Company Accounting Oversight
Board (&ldquo;PCAOB&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(vii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Financial
Statements</U>. The financial statements included or incorporated by reference in the Registration Statement, the General Disclosure
Package and the Prospectus, together with the related schedules and notes, if any, included or incorporated by reference in the
Registration Statement, the General Disclosure Package and the Prospectus, present fairly, in all material respects, the consolidated
financial position of the Company and its consolidated subsidiaries at the dates indicated and the statements of income, comprehensive
loss, changes in shareholders&rsquo; equity and cash flow of the Company and its consolidated subsidiaries for the periods specified;
said financial statements have been prepared in conformity with generally accepted accounting principles in the United States
(&ldquo;GAAP&rdquo;) applied on a consistent basis throughout the periods involved except as may be expressly stated in the notes
thereto.&nbsp; The selected financial data and the summary financial information included or incorporated by reference in the
Registration Statement, the General Disclosure Package and the Prospectus present fairly the information shown therein and have
been compiled on a basis consistent with that of the audited financial statements included or incorporated by reference in the
Registration Statement. The interactive data in eXtensible Business Reporting Language incorporated by reference in the Registration
Statement, the General Disclosure Package and the Prospectus fairly presents the information called for in all material respects
and has been prepared in accordance with the Commission&rsquo;s rules and guidelines applicable thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(viii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&nbsp;<U>No Material Adverse Change in Business</U>. Except as otherwise stated therein, since the respective dates as
of which information is given in the Registration Statement, the General Disclosure Package or the Prospectus, (A)&nbsp;there
has been no material adverse change in the condition, financial or otherwise, or in the earnings, business affairs or business
prospects of the Company and its subsidiaries considered as one enterprise, whether or not arising in the ordinary course of business
(a &ldquo;Material Adverse Effect&rdquo;), (B)&nbsp;there have been no transactions entered into by the Company or any of its
subsidiaries, other than those in the ordinary course of business, which are material with respect to the Company and its subsidiaries
considered as one enterprise, and (C)&nbsp;there has been no dividend or distribution of any kind declared, paid or made by the
Company on any class of its share capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ix)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Good Standing of the Company</U>. The Company has been duly organized and is validly existing in good standing under
the laws of England and Wales (to the extent such concepts are applicable in England and Wales) and has corporate or similar power
and authority to own, lease and operate its properties and to conduct its business as described in the Registration Statement,
the General Disclosure Package and the Prospectus and to enter into and perform its obligations under this Agreement and the Deposit
Agreement; and the Company is duly qualified to transact business and is in good standing in each other jurisdiction in which such
qualification is required (to the extent such concepts are applicable in such jurisdictions), whether by reason of the ownership
or leasing of property or the conduct of business, except where the failure so to qualify or to be in good standing would not result
in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(x)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Good
Standing of Subsidiaries</U>. Each subsidiary of the Company has been duly organized and is validly existing in good standing
under the laws of the jurisdiction of its incorporation or organization (to the extent such concepts are applicable in such jurisdictions),
has corporate or similar power and authority to own, lease and operate its properties and to conduct its business as described
in the Registration Statement, the General Disclosure Package and the Prospectus and is duly qualified to transact business and
is in good standing in each jurisdiction in which such qualification is required (to the extent such concepts are applicable in
such jurisdictions), whether by reason of the ownership or leasing of property or the conduct of business, except where the failure
to so qualify or to be in good standing would not, individually or in the aggregate, result in a Material Adverse Effect. All
of the issued and outstanding shares in the Company&rsquo;s capital or similar ownership interests of each of the Company&rsquo;s
subsidiaries has been duly authorized and validly issued and is fully paid and is owned by the Company, directly or through subsidiaries,
free and clear of any security interest, mortgage, pledge, lien, encumbrance, claim or equity. None of the issued shares in the
capital of any subsidiary were issued in violation of the preemptive or similar rights of any securityholder of such subsidiary.
The only subsidiaries of the Company are Adaptimmune Limited (incorporated in England and Wales) and Adaptimmune LLC (incorporated
in Delaware).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Capitalization</U>.
The issued shares in the capital of the Company have been duly authorized and validly issued and are fully paid.&nbsp; None of
the issued shares in the capital of the Company were issued in violation of the preemptive or other similar rights of any securityholder
of the Company. The Shares may be issued to the Depositary against issuance of ADRs evidencing ADSs; the ADSs, when issued and
delivered against payment therefor, will be freely transferable by the several Underwriters and (to the extent described in the
Registration Statement, the General Disclosure Package and the Prospectus) the initial purchasers thereof; and there are no legal
restrictions on subsequent transfers of the ADSs under the laws of England or the United States except as described in the Registration
Statement, the General Disclosure Package and the Prospectus under the captions &ldquo;Description of Share Capital&rdquo; and
 &ldquo;Description of American Depositary Shares&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Authorization
of this Agreement</U>. This Agreement has been duly authorized, executed and delivered by, and is a valid and binding agreement
of, the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xiii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Authorization
of the Deposit Agreement</U>. The Deposit Agreement was duly authorized and constitutes a valid and legally binding agreement
of the Company, enforceable in accordance with its terms, subject, as to enforceability, to bankruptcy, insolvency, reorganization
and similar laws of general applicability relating to or affecting creditors&rsquo; rights and to general equity principles; upon
issuance by the Depositary of ADRs evidencing ADSs and the deposit of Ordinary Shares in respect thereof in accordance with the
provisions of the Deposit Agreement, such ADSs will be duly and validly issued and the persons in whose names the ADSs are registered
will be entitled to the rights specified therein and in the Deposit Agreement; and the Deposit Agreement and the ADRs and ADSs
conform in all material respects to the descriptions thereof contained in the Registration Statement, the General Disclosure Package
and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xiv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Authorization and Description of Securities</U>. The Securities to be purchased by the Underwriters from the Company
have been duly authorized for issuance and sale to the Underwriters pursuant to this Agreement and, when issued and delivered by
the Company pursuant to this Agreement against payment of the consideration set forth herein, will be validly issued and fully
paid; and the issuance of the Securities is not subject to the preemptive or other similar rights of any securityholder of the
Company. The Securities conform in all material respects to all statements relating thereto contained in the Registration Statement,
the General Disclosure Package and the Prospectus and such descriptions conform in all material respects to the rights set forth
in the instruments defining the same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Registration Rights</U>. There are no persons with registration rights or other similar rights to have any securities
registered for sale pursuant to the Registration Statement or otherwise registered for sale or sold by the Company under the 1933
Act pursuant to this Agreement or in connection with any other offering, other than those rights that have been disclosed in the
Registration Statement, the General Disclosure Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xvi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Absence of Violations, Defaults and Conflicts</U>. Neither the Company nor any of its subsidiaries is (A) in violation
of its charter, by-laws or equivalent organizational document, (B) in default in the performance or observance of any obligation,
agreement, covenant or condition contained in any contract, indenture, mortgage, deed of trust, loan or credit agreement, note,
lease or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which it or any of them
may be bound or to which any of the properties or assets of the Company or any subsidiary is subject (collectively, &ldquo;Agreements
and Instruments&rdquo;), except for such defaults that would not, singly or in the aggregate, result in a Material Adverse Effect,
or (C) in violation of any law, statute, rule, regulation, judgment, order, writ or decree of any arbitrator, court, governmental
body, regulatory body, administrative agency or other authority, body or agency having jurisdiction over the Company or any of
its subsidiaries or any of their respective properties, assets or operations (each, a &ldquo;Governmental Entity&rdquo;), except
for such violations that would not, singly or in the aggregate, result in a Material Adverse Effect. The execution, delivery and
performance of this Agreement and the Deposit Agreement and the consummation of the transactions contemplated herein and therein
and in the Registration Statement, the General Disclosure Package and the Prospectus (including the issuance and sale of the Securities
and the use of the proceeds from the sale of the Securities as described therein under the caption &ldquo;Use of Proceeds&rdquo;)
and compliance by the Company with its obligations hereunder have been duly authorized by all necessary corporate action and do
not and will not, whether with or without the giving of notice or passage of time or both, conflict with or constitute a breach
of, or default or Repayment Event (as defined below) under, or result in the creation or imposition of any lien, charge or encumbrance
upon any properties or assets of the Company or any subsidiary pursuant to, the Agreements and Instruments (except for such conflicts,
breaches, defaults or Repayment Events or liens, charges or encumbrances that would not, singly or in the aggregate, result in
a Material Adverse Effect), nor will such action result in any violation of the provisions of the charter, by-laws or equivalent
organizational document of the Company or any of its subsidiaries or any law, statute, rule, regulation, judgment, order, writ
or decree of any Governmental Entity. As used herein, a &ldquo;Repayment Event&rdquo; means any event or condition which gives
the holder of any note, debenture or other evidence of indebtedness (or any person acting on such holder&rsquo;s behalf) the right
to require the repurchase, redemption or repayment of all or a portion of such indebtedness by the Company or any of its subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xvii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Listing of the ADSs</U>. The Company is subject to and in compliance in all material respects with the reporting requirements
of Section 13 or Section 15(d) of the 1934 Act. The ADSs are registered pursuant to Section 12(b) or Section 12(g) of the 1934
Act and are listed on the Nasdaq Global Select Market, and the Company has taken no action designed to, or reasonably likely to
have the effect of, terminating the registration of the ADSs under the 1934 Act or delisting the ADSs from such exchange, nor has
the Company received any notification that the Commission or the Nasdaq Global Select Market is contemplating terminating such
registration or listing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xviii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Absence of Labor Dispute</U>. No labor dispute with the employees of the Company or any of its subsidiaries exists or,
to the knowledge of the Company, is imminent, and the Company is not aware of any existing or imminent labor disturbance by the
employees of any of its or any subsidiary&rsquo;s principal suppliers, manufacturers, customers or contractors, which, in either
case, would result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xix)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Absence of Proceedings</U>. There is no action, suit, proceeding, inquiry or investigation before or brought by any Governmental
Entity now pending or, to the knowledge of the Company, threatened, against or affecting the Company or any of its subsidiaries,
which might result in a Material Adverse Effect, or which might materially and adversely affect their respective properties or
assets or the consummation of the transactions contemplated in this Agreement or the performance by the Company of its obligations
hereunder; and the aggregate of all pending legal or governmental proceedings to which the Company or any such subsidiary is a
party or of which any of their respective properties or assets is the subject which are not described in the Registration Statement,
the General Disclosure Package and the Prospectus, including ordinary routine litigation incidental to the business, if the subject
of an unfavorable decision, ruling or finding, would not reasonably be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xx)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Accuracy of Descriptions and Exhibits</U>. There are no contracts or documents which are required to be described in
the Registration Statement, the General Disclosure Package or the Prospectus or the documents incorporated therein by reference
or to be filed as exhibits thereto which have not been so described and filed as required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Absence of Further Requirements</U>. No filing with, or authorization, approval, consent, license, order, registration,
qualification or decree of, any Governmental Entity is necessary or required for the deposit of the Ordinary Shares being deposited
with the Depositary against issuance of ADRs evidencing the ADSs to be delivered, performance by the Company of its obligations
hereunder and under the Deposit Agreement, in connection with the offering, issuance or sale of the Shares or the Securities hereunder
or the consummation of the transactions contemplated by this Agreement and the Deposit Agreement, except (A) such as have been
already obtained or (B) as may be required under the 1933 Act, the 1933 Act Regulations, the rules of the Nasdaq Global Select
Market, state securities laws, the rules of the Financial Industry Regulatory Authority, Inc. (&ldquo;FINRA&rdquo;) or the United
Kingdom Companies Act 2006.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Possession of Licenses and Permits</U>. The Company and its subsidiaries possess such permits, licenses, approvals, consents
and other authorizations (collectively, &ldquo;Governmental Licenses&rdquo;) issued by the appropriate Governmental Entities necessary
to conduct the business now operated by them, except where the failure so to possess would not, singly or in the aggregate, result
in a Material Adverse Effect. The Company and its subsidiaries are in compliance with the terms and conditions of all Governmental
Licenses, except where the failure so to comply would not, singly or in the aggregate, result in a Material Adverse Effect. All
of the Governmental Licenses are valid and in full force and effect, except when the invalidity of such Governmental Licenses or
the failure of such Governmental Licenses to be in full force and effect would not, singly or in the aggregate, result in a Material
Adverse Effect. Neither the Company nor any of its subsidiaries has received any notice of proceedings relating to the revocation
or modification of any Governmental Licenses which, singly or in the aggregate, if the subject of an unfavorable decision, ruling
or finding, would result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxiii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Title to Property</U>. The Company and its subsidiaries have good and marketable title to all freehold property owned
by them and good title to lease or otherwise use all other real properties owned by them, in each case, free and clear of all mortgages,
pledges, liens, security interests, claims, restrictions or encumbrances of any kind except such as (A) are described in the Registration
Statement, the General Disclosure Package and the Prospectus or (B) do not, singly or in the aggregate, materially affect the value
of such property and do not interfere with the use made and proposed to be made of such property by the Company or any of its subsidiaries;
and all of the leases and subleases material to the business of the Company and its subsidiaries, considered as one enterprise,
and under which the Company or any of its subsidiaries holds properties described in the Registration Statement, the General Disclosure
Package or the Prospectus, are in full force and effect, and neither the Company nor any such subsidiary has any notice of any
material claim of any sort that has been asserted by anyone adverse to the rights of the Company or any subsidiary under any of
the leases or subleases mentioned above, or affecting or questioning the rights of the Company or such subsidiary to the continued
possession of the leased or subleased premises under any such lease or sublease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxiv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&nbsp;<U>Possession of Intellectual Property</U>. Except as described in the Registration Statement, the General Disclosure
Package and the Prospectus, the Company and its subsidiaries own, jointly own, have a valid license to use or possess, or can acquire
on reasonable terms, adequate patents, patent rights, licenses, inventions, copyrights, know-how (including trade secrets and other
unpatented and/or unpatentable proprietary or confidential information, systems or procedures), trademarks, service marks, trade
names or other intellectual property (collectively, &ldquo;Intellectual Property&rdquo;) necessary to carry on the business as
currently conducted and as proposed to be conducted as described in the Registration Statement, the General Disclosure Package
and the Prospectus, and neither the Company nor any of its subsidiaries has received any notice or is otherwise aware of any infringement
of or conflict with the rights of others with respect to any Intellectual Property or of any facts or circumstances which would
render any Intellectual Property invalid or unenforceable to protect the interest of the Company or any of its subsidiaries therein,
and which infringement or conflict (if the subject of any unfavorable decision, ruling or finding) or invalidity or unenforceability,
individually or in the aggregate, would result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Clinical Trials</U>. The studies, tests and preclinical or clinical trials conducted by or on behalf of the Company that
are described in the General Disclosure Package and the Prospectus (the &ldquo;Company Studies and Trials&rdquo;) were and, if
still pending, are being, conducted in all material respects in accordance with experimental protocols, procedures and controls
pursuant to, where applicable, accepted professional scientific standards; the descriptions of the results of the Company Studies
and Trials contained in the General Disclosure Package and Prospectus are accurate in all material respects; and except as provided
in the General Disclosure Package and the Prospectus or disclosed to the Representative, the Company has not received any notices
or correspondence with the U.S. Food and Drug Administration or any foreign, state or local governmental body exercising comparable
authority requiring the termination, suspension or material modification of any open Company Studies or Trials, which termination,
suspension or material modification would reasonably be expected to have a Material Adverse Effect.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxvi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Environmental Laws</U>. Except as described in the Registration Statement, the General Disclosure Package and the Prospectus
or would not, individually or in the aggregate, result in a Material Adverse Effect, (A)&nbsp;neither the Company nor any of its
subsidiaries is in violation of any federal, state, local or foreign statute, law, rule, regulation, ordinance, code, policy or
rule&nbsp;of common law or any judicial or administrative interpretation thereof, including any judicial or administrative order,
consent, decree or judgment, relating to pollution or protection of human health, the environment (including, without limitation,
ambient air, surface water, groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and
regulations relating to the release or threatened release of chemicals, pollutants, contaminants, wastes, toxic substances, hazardous
substances, petroleum or petroleum products, asbestos-containing materials or mold (collectively, &ldquo;Hazardous Materials&rdquo;)
or to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials
(collectively, &ldquo;Environmental Laws&rdquo;), (B)&nbsp;the Company and its subsidiaries have all permits, authorizations and
approvals required under any applicable Environmental Laws and are each in compliance with their requirements, (C)&nbsp;there are
no pending or threatened administrative, regulatory or judicial actions, suits, demands, demand letters, claims, liens, notices
of noncompliance or violation, investigations or proceedings relating to any Environmental Law against the Company or any of its
subsidiaries and (D)&nbsp;there are no events or circumstances that would reasonably be expected to form the basis of an order
for clean-up or remediation, or an action, suit or proceeding by any private party or Governmental Entity, against or affecting
the Company or any of its subsidiaries relating to Hazardous Materials or any Environmental Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxvii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>ERISA</U>. None of the following events has occurred or exists: (A) a material failure to fulfill the obligations, if
any, under the minimum funding standards of Section 302 of the United States Employee Retirement Income Security Act of 1974, as
amended (&ldquo;ERISA&rdquo;), and the regulations and published interpretations thereunder with respect to a Plan; (B) an audit
or investigation by the Internal Revenue Service, the U.S. Department of Labor, the Pension Benefit Guaranty Corporation or any
other federal or state governmental agency or any foreign regulatory agency with respect to the employment or compensation of employees
by any of the Company or any of its subsidiaries that would reasonably be expected to result in a Material Adverse Effect; or (C)
any breach of any contractual obligation, or any violation of law or applicable qualification standards, with respect to the employment
or compensation of employees by the Company or any of its subsidiaries that would reasonably be expected to result in a Material
Adverse Effect. None of the following events has occurred or is reasonably likely to occur in the Company&rsquo;s reasonable belief:
(w) a material increase in the aggregate amount of contributions required to be made to all Plans in the current fiscal year of
the Company and its subsidiaries compared to the amount of such contributions made in the most recently completed fiscal year of
the Company and its subsidiaries; (x) a material increase in the &ldquo;accumulated post-retirement benefit obligations&rdquo;
(within the meaning of Statement of Financial Accounting Standards 106) of the Company and its subsidiaries compared to the amount
of such obligations in the most recently completed fiscal year of the Company and its subsidiaries; (y) any event or condition
giving rise to a liability under Title IV of ERISA that would reasonably be expected to result in a Material Adverse Effect; or
(z) the filing of a claim by one or more employees or former employees of the Company or any of its subsidiaries related to their
employment that would reasonably be expected to result in a Material Adverse Effect. For purposes of this paragraph, the term &ldquo;Plan&rdquo;
means a plan (within the meaning of Section 3(3) of ERISA) subject to Title IV of ERISA with respect to which the Company or any
of its subsidiaries may have any liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxviii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Cybersecurity</U>. (A) (x) to the Company&rsquo;s knowledge, there has been no material security breach or other material
compromise of or relating to any of the Company&rsquo;s or any of its subsidiaries&rsquo; information technology and computer systems,
networks, hardware, software, data (including the data of their respective customers, employees, suppliers, vendors and any third-party
data maintained by or on behalf of them), equipment or technology (collectively, &ldquo;IT Systems and Data&rdquo;) and (y) the
Company has not been notified of, and has no knowledge of any event or condition that would reasonably be expected to result in,
any material security breach or other material compromise to their IT Systems and Data; (B) the Company and each of its subsidiaries
are presently in material compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any
court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy
and security of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation
or modification, except, in the case of this clause (B), as would not, singly or in the aggregate, result in a Material Adverse
Effect; and (C) the Company and each of its subsidiaries have implemented backup and disaster recovery technology consistent with
industry standards and practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxix)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Privacy Laws</U>.&nbsp; The Company and its subsidiaries are, and at all prior times were, in material compliance with
all applicable data privacy and security laws and regulations, including, without limitation, the Health Insurance Portability
and Accountability Act (&ldquo;HIPAA&rdquo;), as amended by the Health Information Technology for Economic and Clinical Health
Act (the &ldquo;HITECH Act&rdquo;) (42 U.S.C. Section 17921 et seq.); and the Company and its subsidiaries have taken all necessary
actions to comply with the European Union General Data Protection Regulation (&ldquo;GDPR&rdquo;) (EU 2016/679) (collectively,
 &ldquo;Privacy Laws&rdquo;).&nbsp;To ensure compliance with the Privacy Laws, the Company and its subsidiaries have in place, comply
with, and take appropriate steps reasonably designed to ensure compliance in all material respects with their policies and procedures
relating to data privacy and security and the collection, storage, use, disclosure, handling and analysis of Personal Data (the
 &ldquo;Policies&rdquo;).&nbsp;The Company provides accurate notice of its Policies to its customers, employees, third-party vendors
and representatives.&nbsp;The Policies provide accurate and sufficient notice of the Company&rsquo;s then-current privacy practices
relating to its subject matter, and such Policies do not contain any material omissions of the Company&rsquo;s then-current privacy
practices.&nbsp;&ldquo;Personal Data&rdquo; means (A) a natural person&rsquo;s name, street address, telephone number, email address,
photograph, social security number, bank information, or customer or account number, (B) any information which would qualify as
 &ldquo;personally identifying information&rdquo; under the Federal Trade Commission Act, as amended, (C) Protected Health Information
as defined by HIPAA, (D) &ldquo;personal data&rdquo; as defined by GDPR and (E) any other piece of information that allows the
identification of such natural person, or his or her family, or permits the collection or analysis of any data related to an identified
person&rsquo;s health or sexual orientation.&nbsp;None of such disclosures made or contained in any of the Policies have been inaccurate,
misleading, deceptive or in violation of any Privacy Laws or Policies in any material respect.&nbsp;The execution, delivery and
performance of this Agreement or any other agreement referred to in this Agreement will not result in a breach of any Privacy Laws
or Policies.&nbsp;Neither the Company nor any of its subsidiaries (x) has received notice of any actual or potential liability
under or relating to, or actual or potential violation of, any of the Privacy Laws, and has no knowledge of any event or condition
that would reasonably be expected to result in any such notice; (y) is currently conducting or paying for, in whole or in part,
any investigation, remediation or other corrective action pursuant to any Privacy Law; or (z) is a party to any order, decree,
or agreement that imposed any obligation or liability under any Privacy Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxx)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Accounting Controls</U>. The Company and each of its subsidiaries will maintain effective internal control over financial
reporting (as defined under Rule 13-a15 and 15d-15 under the rules and regulations of the Commission under the 1934 Act Regulations)
and currently maintain a system of internal accounting controls sufficient to provide reasonable assurances that (A) transactions
are executed in accordance with management&rsquo;s general or specific authorization; (B) transactions are recorded as necessary
to permit preparation of financial statements in conformity with GAAP and to maintain accountability for assets; (C) access to
assets is permitted only in accordance with management&rsquo;s general or specific authorization; and (D) the recorded accountability
for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences.
Since the end of the Company&rsquo;s most recent audited fiscal year, there has been (x) no material weakness in the Company&rsquo;s
internal control over financial reporting (whether or not remediated) and (y) no change in the Company&rsquo;s internal control
over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company&rsquo;s internal
control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxxi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Compliance with the Sarbanes-Oxley Act</U>.&nbsp; There is and has been no failure on the part of the Company or any
of the Company&rsquo;s directors or officers, in their capacities as such, to comply in all material respects with any applicable
provision of the Sarbanes-Oxley Act of 2002 and all rules and regulations promulgated thereunder or implementing the provisions
thereof (the &ldquo;Sarbanes-Oxley Act&rdquo;), including Section 402 related to loans and Sections 302 and 906 related to certifications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxxii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Payment of Taxes</U>. The Company and its subsidiaries have filed all United States federal income tax returns and other
material tax returns required by law to be filed by them through the date hereof or have timely requested extensions thereof, except
insofar as the failure to file such returns would not reasonably be expected to result in a Material Adverse Effect, and all taxes
that are due and payable have been paid, except insofar as the failure to pay such taxes, if any, would not reasonably be expected
to result in a Material Adverse Effect or such taxes, if any, are being contested in good faith and as to which adequate reserves
have been provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxxiii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Insurance</U>. The Company and each of its subsidiaries are insured by insurers of recognized financial responsibility
against such losses and risks and in such amounts as the directors of the Company consider prudent and bearing in mind the businesses
in which they are engaged; neither the Company nor any of its subsidiaries has been refused any insurance coverage sought or applied
for; and neither the Company nor any of its subsidiaries has any reason to believe that it will not be able to renew its existing
insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to
continue its business at a cost that would not have a Material Adverse Effect on the Company and its subsidiaries, taken as a whole.
The Company has no reason to believe that it or any of its subsidiaries will not be able (A)&nbsp;to renew its existing insurance
coverage as and when such policies expire or (B)&nbsp;to obtain comparable coverage from similar institutions as may be necessary
or appropriate to conduct its business as now conducted and at a cost that would not result in a Material Adverse Effect. Neither
of the Company nor any of its subsidiaries has been denied any insurance coverage which it has sought or for which it has applied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxxiv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Investment Company Act</U>. The Company is not required, and upon the issuance and sale of the Securities as herein contemplated
and the application of the net proceeds therefrom as described in the Registration Statement, the General Disclosure Package and
the Prospectus will not be required, to register as an &ldquo;investment company&rdquo; under the Investment Company Act of 1940,
as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxxv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Absence of Manipulation</U>. Neither the Company nor any affiliate of the Company has taken, nor will the Company or
any affiliate take, directly or indirectly, any action which is designed, or would be expected, to cause or result in, or which
constitutes, the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of
the Securities or to result in a violation of Regulation M under the 1934 Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxxvi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Foreign Corrupt Practices Act</U>. None of the Company, any of its subsidiaries or, to the knowledge of the Company,
any director, officer, agent, employee, affiliate or other person acting on behalf of the Company or any of its subsidiaries is
aware of or has taken any action, directly or indirectly, that would result in a violation by such persons, when acting on behalf
of the Company or its subsidiaries, of the Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder
(the &ldquo;FCPA&rdquo;), including, without limitation, making use of the mails or any means or instrumentality of interstate
commerce corruptly in furtherance of an offer, payment, promise to pay or authorization of the payment of any money, or other property,
gift, promise to give, or authorization of the giving of anything of value to any &ldquo;foreign official&rdquo; (as such term
is defined in the FCPA) or any foreign political party or official thereof or any candidate for foreign political office, in contravention
of the FCPA and the Company and, to the knowledge of the Company, its affiliates have conducted their businesses in compliance
with the FCPA and have instituted and maintain policies and procedures designed to ensure, and which are reasonably expected to
continue to ensure, continued compliance therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxxvii)
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Money Laundering Laws</U>. The operations of the Company and its subsidiaries are and have been conducted at all times in compliance
with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970,
as amended, the applicable money laundering statutes of all relevant jurisdictions, the rules and regulations thereunder and any
related or similar applicable rules, regulations or guidelines, issued, administered or enforced by any Governmental Entity (collectively,
the &ldquo;Money Laundering Laws&rdquo;); and no action, suit or proceeding by or before any Governmental Entity involving the
Company or any of its subsidiaries with respect to the Money Laundering Laws is pending or, to the best knowledge of the Company,
threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxxviii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>OFAC</U>. None of the Company, any of its subsidiaries or, to the knowledge of the Company, any director, officer, agent,
employee, affiliate or representative of the Company or any of its subsidiaries is an individual or entity (&ldquo;Person&rdquo;)
currently the subject or target of any sanctions administered or enforced by the United States Government, including, without limitation,
the U.S. Department of the Treasury&rsquo;s Office of Foreign Assets Control (&ldquo;OFAC&rdquo;), the United Nations Security
Council (&ldquo;UNSC&rdquo;), the European Union, Her Majesty&rsquo;s Treasury (&ldquo;HMT&rdquo;), or other relevant sanctions
authority (collectively, &ldquo;Sanctions&rdquo;), nor is the Company located, organized or resident in a country or territory
that is the subject of comprehensive territorial Sanctions; and the Company will not directly or indirectly use the proceeds of
the sale of the Securities, or lend, contribute or otherwise make available such proceeds to any subsidiaries, joint venture partners
or other Person, to fund any activities of or business with any Person, or in any country or territory, that, at the time of such
funding, is the subject of Sanctions or in any other manner that will result in a violation by any Person (including any Person
participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxxix)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Lending Relationship</U><I>. </I>Except as disclosed in the General Disclosure Package and the Prospectus, the Company
(i)&nbsp;does not have any&nbsp;material lending or other relationship with any bank or lending affiliate of any Underwriter and
(ii)&nbsp;does not intend to use any of the proceeds from the sale of the Securities to repay any outstanding debt owed to any
affiliate of any Underwriter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xl)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Statistical
and Market-Related Data</U>. Any statistical and market-related data included in the Registration Statement, the General Disclosure
Package or the Prospectus are based on or derived from sources that the Company believes, after reasonable inquiry, to be reliable
and accurate and, to the extent required, the Company has obtained the written consent to the use of such data from such sources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xli)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Ratings</U>. Neither the Company nor its subsidiaries have any debt securities or preferred shares that are rated
by any &ldquo;nationally recognized statistical rating agency&rdquo; (as defined in Section 3(a)(62) of the 1934 Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xlii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Dividends
and Distributions</U>. Except as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, there
are no restrictions under applicable law nor any governmental approvals currently required (including any foreign exchange or
foreign currency approvals) in order for the Company to pay dividends or other distributions declared by the Company to holders
of ordinary shares in its capital, or for the conversion by such holders of any dividends to U.S. dollars or the repatriation
thereof out of the jurisdiction of organization of the Company. No subsidiary of the Company is currently contractually prohibited,
directly or indirectly, from paying any dividends to the Company, from making any other distribution on shares of such subsidiary&rsquo;s
capital, from repaying to the Company any loans or advances to such subsidiary from the Company or from transferring any of such
subsidiary&rsquo;s property or assets to the Company or any other subsidiary of the Company. No such dividends and other distributions,
including such dividends to persons not resident in the United Kingdom, are currently subject to withholding taxes under applicable
laws and regulations in the United Kingdom.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xliii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Immunity</U>. Neither the Company nor any of its subsidiaries nor any of its or their properties or assets has any
immunity from the jurisdiction of any court or from any legal process (whether through service or notice, attachment prior to judgment,
attachment in aid of execution or otherwise) under the laws of England and Wales. Upon execution and delivery, this Agreement will
be in proper legal form under the laws of England and Wales for the enforcement hereof against the Company, and to ensure the legality,
validity, enforceability, priority or admissibility in evidence of this Agreement, it is not necessary that this Agreement or any
other document related hereto be filed, registered or recorded with or executed or notarized before any governmental or regulatory
authority or agency of the United Kingdom.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xliv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Stamp and Other Transfer Taxes</U>. Other than as set forth in the Registration Statement, the General Disclosure Package
and the Prospectus, under the laws of the United Kingdom, no stamp duty or other issuance or transfer tax or duty is or will be
payable by or on behalf of the Underwriters in connection with (A) the deposit by the Company of the Ordinary Shares in accordance
with the terms of the Deposit Agreement against the issuance of ADSs or ADRs evidencing the ADSs; (B) the issuance by the Depositary
of the ADSs or ADRs evidencing the ADSs in accordance with the terms of the Deposit Agreement; (C) the sale, issuance or delivery
of the ADSs or ADRs evidencing the ADSs to the Underwriters; (D) the initial sale by the Underwriters of the ADSs or ADRs evidencing
the ADSs to purchasers thereof; or (E) the execution and delivery of this Agreement or the Deposit Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xlv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Choice of Law</U>. The choice of the laws of the State of New York as the governing law of this Agreement is a valid
choice of law under the laws of the jurisdiction of organization of the Company, and courts in this jurisdiction will honor this
choice of law. The Company has the power to submit, and pursuant to this Agreement, has validly and irrevocably submitted, to the
personal jurisdiction of the Specified Courts (as defined in Section 17 hereof) in any suit, action or proceeding against it arising
out of or related to this Agreement, or with respect to its obligations, liabilities or any other matter arising out of or in connection
with the sale of the Securities, and has validly and irrevocably waived any objection to the venue of a proceeding in any such
court, and the Company has the power to designate, appoint and empower, and pursuant to this Agreement, has validly appointed the
authorized agent named in Section 17 hereof, and service of process effected in the manner set forth in Section 17 hereof will
be effective to confer valid personal jurisdiction over the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xlvi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Related-Party Transactions</U>. There are no business relationships or related-party transactions involving the Company
or any subsidiary or any other person required to be described in the Prospectus which have not been described as required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xlvii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Disclosure Controls</U>. The Company and each of its subsidiaries maintain an effective system of disclosure controls
and procedures (as defined in Rule 13a-15 and Rule 15d-15 under the 1934 Act Regulations) that are designed to ensure that information
required to be disclosed by the Company in the reports that it files or submits under the 1934 Act is recorded, proceeded, summarized
and reported, within the time periods specified in the Commission&rsquo;s rules and forms, and is accumulated and communicated
to the Company&rsquo;s management, including its principal executive officer or officers and principal financial officer or officers,
as appropriate, to allow timely decisions regarding disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xlviii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Brokers</U>. Except for the Representative, there is no broker, finder or other party that is entitled to receive from
the Company any brokerage or finder&rsquo;s fee or other fee or commission as a result of any transactions contemplated by this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Officer&rsquo;s Certificates</I>. Any certificate signed by any officer of the Company or any of its subsidiaries delivered
to the Representative or to counsel for the Underwriters shall be deemed a representation and warranty by the Company to each Underwriter
as to the matters covered thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Sale and Delivery to Underwriters; Closing</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Initial Securities</I>. On the basis of the representations and warranties herein contained and subject to the terms
and conditions herein set forth, the Company agrees to issue and sell to each Underwriter, severally and not jointly, and each
Underwriter, severally and not jointly, agrees to purchase from the Company, at the price per ADS set forth in Schedule A, that
number of Initial Securities set forth in Schedule A opposite the name of such Underwriter, plus any additional number of Initial
Securities which such Underwriter may become obligated to purchase pursuant to the provisions of Section 10 hereof, subject, in
each case, to such adjustments among the Underwriters as the Representative in its sole discretion shall make to eliminate any
sales or purchases of fractional ADSs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Option Securities</I>. In addition, on the basis of the representations and warranties herein contained and subject to
the terms and conditions herein set forth, the Company hereby grants an option to the Underwriters, severally and not jointly,
to purchase up to an additional 3,150,000 ADSs, at the price per ADS set forth in Schedule A, less an amount per share equal to
any dividends or distributions declared by the Company and payable on the Initial Securities but not payable on the Option Securities.
The option hereby granted may be exercised for 30&nbsp;days after the date hereof and may be exercised in whole or in part at any
time from time to time upon notice by the Representative to the Company setting forth the number of Option Securities as to which
the several Underwriters are then exercising the option and the time and date of payment and delivery for such Option Securities.
Any such time and date of delivery (a &ldquo;Date of Delivery&rdquo;) shall be determined by the Representative, but shall not
be later than seven full business days after the exercise of said option, nor in any event prior to the Closing Time. If the option
is exercised as to all or any portion of the Option Securities, each of the Underwriters, acting severally and not jointly, will
purchase that proportion of the total number of Option Securities then being purchased which the number of Initial Securities set
forth in Schedule A opposite the name of such Underwriter bears to the total number of Initial Securities, subject, in each case,
to such adjustments as the Representative in its sole discretion shall make to eliminate any sales or purchases of fractional ADSs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Payment</I>. Payment of the purchase price for, and delivery of certificates or security entitlements for, the Initial
Securities shall be made at the offices of Covington &amp; Burling LLP, 620 8<SUP>th</SUP> Avenue, New York, NY 10018, or at such
other place as shall be agreed upon by the Representative and the Company, at 9:00&nbsp;A.M. (New York City time) on the second
(third, if the pricing occurs after 4:30 P.M. (New York City time) on any given day) business day after the date hereof (unless
postponed in accordance with the provisions of Section&nbsp;10), or such other time not later than ten business days after such
date as shall be agreed upon by the Representative and the Company (such time and date of payment and delivery being herein called
 &ldquo;Closing Time&rdquo;). Delivery of the Initial Securities at the Closing Time shall be made through the facilities of DTC
unless the Representative otherwise instructs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, in the
event that any or all of the Option Securities are purchased by the Underwriters, payment of the purchase price for, and delivery
of certificates or security entitlements for, such Option Securities shall be made at the above-mentioned offices, or at such other
place as shall be agreed upon by the Representative and the Company, on each Date of Delivery as specified in the notice from the
Representative to the Company. Delivery of the Option Securities at each Date of Delivery shall be made through the facilities
of DTC unless the Representative otherwise instructs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Payment shall be made
to the Company by wire transfer of immediately available funds to a bank account designated by the Company against delivery to
the Representative for the respective accounts of the Underwriters of certificates or security entitlements for the Securities
to be purchased by them. It is understood that each Underwriter has authorized the Representative, for its account, to accept delivery
of, receipt for, and make payment of the purchase price for, the Initial Securities and the Option Securities, if any, which it
has agreed to purchase. The Representative, individually and not as representative of the Underwriters, may (but shall not be obligated
to) make payment of the purchase price for the Initial Securities or the Option Securities, if any, to be purchased by any Underwriter
whose funds have not been received by the Closing Time or the relevant Date of Delivery, as the case may be, but such payment shall
not relieve such Underwriter from its obligations hereunder. The Company undertakes to apply such funds forthwith upon receipt
in paying up in full the nominal value of, and any premium payable on, the relevant number of Shares underlying the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event that the
Closing Time shall not occur, including because the conditions of the Underwriters&rsquo; obligations pursuant to Section 5 are
not met or this Agreement is terminated pursuant to Section 5(p), Section 9 or otherwise, then the Company shall promptly transmit
by wire transfer to the Representative any amounts previously paid by the Representative to the Company representing the purchase
price for the Securities prior to the Closing Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Covenants of the Company</U>. The Company covenants with each Underwriter as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Compliance with Securities Regulations and Commission Requests</I>. The Company, subject to Section 3(b), will comply
with the requirements of Rule 430B, and will notify the Representative promptly, and confirm the notice in writing, (i) when any
post-effective amendment to the Registration Statement shall become effective or any amendment or supplement to the Prospectus
or any Rule 462(b) Registration Statement shall have been filed, (ii)&nbsp;of the receipt of any comments from the Commission,
(iii)&nbsp;of any request by the Commission for any amendment to the Registration Statement or any amendment or supplement to the
Prospectus, including any document incorporated by reference therein or for additional information, (iv)&nbsp;of the issuance by
the Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment or
of any order preventing or suspending the use of any preliminary prospectus or the Prospectus, or of the suspension of the qualification
of the Securities for offering or sale in any jurisdiction, or of the initiation or threatening of any proceedings for any of such
purposes or of any examination pursuant to Section 8(d) or 8(e) of the 1933 Act concerning the Registration Statement and (v) if
the Company becomes the subject of a proceeding under Section 8A of the 1933 Act in connection with the offering of the Securities.
The Company will effect all filings required under Rule 424(b), in the manner and within the time period required by Rule 424(b)
(without reliance on Rule 424(b)(8)), and will take such steps as it deems necessary to ascertain promptly whether the form of
prospectus transmitted for filing under Rule 424(b) was received for filing by the Commission and, in the event that it was not,
it will promptly file such prospectus. The Company will make every reasonable effort to prevent the issuance of any stop order,
prevention or suspension and, if any such order is issued, to obtain the lifting thereof at the earliest possible moment. The Company
has paid or shall pay the required Commission filing fees relating to the Securities in accordance with Rule 456(a) and 457(o)
under the 1933 Act Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Continued Compliance with Securities Laws</I>. The Company will comply with the 1933 Act, the 1933 Act Regulations, the
1934 Act and the 1934 Act Regulations so as to permit the completion of the distribution of the Securities as contemplated in this
Agreement and in the Registration Statement, the General Disclosure Package and the Prospectus. If at any time when a prospectus
relating to the Securities is (or, but for the exception afforded by Rule 172 of the 1933 Act Regulations (&ldquo;Rule 172&rdquo;),
would be) required by the 1933 Act to be delivered in connection with sales of the Securities, any event shall occur or condition
shall exist as a result of which it is necessary, in the opinion of counsel for the Underwriters or for the Company, to (i) amend
the Registration Statement in order that the Registration Statement will not include an untrue statement of a material fact or
omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading, (ii) amend
or supplement the General Disclosure Package or the Prospectus in order that the General Disclosure Package or the Prospectus,
as the case may be, will not include any untrue statement of a material fact or omit to state a material fact necessary in order
to make the statements therein not misleading in the light of the circumstances existing at the time it is delivered to a purchaser
or (iii) amend the Registration Statement or amend or supplement the General Disclosure Package or the Prospectus, as the case
may be, in order to comply with the requirements of the 1933 Act or the 1933 Act Regulations, the Company will promptly (A) give
the Representative notice of such event, (B) prepare any amendment or supplement as may be necessary to correct such statement
or omission or to make the Registration Statement, the General Disclosure Package or the Prospectus, as the case may be, comply
with such requirements and, a reasonable amount of time prior to any proposed filing or use, furnish the Representative with copies
of any such amendment or supplement and (C) file with the Commission any such amendment or supplement; provided that the Company
shall not file or use any such amendment or supplement to which the Representative or counsel for the Underwriters shall reasonably
object. The Company will furnish to the Underwriters such number of copies of such amendment or supplement as the Underwriters
may reasonably request. The Company has given the Representative notice of any filings made pursuant to the 1934 Act or 1934 Act
Regulations within 48 hours prior to the Applicable Time; the Company will give the Representative notice of its intention to make
any such filing from the Applicable Time to the Closing Time and will furnish the Representative with copies of any such documents
a reasonable amount of time prior to such proposed filing, as the case may be, and will not file or use any such document to which
the Representative or counsel for the Underwriters shall reasonably object.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Delivery of Registration Statements</I>. The Company has furnished or will deliver to the Representative and counsel
for the Underwriters, without charge, conformed copies of the Registration Statement as originally filed and each amendment thereto
(including exhibits filed therewith or incorporated by reference therein and documents incorporated or deemed to be incorporated
by reference therein) and signed copies of all consents and certificates of experts, and will also deliver to the Representative,
without charge, a conformed copy of the Registration Statement as originally filed and each amendment thereto (without exhibits)
for each of the Underwriters. The copies of the Registration Statement and each amendment thereto furnished to the Underwriters
will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent
permitted by Regulation S-T.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Delivery of Prospectuses</I>. The Company has delivered to each Underwriter, without charge, as many copies of each preliminary
prospectus as such Underwriter reasonably requested, and the Company hereby consents to the use of such copies for purposes permitted
by the 1933 Act. The Company will furnish to each Underwriter, without charge, during the period when a prospectus relating to
the Securities is (or, but for the exception afforded by Rule 172, would be) required to be delivered under the 1933 Act, such
number of copies of the Prospectus (as amended or supplemented) as such Underwriter may reasonably request. The Prospectus and
any amendments or supplements thereto furnished to the Underwriters will be identical to the electronically transmitted copies
thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Blue Sky Qualifications</I>. The Company will use its commercially reasonable efforts, in cooperation with the Underwriters,
to qualify the Securities for offering and sale under the applicable securities laws of such states and other jurisdictions (domestic
or foreign) as the Representative may designate and to maintain such qualifications in effect so long as required to complete the
distribution of the Securities; provided, however, that the Company shall not be obligated to file any general consent to service
of process or to qualify as a foreign corporation or as a dealer in securities in any jurisdiction in which it is not so qualified
or to subject itself to taxation in respect of doing business in any jurisdiction in which it is not otherwise so subject.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Rule 158</I>. The Company will timely file such reports pursuant to the 1934 Act as are necessary in order to make generally
available to its securityholders as soon as practicable an earnings statement for the purposes of, and to provide to the Underwriters
the benefits contemplated by, the last paragraph of Section 11(a) of the 1933 Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Use of Proceeds</I>. The Company will use the net proceeds received by it from the sale of the Securities in the manner
specified in the Registration Statement, the General Disclosure Package and the Prospectus under &ldquo;Use of Proceeds.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Listing</I>. The Company will use its best efforts to effect and maintain the listing of the ADSs on the Nasdaq Global
Select Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Restriction on Sale of Securities</I>. During a period of 60 days from the date of the Prospectus, the Company will not,
without the prior written consent of the Representative, (i) directly or indirectly, offer, pledge, sell, contract to sell, sell
any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase or
otherwise transfer or dispose of any ADSs or Ordinary Shares or any securities convertible into or exercisable or exchangeable
for ADSs or Ordinary Shares or file any registration statement under the 1933 Act with respect to any of the foregoing or (ii)
enter into any swap or any other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the
economic consequence of ownership of the ADSs or Ordinary Shares, whether any such swap or transaction described in clause (i)
or (ii) above is to be settled by delivery of ADSs or Ordinary Shares or such other securities, in cash or otherwise. The foregoing
sentence shall not apply to (A) the Securities to be sold hereunder, (B) any ADSs or Ordinary Shares issued by the Company upon
the exercise of an option or warrant or the conversion of a security outstanding on the date hereof and referred to in the Registration
Statement, the General Disclosure Package and the Prospectus, (C) any ADSs or Ordinary Shares issued or options to purchase ADSs
or Ordinary Shares granted pursuant to existing employee benefit plans of the Company referred to in the Registration Statement,
the General Disclosure Package and the Prospectus, (D) any ADSs or Ordinary Shares issued pursuant to any non-employee director
share plan or dividend reinvestment plan referred to in the Registration Statement, the General Disclosure Package and the Prospectus
or (E) the filing of one or more registration statements on Form S-8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Reporting Requirements</I>. The Company, during the period when a Prospectus relating to the Securities is (or, but for
the exception afforded by Rule 172, would be) required to be delivered under the 1933 Act, will file all documents required to
be filed with the Commission pursuant to the 1934 Act within the time periods required by the 1934 Act and 1934 Act Regulations.
Additionally, the Company shall report the use of proceeds from the issuance of the Securities as may be required under Rule 463
under the 1933 Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Issuer Free Writing Prospectuses</I>. The Company agrees that, unless it obtains the prior written consent of the Representative,
it will not make any offer relating to the Securities that would constitute an Issuer Free Writing Prospectus or that would otherwise
constitute a &ldquo;free writing prospectus,&rdquo; or a portion thereof, required to be filed by the Company with the Commission
or retained by the Company under Rule 433; provided that the Representative will be deemed to have consented to the Issuer Free
Writing Prospectuses listed on Schedule B-2 hereto and any &ldquo;road show that is a written communication&rdquo; within the meaning
of Rule 433(d)(8)(i) that has been reviewed by the Representative. The Company represents that it has treated or agrees that it
will treat each such free writing prospectus consented to, or deemed consented to, by the Representative as an &ldquo;issuer free
writing prospectus,&rdquo; as defined in Rule 433, and that it has complied and will comply with the applicable requirements of
Rule 433 with respect thereto, including timely filing with the Commission where required, legending and recordkeeping. If at any
time following issuance of an Issuer Free Writing Prospectus there occurred or occurs an event or development as a result of which
such Issuer Free Writing Prospectus conflicted or would conflict with the information contained in the Registration Statement,
any preliminary prospectus or the Prospectus or included or would include an untrue statement of a material fact or omitted or
would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances existing
at that subsequent time, not misleading, the Company will promptly notify the Representative and will promptly amend or supplement,
at its own expense, such Issuer Free Writing Prospectus to eliminate or correct such conflict, untrue statement or omission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Deposit of Shares. </I>The Company agrees, at or prior to the Closing Time, to facilitate the issue of the Shares underlying
the Securities to the custodian for the Depositary in accordance with the provisions of the Deposit Agreement and otherwise to
comply with the Deposit Agreement so that ADSs will be issued by the Depositary against receipt of such Shares and delivered to
the Underwriters at the Closing Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(m)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Filings with Companies House. </I>The Company will make the appropriate filings with the Companies House in England in
relation to allotment of the Shares underlying the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Payment of Expenses</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Expenses</I>. The Company will pay or cause to be paid all expenses incident to the performance of its obligations under
this Agreement, including (i) the preparation, printing and filing of the Registration Statement (including financial statements
and exhibits) as originally filed and each amendment thereto, (ii)&nbsp;the preparation, printing and delivery to the Underwriters
of copies of each preliminary prospectus, each Issuer Free Writing Prospectus and the Prospectus and any amendments or supplements
thereto and any costs associated with electronic delivery of any of the foregoing by the Underwriters to investors, (iii) the preparation,
issuance and delivery of the certificates or security entitlements for the Securities to the Underwriters, including any share
or other transfer taxes and any stamp or other similar duties payable upon the deposit of the Shares with the Depositary against
issuance of ADRs evidencing the ADSs or the sale, issuance or delivery of the Securities to the Underwriters in accordance with
the terms of this Agreement, (iv)&nbsp;the fees and disbursements of the Company&rsquo;s counsel, accountants and other advisors,
(v)&nbsp;the qualification of the Securities and the Shares under securities laws in accordance with the provisions of Section&nbsp;3(e)
hereof, including filing fees and the reasonable fees and disbursements of counsel for the Underwriters in connection therewith
and in connection with the preparation of the Blue Sky Survey and any supplement thereto, (vi) the fees and expenses of any transfer
agent or registrar or depositary for the Securities and the Shares underlying the Securities in accordance with the relevant terms
of such engagement, (vii) the costs and expenses of the Company relating to investor presentations on any &ldquo;road show&rdquo;
undertaken in connection with the marketing of the Securities, including, without limitation, expenses associated with the production
of road show slides and graphics, fees and expenses of any consultants engaged in connection with the road show presentations,
travel and lodging expenses of the representatives and officers of the Company and any such consultants (provided that the travel
and lodging expenses of the representatives of the Underwriters shall be paid by the Underwriters) and 50% of the cost of aircraft
and other transportation chartered in connection with the road show, (viii) the reasonable fees and disbursements of counsel to
the Underwriters in connection with determining the offering&rsquo;s compliance with the rules and regulations of FINRA, including
filing fees incident to any review by FINRA of the terms of the sale of the Securities, (ix) the fees and expenses incurred in
connection with the listing of the Securities on the Nasdaq Global Select Market, (x) the costs and expenses (including, without
limitation, any damages or other amounts payable in connection with legal or contractual liability) associated with the reforming
of any contracts for sale of the Securities made by the Underwriters caused by a breach of the representation contained in the
third sentence of Section 1(a)(ii); provided that the amount payable by the Company pursuant to the foregoing clauses (v) and (viii)
shall not exceed $25,000 in the aggregate. Notwithstanding the foregoing, it is understood that, except as provided in this Section
4(a) and Section 4(b) hereof, the Underwriters shall pay all of their own costs and expenses, including fees and disbursements
of their counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Termination of Agreement</I>. If this Agreement is terminated by the Representative in accordance with the provisions
of Section&nbsp;5, Section&nbsp;9(a)(i) or (iii) or Section 10 hereof, the Company shall reimburse the Underwriters for all of
their reasonably and properly incurred out-of-pocket expenses, including the reasonable fees and disbursements of counsel for the
Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 5.<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Conditions of Underwriters&rsquo; Obligations</U>. The obligations of the several Underwriters hereunder are subject
to the accuracy of the representations and warranties of the Company contained herein or in certificates of any officer of the
Company or any of its subsidiaries delivered pursuant to the provisions hereof, to the performance by the Company of its covenants
and other obligations hereunder, and to the following further conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Effectiveness of Registration Statement; Rule 430B Information</I>. The Registration Statement, including any Rule 462(b)
Registration Statement, has become effective and, at the Closing Time, no stop order suspending the effectiveness of the Registration
Statement or any post-effective amendment thereto has been issued under the 1933 Act, no order preventing or suspending the use
of any preliminary prospectus or the Prospectus has been issued and no proceedings for any of those purposes have been instituted
or are pending or, to the Company&rsquo;s knowledge, contemplated; and the Company has complied with each request (if any) from
the Commission for additional information. A prospectus containing any information deemed to be a part thereof pursuant to Rule
430B shall have been filed with the Commission in the manner and within the time frame required by Rule 424(b) without reliance
on Rule 424(b)(8), or a post-effective amendment providing such information shall have been filed with, and declared effective
by, the Commission in accordance with the requirements of Rule 430B. The Company shall have paid the required Commission filing
fees relating to the Securities in accordance with Rules 456(a) and 457(o) under the 1933 Act Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Opinions of Counsel for Company</I>. At the Closing Time, the Representative shall have received the favorable opinion,
dated the Closing Time, of (i) Mayer Brown LLP, U.S. counsel for the Company, in form and substance satisfactory to counsel for
the Underwriters, together with signed or reproduced copies of such letter for each of the other Underwriters to the effect set
forth in Exhibit A-1 hereto; (ii) Mayer Brown International LLP, counsel for the Company as to certain matters of English law,
in form and substance satisfactory to counsel for the Underwriters, together with signed or reproduced copies of such letter for
each of the other Underwriters to the effect set forth in Exhibit A-2 hereto; (iii) Mayer Brown LLP, special intellectual property
counsel for the Company, in form and substance satisfactory to counsel for the Underwriters, together with signed or reproduced
copies of such letter for each of the other Underwriters to the effect set forth in Exhibit A-3 hereto and (iv) Mayer Brown LLP,
special regulatory counsel for the Company, in form and substance satisfactory to counsel for the Underwriters, together with signed
or reproduced copies of such letter for each of the other Underwriters to the effect set forth in Exhibit A-4 hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Opinion of Counsel for Underwriters</I>. At the Closing Time, the Representative shall have received the favorable opinion,
dated the Closing Time, of Covington &amp; Burling LLP, counsel for the Underwriters, together with signed or reproduced copies
of such letter for each of the other Underwriters in form and substance satisfactory to the Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Opinion of Counsel for Depositary. </I>At the Closing Time, the Representative shall have received the opinion, dated
the Closing Time, of Patterson Belknap Webb &amp; Tyler LLP, counsel for the Depositary, in form and substance satisfactory to
counsel for the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Officers&rsquo; Certificate</I>. At the Closing Time, there shall not have been, since the date hereof or since the respective
dates as of which information is given in the Registration Statement, the General Disclosure Package or the Prospectus, any material
adverse change in the condition, financial or otherwise, or in the earnings, business affairs or business prospects of the Company
and its subsidiaries considered as one enterprise, whether or not arising in the ordinary course of business, and the Representative
shall have received a certificate of the Chief Executive Officer of the Company and of the chief financial or principal accounting
officer of the Company, dated the Closing Time, to the effect that (i) there has been no such material adverse change, (ii)&nbsp;the
representations and warranties of the Company in this Agreement are true and correct with the same force and effect as though expressly
made at and as of the Closing Time, (iii)&nbsp;the Company has complied with all agreements and satisfied all conditions on its
part to be performed or satisfied at or prior to the Closing Time, and (iv)&nbsp;no stop order suspending the effectiveness of
the Registration Statement under the 1933 Act has been issued, no order preventing or suspending the use of any preliminary prospectus
or the Prospectus has been issued and no proceedings for any of those purposes have been instituted or are pending or, to their
knowledge, contemplated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Accountant&rsquo;s Comfort Letter</I>. At the time of the execution of this Agreement, the Representative shall have
received from KPMG LLP a letter, dated such date, in form and substance satisfactory to the Representative, together with signed
or reproduced copies of such letter for each of the other Underwriters containing statements and information of the type ordinarily
included in accountants&rsquo; &ldquo;comfort letters&rdquo; to underwriters with respect to the financial statements and certain
financial information contained in the Registration Statement, the General Disclosure Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Bring-down Comfort Letter</I>. At the Closing Time, the Representative shall have received from KPMG LLP a letter, dated
as of the Closing Time, to the effect that they reaffirm the statements made in the letter furnished pursuant to subsection (f)
of this Section, except that the specified date referred to shall be a date not more than three business days prior to the Closing
Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Approval of Listing</I>. At the Closing Time, the Securities shall have been approved for listing on the Nasdaq Global
Select Market, subject only to official notice of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>No Objection</I>. If the offering is required to be filed for review with FINRA, FINRA has confirmed that it has not
raised any objection with respect to the fairness and reasonableness of the underwriting terms and arrangements relating to the
offering of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Allotment of Shares</I>. The Ordinary Shares underlying the Securities to be issued at the Closing Time or Date of Delivery
(as applicable) have been allotted conditional only on receipt by the Company of payment of the purchase price for the relevant
Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Deposit of Shares.</I> The Ordinary Shares underlying the Securities to be sold by the Company will, at the Closing Time,
be deposited with the Depositary in accordance with the provisions of the Deposit Agreement and otherwise comply with the Deposit
Agreement so that ADSs representing such Ordinary Shares will be issued by the Depositary against receipt of such Ordinary Shares.
The Depositary shall have furnished or caused to be furnished to the Representative at the Closing Time certificates satisfactory
to the Representative evidencing the deposit with it of the Ordinary Shares underlying the Securities being so deposited against
issuance of the ADSs to be delivered by the Company at the Closing Time, and the issuance and delivery of such ADSs pursuant to
and in accordance with the Deposit Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Lock-up Agreements</I>. At the date of this Agreement, the Representative shall have received an agreement substantially
in the form of Exhibit&nbsp;B hereto signed by each director of the Company and each of the officers of the Company as set forth
on Schedule C hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(m)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Effective Deposit Agreement</I>. The Deposit Agreement shall be in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(n)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Conditions to Purchase of Option Securities</I>. In the event that the Underwriters exercise their option provided in
Section&nbsp;2(b) hereof to purchase all or any portion of the Option Securities, the representations and warranties of the Company
contained herein and the statements in any certificates furnished by the Company and any of its subsidiaries hereunder shall be
true and correct as of each Date of Delivery and, at the relevant Date of Delivery, the Representative shall have received:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Officers&rsquo;
Certificate</U>. A certificate, dated such Date of Delivery, of the Chief Executive Officer of the Company and of the chief financial
or principal accounting officer of the Company confirming that the certificate delivered at the Closing Time pursuant to Section&nbsp;5(e)
hereof remains true and correct as of such Date of Delivery.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Opinions
of Counsel for Company</U>. If requested by the Representative, the favorable opinions of Mayer Brown LLP, U.S. counsel for the
Company, together with the favorable opinions of Mayer Brown International LLP, counsel for the company as to certain matters of
English law, Mayer Brown LLP, special intellectual property counsel for the Company, and Mayer Brown LLP, special regulatory counsel
for the Company, each in form and substance satisfactory to counsel for the Underwriters, dated such Date of Delivery, relating
to the Option Securities to be purchased on such Date of Delivery and otherwise to the same effect as the opinion required by Section&nbsp;5(b)
hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Opinion
of Counsel for Underwriters</U>. If requested by the Representative, the favorable opinion of Covington &amp; Burling LLP, counsel
for the Underwriters, dated such Date of Delivery, relating to the Option Securities to be purchased on such Date of Delivery and
otherwise to the same effect as the opinion required by Section&nbsp;5(c) hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Opinion
of Counsel for Depositary</U>. If requested by the Representative, the opinion of Patterson Belknap Webb &amp; Tyler LLP, counsel
for the Depositary, in form and substance satisfactory to counsel for the Underwriters, dated such Date of Delivery, relating to
the Option Securities to be purchased on such Date of Delivery and otherwise to the same effect as the opinion required by Section
5(d) hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Bring-down
Comfort Letter</U>. If requested by the Representative, a letter from KPMG LLP, in form and substance satisfactory to the Representative
and dated such Date of Delivery, substantially in the same form and substance as the letter furnished to the Representative pursuant
to Section 5(g) hereof, except that the &ldquo;specified date&rdquo; in the letter furnished pursuant to this paragraph shall be
a date not more than three business days prior to such Date of Delivery.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(o)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Additional Documents</I>. At the Closing Time and at each Date of Delivery (if any), counsel for the Underwriters shall
have been furnished with such documents and opinions as they may reasonably require for the purpose of enabling them to pass upon
the issuance and sale of the Securities as herein contemplated, or in order to evidence the accuracy of any of the representations
or warranties, or the fulfillment of any of the conditions, herein contained; and all proceedings taken by the Company in connection
with the issuance and sale of the Securities as herein contemplated shall be satisfactory in form and substance to the Representative
and counsel for the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(p)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Termination of Agreement</I>. If any condition specified in this Section shall not have been fulfilled when and as required
to be fulfilled, this Agreement, or, in the case of any condition to the purchase of Option Securities on a Date of Delivery which
is after the Closing Time, the obligations of the several Underwriters to purchase the relevant Option Securities, may be terminated
by the Representative by notice to the Company at any time at or prior to Closing Time or such Date of Delivery, as the case may
be, and such termination shall be without liability of any party to any other party except as provided in Section 4 and except
that Sections 1, 6, 7, 8, 15, 16 and 17 shall survive any such termination and remain in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Indemnification</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Indemnification of Underwriters</I>. The Company agrees to indemnify and hold harmless each Underwriter, its affiliates
(as such term is defined in Rule 501(b) under the 1933 Act (each, an &ldquo;Affiliate&rdquo;)), its directors, officers, selling
agents and each person, if any, who controls any Underwriter within the meaning of Section 15 of the 1933 Act or Section 20 of
the 1934 Act as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;against
any and all loss, liability, claim, damage and expense whatsoever, as incurred, arising out of any untrue statement or alleged
untrue statement of a material fact contained in the Registration Statement (or any amendment thereto), including any information
deemed to be a part thereof pursuant to Rule 430B, or the omission or alleged omission therefrom of a material fact required to
be stated therein or necessary to make the statements therein not misleading or arising out of any untrue statement or alleged
untrue statement of a material fact included (A) in any preliminary prospectus, any Issuer Free Writing Prospectus, the General
Disclosure Package or the Prospectus (or any amendment or supplement thereto), or (B) in any materials or information provided
to investors by, or with the approval of, the Company in connection with the marketing of the offering of the Securities (&ldquo;Marketing
Materials&rdquo;), including any roadshow or investor presentations made to investors by the Company (whether in person or electronically),
or the omission or alleged omission from any preliminary prospectus, Issuer Free Writing Prospectus, Prospectus or from any Marketing
Materials of a material fact necessary in order to make the statements therein, in the light of the circumstances under which they
were made, not misleading;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;against
any and all loss, liability, claim, damage and expense whatsoever, as incurred, to the extent of the aggregate amount paid in settlement
of any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or of any claim
whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement or omission; provided that (subject
to Section 6(d) below) any such settlement is effected with the written consent of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;against
any and all expense whatsoever, as incurred (including the fees and disbursements of counsel chosen by the Representative), reasonably
incurred in investigating, preparing or defending against any litigation, or any investigation or proceeding by any governmental
agency or body, commenced or threatened, or any claim whatsoever based upon any such untrue statement or omission, or any such
alleged untrue statement or omission, to the extent that any such expense is not paid under (i) or (ii) above;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">provided, however, that
this indemnity agreement shall not apply to any loss, liability, claim, damage or expense to the extent arising out of any untrue
statement or omission or alleged untrue statement or omission made in the Registration Statement (or any amendment thereto), including
any information deemed to be a part thereof pursuant to Rule 430B, the General Disclosure Package or the Prospectus (or any amendment
or supplement thereto) in reliance upon and in conformity with the Underwriter Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Indemnification
of Company, Directors and Officers</I>. Each Underwriter severally agrees to indemnify and hold harmless the Company, its directors,
each officer and director of the Company who signed the Registration Statement, and each person, if any, who controls the Company
within the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act, against any and all loss, liability, claim, damage
and expense described in the indemnity contained in subsection (a) of this Section, as incurred, but only with respect to untrue
statements or omissions, or alleged untrue statements or omissions, made in the Registration Statement (or any amendment thereto),
including any information deemed to be a part thereof pursuant to Rule 430B, the General Disclosure Package or the Prospectus (or
any amendment or supplement thereto) in reliance upon and in conformity with the Underwriter Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Actions
against Parties; Notification</I>. Each indemnified party shall give notice as promptly as reasonably practicable to each indemnifying
party of any action commenced against it in respect of which indemnity may be sought hereunder, but failure to so notify an indemnifying
party shall not relieve such indemnifying party from any liability hereunder to the extent it is not materially prejudiced as a
result thereof and in any event shall not relieve it from any liability which it may have otherwise than on account of this indemnity
agreement. In the case of parties indemnified pursuant to Section 6(a) above, counsel to the indemnified parties shall be selected
by the Representative, and, in the case of parties indemnified pursuant to Section 6(b) above, counsel to the indemnified parties
shall be selected by the Company. An indemnifying party may participate at its own expense in the defense of any such action; provided,
however, that counsel to the indemnifying party shall not (except with the consent of the indemnified party) also be counsel to
the indemnified party. In no event shall the indemnifying parties be liable for fees and expenses of more than one counsel (in
addition to any local counsel) separate from their own counsel for all indemnified parties in connection with any one action or
separate but similar or related actions in the same jurisdiction arising out of the same general allegations or circumstances.
No indemnifying party shall, without the prior written consent of the indemnified parties, settle or compromise or consent to the
entry of any judgment with respect to any litigation, or any investigation or proceeding by any governmental agency or body, commenced
or threatened, or any claim whatsoever in respect of which indemnification or contribution could be sought under this Section 6
or Section 7 hereof (whether or not the indemnified parties are actual or potential parties thereto), unless such settlement, compromise
or consent (i) includes an unconditional release of each indemnified party from all liability arising out of such litigation, investigation,
proceeding or claim and (ii) does not include a statement as to or an admission of fault, culpability or a failure to act by or
on behalf of any indemnified party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Settlement
without Consent if Failure to Reimburse</I>. If at any time an indemnified party shall have requested an indemnifying party to
reimburse the indemnified party for fees and expenses of counsel, such indemnifying party agrees that it shall be liable for any
settlement of the nature contemplated by Section 6(a)(ii) or settlement of any claim in connection with any violation referred
to in Section 6(e) effected without its written consent if (i) such settlement is entered into more than 45 days after receipt
by such indemnifying party of the aforesaid request, (ii) such indemnifying party shall have received notice of the terms of such
settlement at least 30 days prior to such settlement being entered into and (iii) such indemnifying party shall not have reimbursed
such indemnified party in accordance with such request prior to the date of such settlement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Contribution</U>. If the indemnification provided for in Section&nbsp;6 hereof is for any reason unavailable to or insufficient
to hold harmless an indemnified party in respect of any losses, liabilities, claims, damages or expenses referred to therein, then
each indemnifying party shall contribute to the aggregate amount of such losses, liabilities, claims, damages and expenses incurred
by such indemnified party, as incurred, (i) in such proportion as is appropriate to reflect the relative benefits received by the
Company, on the one hand, and the Underwriters, on the other hand, from the offering of the Securities pursuant to this Agreement
or (ii) if the allocation provided by clause (i) is not permitted by applicable law, in such proportion as is appropriate to reflect
not only the relative benefits referred to in clause (i) above but also the relative fault of the Company, on the one hand, and
of the Underwriters, on the other hand, in connection with the statements or omissions, or in connection with any violation of
the nature referred to in Section 6(e) hereof, which resulted in such losses, liabilities, claims, damages or expenses, as well
as any other relevant equitable considerations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The relative benefits
received by the Company, on the one hand, and the Underwriters, on the other hand, in connection with the offering of the Securities
pursuant to this Agreement shall be deemed to be in the same respective proportions as the total net proceeds from the offering
of the Securities pursuant to this Agreement (before deducting expenses) received by the Company, on the one hand, and the total
underwriting discount received by the Underwriters, on the other hand, in each case as set forth on the cover of the Prospectus,
bear to the aggregate public offering price of the Securities as set forth on the cover of the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The relative fault
of the Company, on the one hand, and the Underwriters, on the other hand, shall be determined by reference to, among other things,
whether any such untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact
relates to information supplied by the Company or by the Underwriters and the parties&rsquo; relative intent, knowledge, access
to information and opportunity to correct or prevent such statement or omission or any violation of the nature referred to in Section
6(e) hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company and the
Underwriters agree that it would not be just and equitable if contribution pursuant to this Section 7 were determined by pro rata
allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation which does
not take account of the equitable considerations referred to above in this Section 7. The aggregate amount of losses, liabilities,
claims, damages and expenses incurred by an indemnified party and referred to above in this Section 7 shall be deemed to include
any legal or other expenses reasonably incurred by such indemnified party in investigating, preparing or defending against any
litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or any claim whatsoever
based upon any such untrue or alleged untrue statement or omission or alleged omission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the
provisions of this Section 7, in no event shall an Underwriter be required to contribute any amount in excess of the amount by
which the total underwriting discounts and commissions received by such Underwriter with respect to the offering of the Securities
exceeds the amount of any damages that such Underwriter has otherwise been required to pay by reason of such untrue or alleged
untrue statement or omission or alleged omission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No person guilty of
fraudulent misrepresentation (within the meaning of Section 11(f) of the 1933 Act) shall be entitled to contribution from any person
who was not guilty of such fraudulent misrepresentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of this
Section 7, each person, if any, who controls an Underwriter within the meaning of Section 15 of the 1933 Act or Section 20 of the
1934 Act and each Underwriter&rsquo;s Affiliates and selling agents shall have the same rights to contribution as such Underwriter,
and each director of the Company, each officer and director of the Company who signed the Registration Statement, and each person,
if any, who controls the Company within the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act shall have the
same rights to contribution as the Company. The Underwriters&rsquo; respective obligations to contribute pursuant to this Section
7 are several in proportion to the number of Initial Securities set forth opposite their respective names in Schedule A hereto
and not joint.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION&#8239;8.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Representations,
Warranties and Agreements to Survive</U>. All representations, warranties and agreements contained in this Agreement or in certificates
of officers of the Company or any of its subsidiaries submitted pursuant hereto, shall remain operative and in full force and
effect regardless of (i) any investigation made by or on behalf of any Underwriter or its Affiliates or selling agents, any person
controlling any Underwriter, its officers or directors or any person controlling the Company and (ii) delivery of and payment
for the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 9.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Termination of Agreement</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Termination</I>. The Representative may terminate this Agreement, by written notice to the Company, at any time at or
prior to the Closing Time (i) if there has been, in the judgment of the Representative, since the time of execution of this Agreement
or since the respective dates as of which information is given in the Registration Statement, the General Disclosure Package or
the Prospectus, any material adverse change in the condition, financial or otherwise, or in the earnings, business affairs or business
prospects of the Company and its subsidiaries considered as one enterprise, whether or not arising in the ordinary course of business,
(ii)&nbsp;if there has occurred any material adverse change in the financial markets in the United States or the international
financial markets, any outbreak of hostilities or escalation thereof or other calamity or crisis or any change or development involving
a prospective change in national or international political, financial or economic conditions, in each case the effect of which
is such as to make it, in the judgment of the Representative, impracticable or inadvisable to proceed with the completion of the
offering or to enforce contracts for the sale of the Securities, (iii)&nbsp;if trading in any securities of the Company has been
suspended or materially limited by the Commission or the Nasdaq Global Select Market, (iv) if trading generally on the NYSE American
or the New York Stock Exchange or in the Nasdaq Global Select Market has been suspended or materially limited, or minimum or maximum
prices for trading have been fixed, or maximum ranges for prices have been required, by any of said exchanges or by order of the
Commission, FINRA or any other governmental authority, (v) if&nbsp;a material disruption has occurred in commercial banking or
securities settlement or clearance services in the United States or with respect to Clearstream or Euroclear systems in Europe,
or (vi) if a banking moratorium has been declared by either Federal, New York or United Kingdom authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Liabilities</I>. If this Agreement is terminated pursuant to this Section, such termination shall be without liability
of any party to any other party except as provided in Section 4 hereof, and provided further that Sections 1, 6, 7, 8, 15, 16 and
17 shall survive such termination and remain in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 10.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Default by One or More of the Underwriters</U>. If one or more of the Underwriters shall fail at the Closing Time or
a Date of Delivery to purchase the Securities which it or they are obligated to purchase under this Agreement (the &ldquo;Defaulted
Securities&rdquo;), the Representative shall have the right, within 24&nbsp;hours thereafter, to make arrangements for one or more
of the non-defaulting Underwriters, or any other underwriters, to purchase all, but not less than all, of the Defaulted Securities
in such amounts as may be agreed upon and upon the terms herein set forth; if, however, the Representative shall not have completed
such arrangements within such 24-hour period, then:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>if the number of Defaulted Securities does not exceed 10% of the number of Securities to be purchased on such date, each
of the non-defaulting Underwriters shall be obligated, severally and not jointly, to purchase the full amount thereof in the proportions
that their respective underwriting obligations hereunder bear to the underwriting obligations of all non-defaulting Underwriters,
or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>if the number of Defaulted Securities exceeds 10% of the number of Securities to be purchased on such date, this Agreement
or, with respect to any Date of Delivery which occurs after the Closing Time, the obligation of the Underwriters to purchase, and
the Company to sell, the Option Securities to be purchased and sold on such Date of Delivery shall terminate without liability
on the part of any non-defaulting Underwriter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No action taken pursuant
to this Section shall relieve any defaulting Underwriter from liability in respect of its default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of any
such default which does not result in a termination of this Agreement or, in the case of a Date of Delivery which is after the
Closing Time, which does not result in a termination of the obligation of the Underwriters to purchase and the Company to sell
the relevant Option Securities, as the case may be, either (i) the Representative or (ii) the Company shall have the right to postpone
the Closing Time or the relevant Date of Delivery, as the case may be, for a period not exceeding seven days in order to effect
any required changes in the Registration Statement, the General Disclosure Package or the Prospectus or in any other documents
or arrangements. As used herein, the term &ldquo;Underwriter&rdquo; includes any person substituted for an Underwriter under this
Section 10.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 11.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Recognition of the U.S. Special Resolution Regimes</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution
Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will
be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement,
and any such interest and obligation, were governed by the laws of the United States or a state of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to
a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter
are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution
Regime if this Agreement were governed by the laws of the United States or a state of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>As used in this Section 11, &ldquo;BHC Act Affiliate&rdquo; has the meaning assigned to the term &ldquo;affiliate&rdquo;
in, and shall be interpreted in accordance with, 12 U.S.C. &sect; 1841(k); &ldquo;Covered Entity&rdquo; means any of the following:
(i) a &ldquo;covered entity&rdquo; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect;&nbsp;252.82(b),
(ii) a &ldquo;covered bank&rdquo; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect;&nbsp;47.3(b)
or (iii) a &ldquo;covered FSI&rdquo; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect;&nbsp;382.2(b);
 &ldquo;Default Right&rdquo; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &sect;&sect;
252.81, 47.2 or 382.1, as applicable; and &ldquo;U.S. Special Resolution Regime&rdquo; means each of (i) the Federal Deposit Insurance
Act and the regulations promulgated thereunder and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act
and the regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 12.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notices</U>. All notices and other communications hereunder shall be in writing and shall be deemed to have been duly
given if mailed or transmitted by any standard form of telecommunication. Notices to the Underwriters shall be directed to the
Representative at Cowen and Company, LLC, 599 Lexington Avenue, New York, NY 10022, attention: General Counsel (facsimile: (646)
562-1130), with a copy to Covington &amp; Burling LLP, 620 8<SUP>th</SUP> Avenue, New York, New York 10018, attention: Eric W.
Blanchard (facsimile: (646) 441-9111); notices to the Company shall be directed to it at 60 Jubilee Avenue, Milton Park, Abingdon,
Oxfordshire, OX14 4RX, United Kingdom, attention: Adrian Rawcliffe, Chief Executive Officer (facsimile: 44 1235 430001) with a
copy to Mayer Brown LLP, 1221 Avenue of the Americas, New York, New York 10020-1001, attention: David S. Bakst (facsimile: (212)
849-5551) and a copy to Mayer Brown International LLP, 201 Bishopsgate, London EC2M 3AF, United Kingdom (facsimile: 44 20 3130
3001), attention: Richard Smith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 13.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Advisory or Fiduciary Relationship</U>. The Company acknowledges and agrees that (a) the purchase and sale of the
Securities pursuant to this Agreement, including the determination of the public offering price of the Securities and any related
discounts and commissions, is an arm&rsquo;s-length commercial transaction between the Company, on the one hand, and the several
Underwriters, on the other hand, (b) in connection with the offering of the Securities and the process leading thereto, each Underwriter
is and has been acting solely as a principal and is not the agent or fiduciary of the Company, any of its subsidiaries or their
respective shareholders, creditors, employees or any other party, (c) no Underwriter has assumed or will assume an advisory or
fiduciary responsibility in favor of the Company with respect to the offering of the Securities or the process leading thereto
(irrespective of whether such Underwriter has advised or is currently advising the Company or any of its subsidiaries on other
matters) and no Underwriter has any obligation to the Company with respect to the offering of the Securities except the obligations
expressly set forth in this Agreement, (d) the Underwriters and their respective affiliates may be engaged in a broad range of
transactions that involve interests that differ from those of the Company and (e) the Underwriters have not provided any legal,
accounting, regulatory or tax advice with respect to the offering of the Securities and the Company has consulted its own respective
legal, accounting, regulatory and tax advisors to the extent it deemed appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 14.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Parties</U>. This Agreement shall each inure to the benefit of and be binding upon the Underwriters and the Company and
their respective successors. Nothing expressed or mentioned in this Agreement is intended or shall be construed to give any person,
firm or corporation, other than the Underwriters and the Company and their respective successors and the controlling persons and
officers and directors referred to in Sections&nbsp;6 and 7 and their heirs and legal representatives, any legal or equitable right,
remedy or claim under or in respect of this Agreement or any provision herein contained. This Agreement and all conditions and
provisions hereof are intended to be for the sole and exclusive benefit of the Underwriters and the Company and their respective
successors, and said controlling persons and officers and directors and their heirs and legal representatives, and for the benefit
of no other person, firm or corporation. No purchaser of Securities from any Underwriter shall be deemed to be a successor by reason
merely of such purchase.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 15.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Trial by Jury</U>. The Company (on its behalf and, to the extent permitted by applicable law, on behalf of its affiliates)
and each of the Underwriters hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to
trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 16.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>GOVERNING LAW</U>. THIS AGREEMENT AND ANY CLAIM, CONTROVERSY OR DISPUTE ARISING UNDER OR RELATED TO THIS AGREEMENT SHALL
BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF, THE STATE OF NEW YORK WITHOUT REGARD TO ITS CHOICE OF LAW PROVISIONS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 17.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Consent to Jurisdiction; Waiver of Immunity</U>. Any legal suit, action or proceeding arising out of or based upon this
Agreement or the transactions contemplated hereby (&ldquo;Related Proceedings&rdquo;) shall&nbsp;be instituted in (a) the federal
courts of the United States of America located in the City and County of New York, Borough of Manhattan or&nbsp;(b) the courts
of the State of New York located in the City and County of New York, Borough of Manhattan (collectively, the &ldquo;Specified Courts&rdquo;),
and each party irrevocably submits to the exclusive jurisdiction (except for proceedings instituted in regard to the enforcement
of a judgment of any such court (a &ldquo;Related Judgment&rdquo;), as to which such jurisdiction is non-exclusive) of such courts
in any such suit, action or proceeding. Service of any process, summons, notice or document by mail to such party&rsquo;s address
set forth above shall be effective service of process for any suit, action or other proceeding brought in any such court. The parties
irrevocably and unconditionally waive any objection to the laying of venue of any suit, action or other proceeding in the Specified
Courts and irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such suit, action or
other proceeding brought in any such court has been brought in an inconvenient forum. Each party not located in the United States
irrevocably appoints Adaptimmune LLC as its agent to receive service of process or other legal summons for purposes of any such
suit, action or proceeding that may be instituted in any state or federal court in the City and County of New York. With respect
to any Related Proceeding, each party irrevocably waives, to the fullest extent permitted by applicable law, all immunity (whether
on the basis of sovereignty or otherwise) from jurisdiction, service of process, attachment (both before and after judgment) and
execution to which it might otherwise be entitled in the Specified Courts, and with respect to any Related Judgment, each party
waives any such immunity in the Specified Courts or any other court of competent jurisdiction, and will not raise or claim or cause
to be pleaded any such immunity at or in respect of any such Related Proceeding or Related Judgment, including, without limitation,
any immunity pursuant to the United States Foreign Sovereign Immunities Act of 1976, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 18.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Judgment Currency</U>. The obligations of the Company pursuant to this Agreement in respect of any sum due to any Underwriter
shall, notwithstanding any judgment in a currency other than United States dollars, not be discharged until the first business
day following receipt by such Underwriter of any sum adjudged to be so due in such other currency, on which (and only to the extent
that) such Underwriter may in accordance with normal banking procedures purchase United States dollars with such other currency;
if the United States dollars so purchased are less than the sum originally due to such Underwriter hereunder, the Company agrees,
as a separate obligation and notwithstanding any such judgment, to indemnify such Underwriter against such loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 19.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>TIME</U>. TIME SHALL BE OF THE ESSENCE OF THIS AGREEMENT. EXCEPT AS OTHERWISE SET FORTH HEREIN, SPECIFIED TIMES OF DAY
REFER TO NEW YORK CITY TIME.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 20.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Counterparts</U>. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an
original, but all such counterparts shall together constitute one and the same Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 21.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Effect of Headings</U>. The Section headings herein are for convenience only and shall not affect the construction hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Split-Segment; Name: a_001 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the foregoing is
in accordance with your understanding of our agreement, please sign and return to the Company a counterpart hereof, whereupon this
instrument, along with all counterparts, will become a binding agreement among the Underwriters and the Company in accordance with
its terms.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">Very truly yours,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">Adaptimmune Therapeutics plc</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">By</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">/s/ Adrian Rawcliffe</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title: Chief Executive Officer</TD></TR>
</TABLE>




<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CONFIRMED AND ACCEPTED,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;as of the date first above written:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; text-align: left">Cowen and Company, LLC</TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 2%">By&nbsp;&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> /s/ Bill Follis</TD>
    <TD STYLE="padding-bottom: 1pt; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.625in; text-align: left">Authorized Signatory</TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For themselves and as Representative of the other Underwriters
named in Schedule A hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 31; Options: NewSection; Value: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SCHEDULE A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The public offering price per ADS for the Securities shall be
$4.00.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">The purchase price per ADS for the Securities to be paid by
the several Underwriters shall be $3.76, being an amount equal to the public offering price set forth above less $0.24 per ADS,
subject to adjustment in accordance with Section 2(b) for dividends or distributions declared by the Company and payable on the
Initial Securities but not payable on the Option Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">Name of Underwriter</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Number of<BR> Initial Securities</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 86%; font-size: 10pt; text-align: left">Cowen and Company, LLC</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">18,900,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Roth Capital Partners</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,100,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; padding-left: 0.125in">Total</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">21,000,000</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Sch A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SCHEDULE B-1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Pricing Terms</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company is selling 21,000,000 American Depositary Shares (&ldquo;ADSs&rdquo;) representing 126,000,000 Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company has granted an option to the Underwriters, severally and not jointly, to purchase up to an additional 3,150,000 ADSs representing
18,900,000 Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The public offering
price per ADS for the Securities shall be $4.00.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SCHEDULE B-2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Free Writing Prospectuses</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 33; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Sch B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SCHEDULE C</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>List of Locked Up Parties</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Directors:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Adrian Rawcliffe</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">David M. Mott</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Lawrence M. Alleva</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ali Behbahani</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Barbara Duncan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">John Furey</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Giles Kerr</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">James Noble</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Elliott Sigal</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tal Zaks</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Officers:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Michael Garone</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">William C. Bertrand Jr.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Helen Tayton-Martin</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">John Lunger</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Elliot Norry</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 34; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Sch C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit A-1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM OF OPINION OF COMPANY&rsquo;S U.S.
COUNSEL<BR>
TO BE DELIVERED PURSUANT TO SECTION 5(b)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>assuming that each of the Underwriting Agreement and the Deposit Agreement have been duly authorized, executed and delivered
by the Company under the laws of England and Wales, each such agreement has been duly executed and delivered by the Company insofar
as New York law applies to such execution and delivery;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>assuming the Deposit Agreement has been duly authorized by the Company in accordance with the laws of England and Wales
and assuming due authorization, execution and delivery by the Depositary, the Deposit Agreement constitutes a valid and binding
obligation of the Company, enforceable in accordance with its terms (subject as to enforceability, to applicable bankruptcy, insolvency,
reorganization, moratorium or other similar laws affecting creditors&rsquo; rights generally from time to time in effect and to
general principles of equity regardless of whether enforceability is considered in a proceeding in equity or at law; except to
the extent that rights to indemnity may be limited by United States federal or state securities laws or public policy);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>assuming the Ordinary Shares have been duly and validly authorized and issued, are fully paid and non-assessable, are not
subject to any preemptive or similar rights and that the Ordinary Shares have been duly deposited in accordance with the laws of
England and Wales, upon the issuance by the Depositary of the ADSs against the deposit of the Ordinary Shares and, if applicable,
the ADRs evidencing such ADSs in accordance with the Deposit Agreement and due execution by one of the Depositary&rsquo;s authorized
officers, such ADSs will be duly and validly issued and will entitle the persons in whose names such ADSs are registered to the
rights specified therein, in the Deposit Agreement and, if applicable, in the ADRs evidencing such ADSs;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the Company and each subsidiary is duly qualified as a foreign corporation to transact business and each U.S. subsidiary
is in good standing in each jurisdiction in which such qualification is required, whether by reason of the ownership or leasing
of property or the conduct of business, except where the failure so to qualify or to be in good standing would not result in a
Material Adverse Effect;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the Registration Statement, the F-6 Registration Statements, the General Disclosure Package and the Prospectus, and each
amendment or supplement to the Registration Statement, the F-6 Registration Statements, the General Disclosure Package and the
Prospectus, as of their respective effective or issue dates (except for the financial statements and supporting schedules included
therein or omitted therefrom, as to which we express no opinion) appear on their face to be appropriately responsive in all material
respects to the requirements of the 1933 Act and the 1933 Act Regulations;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(vi)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>to our knowledge, except as described in the Registration Statement, the General Disclosure Package and the Prospectus,
there is not pending or threatened any action, suit, proceeding, inquiry or investigation, to which the Company or any subsidiary
is a party, or to which the property of the Company or any subsidiary is subject, before or brought by any Governmental Entity,
which, if determined adversely to the Company or such subsidiary, would reasonably be expected to result in a Material Adverse
Effect, or which would reasonably be expected to materially and adversely affect the consummation of the transactions contemplated
in the Underwriting Agreement or the Deposit Agreement, or the performance by the Company of its obligations thereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 35; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-1-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(vii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>to our knowledge, after inquiry of officers of the Company and based solely on such inquiry, we do not know of any contract
or other document that is required to be described in the Registration Statement, the General Disclosure Package or the Prospectus,
or to be filed as an exhibit to the Registration Statement, that is not described or filed as required;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(viii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the information in the Registration Statement, the General Disclosure Package and the Prospectus under &ldquo;Description
of Share Capital&rdquo; and &ldquo;Description of American Depositary Shares&rdquo; and in the Registration Statement under Item
15, to the extent that it constitutes matters of law, summaries of legal matters or legal conclusions, fairly summarize the matters
described therein in all material respects, except that we do not express any opinion in this paragraph with respect to any statements
regarding the number of outstanding shares of any class of share capital of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(ix)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the information in the Registration Statement, the General Disclosure Package and the Prospectus under &ldquo;Taxation &mdash;
Material U.S. Federal Income Tax Consequences,&rdquo; to the extent that it purports to describe matters of United States federal
tax law and regulations or legal conclusions with respect thereto, fairly summarize the matters described therein in all material
respects;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(x)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>based upon our review of those state laws of the State of New York and those federal laws of the United States of America
which, in our experience and without independent investigation, are normally applicable to transactions of the type contemplated
by the Underwriting Agreement and the Deposit Agreement, but excluding federal or state securities or blue sky laws (including,
without limitation, the 1933 Act, the 1934 Act or the 1940 Act, or antifraud laws or, in each case, any rules or regulations thereunder)
or the rules of FINRA (&ldquo;United States Applicable Laws&rdquo;), no filing with, or authorization, approval, consent, license,
order, registration, qualification or decree of, any United States federal or New York State governmental body or agency is necessary
or required to be obtained by the Company in connection with the performance by the Company of its obligations under the Underwriting
Agreement and the Deposit Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(xi)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the execution, delivery and performance of the Underwriting Agreement and the Deposit Agreement and the consummation of
the transactions contemplated in the Underwriting Agreement, the Deposit Agreement and in the Registration Statement, the General
Disclosure Package and the Prospectus (including the issuance and sale of the ADSs) and compliance by the Company with its obligations
under the Underwriting Agreement and the Deposit Agreement do not and will not, whether with or without the giving of notice or
lapse of time or both, conflict with or constitute a breach of, or default or Repayment Event (as defined in Section 1(a)(xvi)
of the Underwriting Agreement) under or result in the creation or imposition of any lien, charge or encumbrance upon any property
or assets of the Company or any subsidiary pursuant to any contract, indenture, mortgage, deed of trust, loan or credit agreement,
note, lease or any other agreement or instrument filed as an exhibit to the Registration Statement and governed by United States
federal or New York State law (except (i) that we do not express any opinion as to any breach of or default under any financial
covenant, any provision requiring a mathematical, accounting or financial computation or determination and (ii) for such conflicts,
breaches, defaults or Repayment Events or liens, charges or encumbrances that would not reasonably be expected to have a Material
Adverse Effect), nor will such action result in any violation of the provisions of any United States Applicable Laws;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 36; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-1-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(xii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>to our knowledge, after inquiry of officers of the Company and based solely on such inquiry, except as described in the
Registration Statement, the General Disclosure Package and the Prospectus, there are no contracts, agreements or understandings
between the Company and any person granting such person the right (other than rights which have been waived in writing or otherwise
satisfied) to require the Company to file a registration statement under the 1933 Act with respect to any securities of the Company
owned or to be owned by such person or to require the Company to include such securities in the securities registered pursuant
to the Registration Statement or in any securities being registered pursuant to any other registration statement filed by the Company
under the 1933 Act;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(xiii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>under the laws of the State of New York relating to the submission to jurisdiction and assuming the validity of such action
under English law, the Company, pursuant to Section 16 of the Underwriting Agreement and Section 7.6 of the Deposit Agreement has
(i) validly and irrevocably submitted to the personal jurisdiction of the federal courts of the United States of America located
in the City and County of New York or the courts of the State of New York in each case located in the City and County of New York
(collectively, the &ldquo;Specified Courts&rdquo;) in any action arising out of or related to the Underwriting Agreement or the
Deposit Agreement, (ii) to the fullest extent permitted by law, validly and irrevocably waived any objection to the venue of a
proceeding in any of the Specified Courts, and (iii) to the fullest extent permitted by law, has validly and irrevocably designated
and appointed Adaptimmune LLC as its authorized agent for service of process pursuant to Section 17 of the Underwriting Agreement
and Section 7.6 of the Deposit Agreement; and service of process effected in the manner set forth in Section 17 of the Underwriting
Agreement and Section 7.6 of the Deposit Agreement will be effective to confer valid personal jurisdiction over the Company in
any such action; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(xiv)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the Company is not required, and upon the issuance and sale of the ADSs as contemplated by the Underwriting Agreement and
the application of the net proceeds therefrom as described in the Registration Statement, the General Disclosure Package and the
Prospectus will not be required, to register as an &ldquo;investment company&rdquo; under the 1940 Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, each of the Registration Statement
and the F-6 Registration Statements has been declared effective by the Commission under the 1933 Act and the 1933 Act Regulations;
any required filing of the Prospectus pursuant to Rule 424(b) has been made in the manner and within the time period required by
Rule 424(b) (without reference to Rule 424(b)(8)); any required filing of each Issuer Free Writing Prospectus pursuant to Rule
433 has been made in the manner and within the time period required by Rule 433(d); and, to our knowledge, no stop order suspending
the effectiveness of the Registration Statement, the F-6 Registration Statements or any Rule 462(b) Registration Statement has
been issued under the 1933 Act or any order preventing or suspending the use of any preliminary prospectus, any Issuer Free Writing
Prospectus or the Prospectus has been issued and no proceedings for any such purpose have been instituted or are pending or threatened
by the Commission or any other Governmental Entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Subject to the foregoing, we confirm to
you that, and in the course of performing the services referred to above, nothing came to our attention that caused us to believe
that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 37; Options: NewSection; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-1-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">the Registration Statement, or any amendment thereto, at the time such Registration Statement or any such amendment became
effective, contained an untrue statement of a material fact or omitted to state a material fact required to be stated therein or
necessary to make the statements therein not misleading;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">the General Disclosure Package, as of the Applicable Time, contained any untrue statement of a material fact or omitted to
state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were
made, not misleading; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify">the Prospectus, as of its date or at the Closing Time, included or includes an untrue statement of a material fact or omitted
or omits to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which
they were made, not misleading.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 38; Options: NewSection; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-1-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit A-2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM OF OPINION OF COMPANY&rsquo;S UK COUNSEL<BR>
TO BE DELIVERED PURSUANT TO SECTION 5(b)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">OPINIONS</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">4.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">General statements regarding opinions</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Basis: </B>the opinions set out in the remainder of this paragraph
4 are given on the basis of the examination and enquiries referred to in paragraph 2 (<I>Examination and enquiries</I>) and the
assumptions made in paragraph 3 (<I>Assumptions</I>) and subject to the qualifications set out in paragraph 5 (<I>Qualifications</I>).</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>No extension:</B> this opinion is strictly limited to the matters
expressly stated in the remainder of this paragraph 4 and is not to be construed as extending by implication to any other matter.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">4.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Status</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Incorporation:</B> each of Adaptimmune and the Company is a limited
liability company duly incorporated under the laws of England and Wales. </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Status: </B>the relevant Company Search and Good Standing Certificate
indicate that each of Adaptimmune and the Company is validly existing and of good standing in England and Wales and do not reveal
any order or resolution for its winding up or any notice of the appointment of a receiver, administrative receiver or administrator
in respect of it or any of its assets. The Central Registry Enquiries do not reveal that any petition for its winding-up has been
presented, that any application for its administration has been made or that any notice of appointment, or of intention to appoint
an administrator, has been filed. </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Definitions: </B> for the purpose of this paragraph 4.2:</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>&quot;duly incorporated&quot;</B> in relation to each of Adaptimmune
and the Company means that the requirements of the Companies Acts in force at the date of incorporation of Adaptimmune or the Company
(as applicable) in respect of registration and all matters precedent and incidental to it have been complied with by it and that
it is authorised to be registered and is duly registered under those Acts; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>&quot;validly existing and of good standing&quot;</B> in relation
to each of Adaptimmune and the Company means Adaptimmune or the Company (as applicable) is subsisting at the date of this opinion
and has not been struck off the register kept by the Registrar of Companies, dissolved or ceased to exist by reason of any merger,
consolidation or limitation on the duration of its existence.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 39; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">4.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Corporate capacity</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Company has the corporate capacity to enter into and deliver
each Document and to exercise its rights and perform its obligations under the Documents and has taken all necessary corporate
action to authorise the execution and delivery of, and the exercise of its rights and performance of its obligations under, the
Documents.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The objects of the Company are unrestricted and do not restrict the
Company's activities.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">4.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Due execution</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company has duly executed
each Document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">4.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Non-violation and approvals</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Based on our review of those
laws and regulations which are normally applicable to transactions of the type contemplated by the Documents:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the execution and delivery by the Company of each Document, and the
performance by the Company of its obligations under each Document, do not and will not conflict with, result in any breach of or
constitute a default under its memorandum or articles of association or regulation having the force of law in England applicable
to it; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">no consent, licence, approval, authorisation, declaration, registration,
filing or recording from or with any court or governmental or regulatory authority or body in England is required in relation to
the execution and delivery of the Documents by the Company or the exercise of the Company's rights or the performance of its obligations
under the Documents (including the issue of the New Shares), or is necessary to ensure the legality, validity, enforceability or
admissibility in evidence in England of the Documents, except:</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">those approvals and other matters contemplated in the Documents;
and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the filings referred to in paragraph 3.10 (<I>Companies House filings</I>),
provided that such filings are not required to ensure the legality, validity, enforceability or admissibility in evidence in England
of the Documents.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">4.6</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Issued share capital</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The copy of the extract of the register of members of the Company
attached to the Officer's Certificate indicates that the issued share capital of the Company as at [&#9679;] 2020 comprised [&#9679;]
ordinary shares of &pound;0.001 each. The latest return of allotment of shares filed with the Registrar of Companies on 14 January
2020 indicates that all shares in issue on 14 January 2020 (i.e. 632,142,026 ordinary shares of &pound;0.001 each) are fully paid
such that members have paid all amounts on account of the nominal value and share premium in respect of such shares. </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The 632,142,026 ordinary shares of &pound;0.001 each in the issued
share capital of the Company conform to the description of the Ordinary Shares under the heading &quot;Description of Share Capital
- Key Provisions of Our Articles of Association Shares and Rights Attaching to Them&quot; in the Prospectus.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The liability of each member of the Company (in its capacity as a
member) is limited to the amount, if any, unpaid on the shares held by it, and in the event of a winding up of the Company no contribution
to the Company's assets is required from that member (in its capacity as member) exceeding the amount, if any, unpaid on the shares
in respect of which that member is liable as a past or present member. The foregoing is without prejudice to any contribution of
the type contemplated pursuant to s74(2)(e) (restrictions on liability of members under policies of insurance, etc.), s74(2)(f)
(sums due to members by way of dividends, profits or otherwise) or s76 (payments out of capital in respect of redemption or purchase
of shares) Insolvency Act 1986.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">4.7</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Authorisation to allot the New Shares</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">To the extent required under the Companies Act 2006, the directors
of the Company have been duly and validly authorised to allot the New Shares and empowered pursuant to s570(1) Companies Act 2006
to allot the New Shares as if s561(1) of that Act did not apply to that allotment.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Upon receipt by the Company of the issue and sale proceeds of the
Initial Securities [and the [&#9679;] Option Securities], and the names of the holder(s) of the New Shares being entered in the
register of members of the Company in respect of those New Shares, those New Shares will:</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">be validly allotted, issued and fully paid such that the member(s)
will have paid all amounts on account of the nominal value and share premium in respect of such shares; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">conform to the description of the Ordinary Shares under the heading
 &quot;Description of Share Capital - Key Provisions of Our Articles of Association Shares and Rights Attaching to Them&quot; in
the Prospectus.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The statements made in the Prospectus under the heading &quot;Description
of Share Capital - Key Provisions of Our Articles of Association&quot; and in the third paragraph under the heading &quot;Service
of Process and Enforcement of Judgments&quot; are accurate statements, it being recognised that such statements are a summary only
and not exhaustive.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The directors of the Company have approved the issue of [&#9679;]
ADSs representing [&#9679;] New Shares.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">4.8</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Choice of law </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The choice of the laws of the
State of New York as the governing law of each Document would be recognised and upheld by the English courts as a valid choice
of governing law for that Document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">4.9</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Submission to jurisdiction</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The submission by the Company
in:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the Underwriting Agreement to the jurisdiction of the federal courts
of the United States of America located in the City and County of New York, Borough of Manhattan or the courts of the State of
New York located in the City and County of New York, Borough of Manhattan; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the Deposit Agreement to the jurisdiction of the federal or state
courts in the City of New York,</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">to settle any disputes arising
out of the relevant Document will, to the extent relevant in determining questions of jurisdiction, be recognised by the English
courts as a valid submission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">4.10</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Stamp duty</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">No stamp duty or stamp duty reserve
tax is required to be paid in England on the execution and delivery of any Document, or on the issuance of the New Shares, or on
the issuance and delivery of the Securities to the Underwriters in accordance with the terms of the Documents or on the initial
sale by the Underwriters of the Securities to purchasers thereof in accordance with the terms of the Documents and the Prospectus
Supplement, or to ensure the enforceability or admissibility in evidence in England of any Document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">4.11</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Enforcement of foreign judgments</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The English courts will enforce
by separate action a final and conclusive money judgment entered against the Company by way of enforcement of each Document in
a court of competent jurisdiction in the State of New York, provided that the judgment satisfies the conditions set out in paragraph
5.7 (<I>Enforcement of foreign judgments qualification</I>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<!-- Field: Split-Segment; Name: a_002 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit A-3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">FORM OF OPINION OF US INTELLECTUAL PROPERTY
COUNSEL FOR THE COMPANY<BR>
TO BE DELIVERED PURSUANT TO SECTION 5(b)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">To our knowledge, nothing has come to our attention causing us to believe that the statements relating
to any intellectual property rights owned by or exclusively licensed to the Company or its subsidiaries, or relating to other intellectual
property rights owned by third parties included in the Registration Statement, the General Disclosure Package and the Prospectus
contain any untrue statement of material fact or fail to state any material fact necessary to make the statements therein not misleading.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">To our knowledge, the Company or one of its subsidiaries owns, jointly owns, or has a valid license
to use all Intellectual Property currently employed by the Company in connection with the business as currently conducted, as described
in the Registration Statement, the General Disclosure Package, and the Prospectus.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify">To our knowledge, except as described in the Registration Statement, the General Disclosure Package,
and the Prospectus, we are not aware of any third party intellectual property rights that, in our opinion, are valid and enforceable
and are necessary for purposes of the manufacture, use, or sale of the Company&rsquo;s currently proposed products as described
in the Registration Statement, the General Disclosure Package and the Prospectus.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: justify">Except as described in the Registration Statement, the General Disclosure Package, and the Prospectus,
to our knowledge, neither the Company nor its subsidiaries has received any communication or notice alleging any act of infringement,
misappropriation, or other conflict by the Company or any of its subsidiaries with any intellectual property rights of any third
party.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">5.</TD><TD STYLE="text-align: justify">To our knowledge, there are no facts or circumstances, apart from such facts or circumstances raised
during prosecution of the Intellectual Property, that form a basis for any legal or governmental entity to make a finding of unenforceability
or invalidity of any of the Intellectual Property rights of the Company or its subsidiaries.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">6.</TD><TD STYLE="text-align: justify">Except as described in the Registration Statement, the General Disclosure Package, and the Prospectus,
or otherwise previously disclosed or made available to the Representative, to our knowledge, there is no pending or threatened
action, suit, proceeding, or claim by any governmental authority or other third person party challenging the validity, scope, use,
ownership, enforceability, or other rights of the Company or its subsidiaries in or to any Intellectual Property.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">7.</TD><TD STYLE="text-align: justify">To our knowledge, no relevant noncumulative prior art that is material to the examination by the
USPTO of any patent application or issued patent, of which we became aware during the pendency of the respective patent application
or prosecution of the respective issued patent, was intentionally not disclosed by the Company or its subsidiaries to the USPTO
during such pendency or prosecution. To our knowledge, the Company and its subsidiaries have complied with the USPTO&rsquo;s duty
of candor and disclosure for the Intellectual Property applications of the Company and its subsidiaries and have made no material
misrepresentation in the Intellectual Property applications of the Company or its subsidiaries.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 43; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A-3-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit A-4</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">FORM OF OPINION OF REGULATORY COUNSEL FOR
THE COMPANY<BR>
TO BE DELIVERED PURSUANT TO SECTION 5(b)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Based on, subject to, and limited by the foregoing,
we are of the opinion that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 10.5pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Insofar
as the statements in the Designated Regulatory Provisions purport to describe or summarize applicable provisions of the Food and
Drug Laws, such statements are accurate in all material respects, subject to any qualifications set forth therein; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 10.5pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nothing has come
to our attention which causes us to believe that the Designated Regulatory Provisions, at the time the Registration Statement became
effective and at all times subsequent thereto up to and on the Closing Date, contained any untrue statement of a material fact
or omitted to state a material fact required to be stated therein or necessary to make the statements therein, in light of the
circumstances under which they were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit B</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in 0pt 0; text-align: right; text-indent: 0">_______________, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cowen and Company, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">599 Lexington Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, NY 10022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">as Representative of the several<BR>
Underwriters to be named in the<BR>
within-mentioned Underwriting Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Re:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Proposed Public
Offering by Adaptimmune Therapeutics plc</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Sirs:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned director
and/or officer of Adaptimmune Therapeutics plc, a public limited company organized under the laws of England and Wales (the &ldquo;Company&rdquo;),
understands that Cowen and Company, LLC, as representative (the &ldquo;Representative&rdquo;) of the several underwriters (the
 &ldquo;Underwriters&rdquo;), proposes to enter into an Underwriting Agreement (the &ldquo;Underwriting Agreement&rdquo;) with the
Company, providing for the public offering (the &ldquo;Offering&rdquo;) of American Depositary Shares (&ldquo;ADSs&rdquo;), each
representing six ordinary shares, par value of &pound;0.001 per share (the &ldquo;Ordinary Shares&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In recognition of the
benefit that such an offering will confer upon the undersigned as a director and/or executive officer of the Company, and for other
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned agrees with each
Underwriter to be named in the Underwriting Agreement that, during the period beginning on the date hereof and ending on the date
that is 60 days from the date of the Underwriting Agreement (subject to extensions as discussed below), the undersigned will not,
without the prior written consent of the Representative, (i) directly or indirectly offer, pledge, sell, contract to sell, sell
any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase or
otherwise transfer or dispose of any ADSs, Ordinary Shares or any securities convertible into or exercisable or exchangeable for
or representing ADSs or Ordinary Shares, whether now owned or hereafter acquired by the undersigned or with respect to which the
undersigned has or hereafter acquires the power of disposition (collectively, the &ldquo;Lock-up Securities&rdquo;), or exercise
any right with respect to the registration of any of the Lock-up Securities, or file or cause to be filed any registration statement
in connection therewith, under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), or (ii) enter into any
swap or any other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence
of ownership of the Lock-up Securities, whether any such swap or transaction is to be settled by delivery of ADSs or Ordinary Shares
or other securities, in cash or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the
foregoing, and subject to the conditions below, the undersigned may transfer the Lock-up Securities without the prior written consent
of the Representative, provided that (1) the Representative receives a signed lock-up agreement for the balance of the lock-up
period from each donee, trustee, distributee or transferee, as the case may be, (2) any such transfer shall not involve a disposition
for value, (3) such transfers are not required to be reported with the Securities and Exchange Commission on Form 4 in accordance
with Section 16 of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), and (4) the undersigned does
not otherwise voluntarily effect any public filing or report regarding such transfers:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">i.</TD><TD STYLE="text-align: justify">as a bona fide gift or gifts, including without limitation
to a charitable organization; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: justify">ii.</TD><TD STYLE="text-align: justify">to any trust for the direct or indirect benefit of the
undersigned or the immediate family of the undersigned (for purposes of this lock-up agreement, &ldquo;immediate family&rdquo;
shall mean any relationship by blood, marriage or adoption, not more remote than first cousin); or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: justify">iii.</TD><TD STYLE="text-align: justify">to the undersigned&rsquo;s affiliates (as defined in
Rule 405 promulgated under the Securities Act) or to any investment fund or other entity controlled or managed by the undersigned;
or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.75in"></TD><TD STYLE="text-align: justify; width: 0.25in">iv.</TD><TD STYLE="text-align: justify">any sale or transfer with the prior written consent of the Representative; or</TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.75in"></TD><TD STYLE="text-align: justify; width: 0.25in">v.</TD><TD STYLE="text-align: justify">the transfer of ADSs or Ordinary Shares (or any security convertible into or exercisable or exchangeable for ADSs or Ordinary
Shares) pursuant to a bona fide third-party tender offer, merger, consolidation or other similar transaction made to all holders
of the ADSs and/or Ordinary Shares involving a Change of Control (as defined below) of the Company (including, without limitation,
entering into any lock-up, voting or similar agreement pursuant to which the undersigned may agree to transfer, sell, tender or
otherwise dispose of ADSs and/or Ordinary Shares or such other securities in connection with any such transaction, or vote any
securities in favor of any such transaction) provided that in the event that the tender offer, merger, consolidation or other such
transaction is not completed, the ADSs and/or Ordinary Shares owned by the undersigned shall remain subject to the restrictions
contained in this agreement.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the
foregoing, the restrictions above shall not prohibit the transfer or disposition of ADSs or Ordinary Shares acquired by the undersigned
in open market transactions, provided that no public announcement or filing under Section 16(a) of the Exchange Act in connection
with such transfer or disposition shall be required of or voluntarily made by or on behalf of the undersigned or the Company (other
than a filing on a Form 5 made after the expiration of the 60-day period referred to above).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the
foregoing, the restrictions above shall not prohibit the establishment of a trading plan or agreement with a broker designed to
comply with Rule 10b5-1 under the Exchange Act (a &ldquo;Rule 10b5-1 Plan&rdquo;) for the transfer of ADSs or Ordinary Shares or
securities representing ADSs or Ordinary Shares, <I>provided</I> that such plan does not provide for the transfer of ADSs or Ordinary
Shares or securities representing ADSs or Ordinary Shares during the lock-up period and no public announcement or filing under
the Exchange Act regarding the establishment of such plan shall be required of or voluntarily made by or on behalf of the undersigned
or the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of clause
(v) above, &ldquo;Change of Control&rdquo; shall mean the consummation of any bona fide third-party tender offer, merger, consolidation
or other similar transaction the result of which is that any &ldquo;person&rdquo; (as defined in Section 13(d)(3) of the Exchange
Act), or group of persons, becomes the beneficial owner (as defined in Rules 13d-3 and 13d-5 of the Exchange Act) of more than
50% of the voting capital stock of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This agreement shall
terminate and be of no further force and effect if the Offering shall not have occurred on or before the earliest of (i) the date,
prior to the execution of the Underwriting Agreement, on which the Company informs the Representative in writing that the Company
has determined not to proceed with the Offering, (ii) the date, prior to the execution of the Underwriting Agreement, on which
the Representative informs the Company in writing that the Representative has determined not to proceed with the Offering, (iii)
if the Underwriting Agreement has not been executed by March 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With respect to the
Offering only, the undersigned waives any registration rights relating to registration under the Securities Act of the offer and
sale of any ADSs or Ordinary Shares owned either of record or beneficially by the undersigned, including any rights to receive
notice of the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned also
agrees and consents to the entry of stop transfer instructions with the transfer agent and registrar of the Company against the
transfer of the Lock-up Securities except in compliance with the foregoing restrictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Very truly yours,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">Signature:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">Print
    Name:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>

<!-- Field: Page; Sequence: 47; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>tm204193d3_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt; text-align: right">Mayer Brown International LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt; text-align: right">201 Bishopsgate</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt; text-align: right">London EC2M 3AF</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt; text-align: right">Telephone: +44 20 3130 3000</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt; text-align: right">Fax: +44 20 3130 3001</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt; text-align: right">www.mayerbrown.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt; text-align: right">DX 556 London and City</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt; text-align: right">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adaptimmune Therapeutics plc</FONT></TD>
    <TD STYLE="text-align: right; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22 January 2020</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60 Jubilee Avenue</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Milton Park</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abingdon</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oxfordshire</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OX14 4RX</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.75pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Our ref:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;20456/19610565</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dear Sirs</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Prospectus Supplement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in">1.</TD>
    <TD STYLE="text-align: justify"><B>Background</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">We have acted for Adaptimmune
Therapeutics plc, a public limited company incorporated under the laws of England and Wales (the <B>&quot;Company&quot;</B>), as
its legal advisers in England in connection with the offering (the <B>&quot;Offering&quot;</B>) by the Company of 126,000,000 new
ordinary shares of &pound;0.001 each in the Company (the <B>&quot;New Shares&quot;</B>). The New Shares are to be offered in the
form of 21,000,000 American Depositary Shares (<B>&quot;ADSs&quot;</B>). Each ADS represents 6 ordinary shares of the Company.
The underwriters to the Offering have the right to purchase up to an additional 3,150,000 ADSs, representing 18,900,000 new ordinary
shares of &pound;0.001 each in the capital of the Company (the <B>&quot;Further Shares&quot;</B>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">This opinion is being furnished
in connection with the Registration Statement on Form S-3 (No. 333-233557) (the <B>&quot;Registration Statement&quot;</B>) filed
with the Securities and Exchange Commission (the <B>&quot;SEC&quot;</B>) under the Securities Act of 1933, as amended (the <B>&quot;Securities
Act&quot;</B>) and the rules and regulations promulgated thereunder (the <B>&quot;Rules&quot;</B>), the prospectus included within
the Registration Statement, and the prospectus supplement dated 22 January 2020 to be filed with the SEC pursuant to Rule 424(b)
of the Rules (the <B>&quot;Prospectus Supplement&quot;</B>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">We understand that the ordinary
shares of &pound;0.001 each in the capital of the Company are not, and are not intended to be, admitted to trading on any market
or exchange, or otherwise listed, in the United Kingdom.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">This is a legal
communication, not a financial communication. Neither this nor any other communication from this firm is intended to be, or
should be construed as, an invitation or inducement (direct or indirect) to any person to engage in investment activity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Mayer Brown International LLP is a
limited liability partnership (registered in England and Wales number OC303359), which is authorised and regulated by the
Solicitors Regulation Authority with SRA number 369822. Mayer Brown is a global services provider comprising an association
of legal practices that are separate entities including Mayer Brown LLP (Illinois, USA), Mayer Brown International LLP
(England), Mayer Brown (a Hong Kong partnership) and Tauil &amp; Chequer Advogados (a Brazilian partnership).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt">We use the term &quot;partner&quot; to refer to a member
of Mayer Brown International LLP, or an employee or consultant who is a lawyer with equivalent standing and qualifications
and to a partner of or lawyer with equivalent status in another Mayer Brown entity. A list of the names of members of Mayer
Brown International LLP and their respective professional qualifications may be inspected at our registered office, 201
Bishopsgate, London EC2M 3AF, England or on www.mayerbrown.com.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in">2.</TD>
    <TD STYLE="text-align: justify"><B>Examination and enquiries</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in">2.1</TD>
    <TD STYLE="text-align: justify">For the purpose of giving this opinion, we have examined:</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.5in">(a)</TD>
    <TD STYLE="text-align: justify">a copy of the Prospectus Supplement; and</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">a certificate dated 22 January 2020 (the <B>&quot;Reference Date&quot;</B>) signed by the company
secretary (the <B>&quot;Officer's Certificate&quot;</B>) relating to certain factual matters as at the Reference Date and having
annexed thereto copies (certified by the company secretary as being true, complete, accurate and up-to-date in each case) of the
following documents:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">the Company's certificate of incorporation, certificate of incorporation on re-registration, memorandum
of association and articles of association;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">shareholder resolutions passed at the annual general meeting of the Company on 2 May 2019 authorising
the directors of the Company for the purposes of s551 Companies Act 2006 and conferring power on the directors of the Company pursuant
to s570 Companies Act 2006 (the <B>&quot;Shareholder Resolutions&quot;</B>);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">minutes of a meeting of the board of directors of the Company held on 16 January 2020 at which
it was resolved, inter alia, to proceed with the Offering and to constitute a committee of the board of directors of the Company
(the <B>&quot;Committee&quot;</B>); and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">minutes of meetings of the Committee held on 21 January 2020 and 22 January 2020 at which it was
resolved, inter alia, to approve and file the Prospectus Supplement and to allot the New Shares;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">draft minutes of a meeting of either the Committee or the board of directors of the Company to
be held to resolve, inter alia, to allot Further Shares in the event that the underwriters to the Offering exercise their right
to purchase the same (such draft resolutions, together with the resolutions of the board of directors of the Company and the Committee
of 16 January 2020, 21 January 2020 and 22 January 2020, the <B>&quot;Board Resolutions&quot;</B>, and the Board Resolutions together
with the Shareholder Resolutions, the <B>&quot;Corporate Approvals&quot;</B>); and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">a copy of the executed underwriting agreement dated 22 January 2020 in connection with the Offering
between (1) the Company and (2) Cowen and Company, LLC as representative of the several underwriters named therein (the <B>&quot;Underwriting
Agreement&quot;</B>), but excluding any exhibits thereto.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">


<TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the purpose of giving this opinion, we have:</FONT></TD>
</TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">arranged for our agents to make on 21 January 2020 an online search of the register kept in respect
of the Company by the Registrar of Companies (the <B>&quot;Company Search&quot;</B>) and reviewed the results of such search; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">arranged for our agents to make on 21 January 2020 at 10.05 a.m. (GMT) an online search in respect
of the Company of the Central Registry of Winding Up Petitions (the <B>&quot;Central Registry
Enquiry&quot;</B>, and together with the Company Search, the <B>&quot;Searches&quot;</B>) and reviewed the results of such search.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 2; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">2.3</TD><TD STYLE="text-align: justify">For the purposes of giving this opinion, we have only examined and relied on those documents and
made those searches and enquiries set out in paragraphs 2.1 and 2.2 respectively. We have made no further enquiries concerning
the Company or any other matter in connection with the giving of this opinion.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">2.4</TD><TD STYLE="text-align: justify">We have made no enquiry, and express no opinion, as to any matter of fact. As to matters of fact
which are material to this opinion, we have relied entirely and without further enquiry on statements made in the documents listed
in paragraph 2.1.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in">3.</TD>
    <TD STYLE="text-align: justify"><B>Assumptions</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in">3.1</TD>
    <TD STYLE="text-align: justify">In giving this opinion we have assumed:</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">the genuineness of all signatures, seals and stamps;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">that each of the individuals who signs as, or otherwise claims to be, an officer of the Company
is the individual whom he or she claims to be and holds the office he or she claims to hold;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">the authenticity and completeness of all documents submitted to us as originals;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">the conformity with the original documents of all documents reviewed by us as drafts, specimens,
pro formas or copies and the authenticity and completeness of all such original documents;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">that each of the meetings referred to in paragraphs 2.1(b)(ii), 2.1(b)(iii), 2.1(b)(iv) and 2.1(c)
(<I>Examination and enquiries</I>) was or will be duly convened, constituted and held in accordance with all applicable laws and
regulations; that in particular, but without limitation, a duly qualified quorum of directors or, as the case may be, shareholders
was or will be present in each case throughout the meeting and voted or will vote in favour of the resolutions; and that, in the
case of a board or Committee meeting, each provision contained in the Companies Act 2006 or the articles of association of the
Company relating to the declaration of directors' interests or the power of interested directors to vote and to count in the quorum
was or will be duly observed;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">that in each case the documents referred to in paragraphs 2.1(b)(ii), 2.1(b)(iii), 2.1(b)(iv) and
2.1(c) (<I>Examination and enquiries</I>) are or will be a true record of the proceedings of the relevant meeting and that each
resolution recorded in those documents has not been and will not be amended or rescinded and remains or will remain in full force
and effect;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify">that the directors of the Company acted and will act in accordance with ss171 to 174 Companies
Act 2006 in approving the resolutions recorded in the minutes referred to in paragraphs 2.1(b)(iii), 2.1(b)(iv) and 2.1(c) (<I>Examination
and enquiries</I>) and that all actions to be carried out by the Company pursuant to the Corporate Approvals are or will be in
its commercial interests;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(h)</TD><TD STYLE="text-align: justify">that no agreement, document or obligation to or by which the Company (or its assets) is a party
or bound and no injunction or other court order against or affecting the Company would be breached or infringed by the matters
contemplated by the performance of the actions to be carried out pursuant to, or any other aspect of the transactions contemplated
by, the Corporate Approvals;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">that the information included in the results of the Searches is true, accurate, complete and up-to-date
and that there is no information which, for any reason, should have been included in those Searches but was not included in them;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(j)</TD><TD STYLE="text-align: justify">that as at each date on which the Company allots or issues New Shares or Further Shares the documents
examined, and the results of the searches and enquiries made, as set out in paragraph 2 (<I>Examination and enquiries</I>) would
not be rendered untrue, inaccurate, incomplete or out-of-date by reference to subsequent facts, matters and circumstances or events;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(k)</TD><TD STYLE="text-align: justify">that the Company is and will at all relevant times remain in compliance with all applicable anti-corruption,
anti-money laundering, anti-terrorism, sanctions, exchange controls and human rights laws and regulations of any applicable jurisdiction;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(l)</TD><TD STYLE="text-align: justify">that all consents, licences, approvals, authorisations, notices, filings and registrations that
are necessary under any applicable laws or regulations in order to permit the performance of the actions to be carried out pursuant
to the Corporate Approvals have been or will be duly made or obtained and are, or will be, in full force and effect;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(m)</TD><TD STYLE="text-align: justify">that there are no provisions of the laws of any jurisdiction outside England and Wales that would
have any implication for the opinions we express and that, insofar as the laws of any jurisdiction outside England and Wales may
be relevant to this opinion letter, such laws have been and will be complied with;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(n)</TD><TD STYLE="text-align: justify">that all New Shares and Further Shares will be issued and allotted pursuant to the authority and
power granted to the directors of the Company respectively under the Shareholder Resolutions and that that authority and that power
are and shall remain unutilized to a sufficient extent to enable the issue and allotment of the New Shares and Further Shares;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(o)</TD><TD STYLE="text-align: justify">that each party to each agreement or instrument pursuant to which New Shares or Further Shares
are offered, issued and/or sold will have the capacity to enter into and deliver, and to exercise its rights and perform its obligations
thereunder, will have taken all necessary corporate action to authorise that entry, delivery, exercise and performance, and will
not be prohibited by any applicable law from that entry, delivery, exercise and performance; that each such agreement or instrument
will have been duly executed by or on behalf of each party to it; and that the obligations created by each such agreement or instrument
will constitute the legal, valid, binding and enforceable obligations of each of the parties to it under the laws by which it is
expressed to be governed;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(p)</TD><TD STYLE="text-align: justify">that no New Shares or Further Shares are acquired as a consequence of a communication made in breach
of s21(1) Financial Services and Markets Act 2000;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(q)</TD><TD STYLE="text-align: justify">that the New Shares and Further Shares have been and will be offered and sold in accordance with
all applicable laws;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(r)</TD><TD STYLE="text-align: justify">that no application has been or will be made for any New Shares or Further Shares to be listed
or admitted to trading on a regulated market situated or operating in the United Kingdom;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(s)</TD><TD STYLE="text-align: justify">that the aggregate issue price in respect of each New Share and Further Share is not less than
the nominal value of that New Share or Further Share;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(t)</TD><TD STYLE="text-align: justify">that there will be no fact or matter (such as bad faith, coercion, duress, undue influence or a
mistake or misrepresentation before or at the time any agreement or instrument is entered into, a subsequent breach, release, waiver
or variation of any right or provision, an entitlement to rectification or circumstances giving rise to an estoppel) which might
affect the allotment and issue of any New Shares or Further Shares and no additional document between any relevant parties which
would or might affect this opinion and which was not revealed to us by the documents examined or the searches and enquiries made
by us or our agents in connection with the giving of this opinion;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(u)</TD><TD STYLE="text-align: justify">that the Company's place of central management and control is not the UK, the Channel Islands or
the Isle of Man for the purposes of the City Code on Takeovers and Mergers.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">3.2</TD><TD STYLE="text-align: justify">In relation to paragraph 3.1(i), it should be noted that this information may not be true, accurate,
complete or up-to-date. In particular, but without limitation:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">there may be matters which should have been registered but which have not been registered or there
may be a delay between the registration of those matters and the relevant entries appearing on the register of the relevant party;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">there is no requirement to register with the Registrar of Companies notice of a petition for the
winding-up of, or application for an administration order in respect of, a company. Such a notice or notice of a winding-up or
administration order having been made, a resolution having been passed for the winding-up of a company or a receiver, manager,
administrative receiver, administrator or liquidator having been appointed may not be filed with the Registrar of Companies immediately
and there may be a delay in any notice appearing on the register of the relevant party;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">the results of the Central Registry Enquiry relate only to petitions for the compulsory winding
up of, or applications for an administration order in respect of, the Company presented prior to the enquiry and entered on the
records of the Central Index of Winding Up Petitions. The presentation of such a petition, or the making of such an application,
may not have been notified to the Central Index or entered on its records immediately or, if presented to a County Court or Chancery
District Registry, at all; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">in each case, further information might have become available on the relevant register after the
Searches were made.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in">4.</TD>
    <TD STYLE="text-align: justify"><B>Opinion</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">4.1</TD><TD STYLE="text-align: justify">On the basis of the examination and enquiries referred to in paragraph 2 (<I>Examination and enquiries</I>)
and the assumptions made in paragraph 3 (<I>Assumptions</I>), we are of the opinion that the New Shares and the Further Shares
will, when the names of the holders of such New Shares and Further Shares respectively are entered into the register of members
of the Company and subject to the receipt by the Company of the aggregate issue price in respect of all the New Shares and the
Further Shares respectively, be validly issued, fully paid and no further amount may be called thereon.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">4.2</TD><TD STYLE="text-align: justify">This opinion is strictly limited to the matters expressly stated in this paragraph 4 and is not
to be construed as extending by implication to any other matter.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in">5.</TD>
    <TD STYLE="text-align: justify"><B>Law</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">5.1</TD><TD STYLE="text-align: justify">This opinion and any non-contractual obligations arising out of or in connection with this opinion
shall be governed by, and construed in accordance with, English law.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">5.2</TD><TD STYLE="text-align: justify">This opinion relates only to English law (being for these purposes, except to the extent we make
specific reference to an English law &quot;<B>conflict of law</B>&quot; (private international law) rule or principle, English
domestic law on the assumption that English domestic law applies to all relevant issues) as applied by the English courts as at
today's date, including the laws of the European Union to the extent having the force of law in England.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">5.3</TD><TD STYLE="text-align: justify">We do not undertake or accept any obligation to update this opinion to reflect subsequent changes
in English law or factual matters.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">5.4</TD><TD STYLE="text-align: justify">We express no opinion as to, and we have not investigated for the purposes of this opinion, the
laws of any jurisdiction other than England. It is assumed that no foreign law which may apply to the matters contemplated by the
Prospectus Supplement, the Offering, the Company, any document or any other matter contemplated by any document would or might
affect this opinion.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We hereby consent to the filing of this
opinion as an exhibit to the Prospectus Supplement. In giving such consent, we do not admit that we are in the category of persons
whose consent is required under section 7 of the Securities Act or the Rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yours faithfully</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">/s/ Mayer Brown International LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mayer Brown International LLP</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>tm204193d3_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm204193d3_ex99-1img01.jpg" ALT=""></P>


<P STYLE="margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Adaptimmune Therapeutics plc Proposes
Public Offering of American Depositary Shares</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">PHILADELPHIA,
Pa. and OXFORD, UK., January </FONT>21<FONT STYLE="font-family: Times New Roman, Times, Serif">, 2020 &mdash; Adaptimmune
Therapeutics plc (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced that it intends to offer and sell
American Depositary Shares (&ldquo;ADSs&rdquo;) in an underwritten public offering. The offering is subject to market conditions,
and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Adaptimmune also expects to grant the underwriters a 30-day option to purchase additional ADSs at the public offering price. All
of the ADSs in the offering are to be sold by Adaptimmune, with net proceeds to be used to advance the development of Adaptimmune&rsquo;s
immunotherapies into and through clinical trials as well as for other general corporate purposes.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cowen is acting as sole book-running manager for the offering.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A shelf registration statement on Form S-3 relating to the public
offering of the ADSs described above was declared effective by the Securities and Exchange Commission (&ldquo;SEC&rdquo;) on September
10, 2019. The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration
statement. A preliminary prospectus supplement relating to and describing the terms of the offering will be filed with the SEC
and will be available on the SEC&rsquo;s web site at www.sec.gov. When available, copies of the preliminary prospectus supplement
relating to these securities may also be obtained by sending a request to: Cowen and Company, LLC, c/o Broadridge Financial Solutions,
1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by email at PostSaleManualRequests@broadridge.com or
by telephone at (833) 297-2926.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release does not constitute an offer to sell or the
solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale is not permitted.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>For readers in the European Economic Area</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In any EEA Member State, this communication is only addressed
to and directed at qualified investors in that Member State within the meaning of the Prospectus Regulation. The term &ldquo;Prospectus
Regulation&rdquo; means Regulation (EU) 2017/1129.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>For readers in the United Kingdom</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This communication, in so far as it constitutes an invitation
or inducement to enter into investment activity (within the meaning of s21 Financial Services and Markets Act 2000 as amended)
in connection with the securities which are the subject of the offering described in this press release or otherwise, is being
directed only at (i) persons who are outside the United Kingdom or (ii) persons who have professional experience in matters relating
to investments who fall within Article 19(5) (Investment professionals) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (the &ldquo;Order&rdquo;) or (iii) certain high value persons and entities who fall within Article 49(2)(a)
to (d) (High net worth companies, unincorporated associations etc) of the Order; or (iv) any other person to whom it may lawfully
be communicated (all such persons in (i) to (iv) together being referred to as &ldquo;relevant persons&rdquo;). The ADSs are only
available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such ADSs will be engaged in only
with, relevant persons. Any person who is not a relevant person should not act or rely on this communication or any of its contents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Adaptimmune</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Adaptimmune is a clinical-stage biopharmaceutical company focused
on the development of novel cancer immunotherapy products for people with cancer. The Company&rsquo;s unique SPEAR&reg; (Specific
Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple
solid tumors.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This release contains &ldquo;forward-looking statements&rdquo;
within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain
risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated
by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities
and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization
processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from
those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our
Quarterly Report on Form 10-Q filed with the SEC on November 6, 2019, and our other SEC filings. The forward-looking statements
contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update
such forward-looking statements to reflect subsequent events or circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Adaptimmune Contacts:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Media Relations:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">S&eacute;bastien Desprez &mdash; VP, Communications and Investor
Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">T: +44 1235 430 583</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">M: +44 7718 453 176</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Sebastien.Desprez@adaptimmune.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investor Relations:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Juli P. Miller, Ph.D. &mdash; Senior Director, Investor Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">T: +1 215 825 9310</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">M: +1 215 460 8920</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Juli.Miller@adaptimmune.com</U></P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>5
<FILENAME>tm204193d3_ex99-2.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;<IMG SRC="tm204193d3_ex99-2img01.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Adaptimmune Therapeutics plc Prices Public
Offering of American Depositary Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">PHILADELPHIA, Pa. and OXFORD, UK., January
22, 2020 &mdash; Adaptimmune Therapeutics plc (&ldquo;Adaptimmune&rdquo;)(Nasdaq: ADAP), a leader in T-cell therapy to treat cancer,
today announced the pricing of an underwritten public offering of 21,000,000 of its American Depositary Shares (&ldquo;ADSs&rdquo;)
at a price to the public of $4.00 per ADS. In connection with the offering, Adaptimmune has granted the underwriters a 30-day option
to purchase up to an additional 3,150,000 ADSs at the public offering price. The gross offering size for this offering is expected
to be approximately $84.0 million, excluding any exercise of the underwriters' option to purchase additional ADSs. All ADSs in
this offering are being sold by Adaptimmune with net proceeds to be used to advance the development of Adaptimmune&rsquo;s immunotherapies
into and through clinical trials as well as for other general corporate purposes. This offering is expected to close on or about
January 24, 2020, subject to customary closing conditions.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Cowen is acting as sole book-running manager
for the offering and Roth Capital Partners is acting as co-manager for the offering.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">A shelf registration statement on Form&nbsp;S-3
relating to the public offering of the ADSs described above was declared effective by the Securities and Exchange Commission (&ldquo;SEC&rdquo;)
on September 10, 2019. The offering was made only by means of a written prospectus and prospectus supplement that form a part of
the registration statement. A preliminary prospectus supplement relating to and describing the terms of the offering has been filed
with the SEC and is available on the SEC&rsquo;s web site at www.sec.gov. Copies of the final prospectus supplement and accompanying
prospectus relating to these securities may also be obtained by sending a request to: Cowen and Company, LLC, c/o Broadridge Financial
Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by email at PostSaleManualRequests@broadridge.com
or by telephone at (833) 297-2926.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">This press release does not constitute an
offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in
any state or other jurisdiction in which such offer, solicitation or sale is not permitted.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>For readers in the European Economic Area</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In any EEA Member State, this communication is only addressed
to and directed at qualified investors in that Member State within the meaning of the Prospectus Regulation. The term &ldquo;Prospectus
Regulation&rdquo; means Regulation (EU) 2017/1129.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>For readers in the United Kingdom</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">This communication, in so far as it constitutes
an invitation or inducement to enter into investment activity (within the meaning of s21 Financial Services and Markets Act 2000
as amended) in connection with the securities which are the subject of the offering described in this press release or otherwise,
is being directed only at (i) persons who are outside the United Kingdom; (ii) persons who have professional experience in matters
relating to investments who fall within Article 19(5) (Investment professionals) of the Financial Services and Markets Act 2000
(Financial Promotion) Order 2005 (the &ldquo;Order&rdquo;); (iii) certain high net worth companies and persons who fall within
Article 49(2)(a) to (d) (High net worth companies, unincorporated associations etc) of the Order; and/or (iv) any other person
to whom it may lawfully be communicated (all such persons in (i) to (iv) together being referred to as &ldquo;relevant persons&rdquo;).
The ADSs are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such ADSs will
be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this communication
or any of its contents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Adaptimmune</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Adaptimmune is a clinical-stage biopharmaceutical company focused
on the development of novel cancer immunotherapy products for people with cancer. The Company&rsquo;s unique SPEAR&reg; (Specific
Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple
solid tumors.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This release contains &ldquo;forward-looking statements&rdquo;
within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain
risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated
by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities
and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization
processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from
those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our
Quarterly Report on Form 10-Q filed with the SEC on November 6, 2019, and our other SEC filings. The forward-looking statements
contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update
such forward-looking statements to reflect subsequent events or circumstances.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Media Relations:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">S&eacute;bastien Desprez &mdash; VP, Communications and Investor
Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">T: +44 1235 430 583</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">M: +44 7718 453 176</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Sebastien.Desprez@adaptimmune.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investor Relations:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Juli P. Miller, Ph.D. &mdash; Senior Director, Investor Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">T: +1 215 825 9310</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">M: +1 215 460 8920</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Juli.Miller@adaptimmune.com</U></P>



<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>tm204193d3_ex99-1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm204193d3_ex99-1img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !  2D# 2(  A$! Q$!_\0
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M\K%BQ8_4FM&NV6(DK1INR1XZ@MV>7^(_" \+6L&NZ7<7,LUI,K/YKY^7_/\
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MK"SU.ZU&"$K=76!*^\G=CVS@5C":C&2?5%-7:*GB_P#Y%#5?^O9OY5P>K_\
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MV=%%5.I*H[R=Q)):(1E5U*L 5(P01P17G>I_"33;S5UNK2ZDL[9FW2P(N?\
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%OW58_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>tm204193d3_ex99-2img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm204193d3_ex99-2img01.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  ] 28# 2(  A$! Q$!_\0
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M;<YH ZVBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGMO#^O:%K&K>!(P;3PSXHTCQ'I7AS4;6W^+N@0S7FBW^B+ 8I(&#%=L\2+O
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MD_PG^/?B7X:^$CHWBGQ!H M_#NE7>M_9X+N.%U.IWRQ.0]^ 9)&P\>""1ZF
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M ,$8OV@/ASH,GQ__ .">O[3<)\+^#/VB[:_\,:%;:U<QV%OX=\=WFEZC\/\
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M=9TB;6M>U31AL;_A*;_7?#=W'?65Y)DZA_90MKB6!Y8K=X)FC8>O:?\ LB>
MK']KC4/VOXO$'BU_B#JW@BR^'UUHK7.F#PM+I=A:BPM[I[6/2H[O[:+==P9;
MQ%\WE0(\Q4L+QKP]E?#E'A[#5'7J8?A_Q)P$,>LK>7O,9<2YOPYC\)B9Q3DZ
MC=+!6E*<FZ'/&C.<F^9SBLOK5,;6Q-352QV"DM?LPP]I;ZZ2;2TL[72V/?/B
MB-WPQ^)1XY\">*F'/IX=U$U^5/\ P0H./V#M"Z<_$?QR/?\ X_+?.#]/;M7Z
M[:_I$'B'PSKNA74TUM:Z[HNIZ/<W%NUNEQ!;ZE9W%C-- ]Y:WUHLT44[/&UU
M97ENLB@S6L\0:)_GG]DO]EWP+^Q_\)+?X,_#O6_$^M^']/\ $&L^)S>^,KK3
M=0UY[OQ%>/<7L<LFBZ/X=M3:@V[1:>_V$-M XD$:J?B,OS/!X3@3BCAYJ3S+
M'9_E^885J-XK#8?'XI5>:2=HMU*\>6ZM)Z)W6OJUL/5GFE/$0^"AAY49*^K<
MYJ2MW^']3\V_^"V?&@?L8#L/VNO N/\ P%(_IFKWQ*&?^"XO[,H]?V4O%)_
MVWQ=8^G8_P#ZZ^_/VJ/V0_ '[6&G?"[3_'GB#Q=H%K\)?B%H7Q+T0>$+SP];
M2WVM:+$T-I;:LGB+PKXG6;3Y93'%<6\3PL\ D5YG8C;:UO\ 9/\  6O_ +5_
M@7]KJ^U[QBOQ"^'WPWO_ (8Z7H4%YI!\&7&CW+^))?ME[ ^A-K9U5&\9ZP(C
M9Z[8Z;(I7S-*=A(6^OR_CC(\#D65X%<_UVAPYXH9+B9*G)P]MFU'!U,/:2=I
M**IR57;V:<7)OF2/)Q.657.>(J6;GF6%J+57Y80Y6^_Q/3TT\_J+6A_Q)-7_
M -G2[XG\+63BOQ%_X(-''[.'Q:]/^%Y>)2?PM;?_ !K]P[J(7=C?6QEDM_M%
MM-;M/"(3-")H'C,L/VB*>#S(\[T$\$T.]5\V*1-R'Y(_9%_9!\ _L8>!M;^'
M_P -]<\5^(-(\3>-;_QE?2^+KO3IKFVU74M.L=-N8K(:3HEC"MF19!C&V!'N
MXD(3<?F<IS; X/@GBCAR=_KV=8CAG%X5I/2AD\L=CJEWLKUI4^6^LGS6VL>E
M7PU>IFN%Q%/X:.'JTYW?_/R:J?\ I*9^?_\ P7N4_P###L(4!C_PMWPBJ@\A
MCY?B @'V.X ^U>7_ +67BWP_\'/^"J/["'Q1\:W']D> M;^"I\$)X@EE6VT^
MQU;4-:\;:3YM].Y"06D2^,M$GN9F8+' &=B0N!^J?[8/[(_@+]L[X31?!SX@
MZYXM\/\ A]?$&C^(8]3\)WVEVVKM<:9%-)';QW6IVUW+% ^XEVC1+@]5;8GF
M12_M,_L??!?]K#X9V'PX^*^C:K?66BK]J\*^(-&OTL?$OAW4C:PVJZCI5_"@
MT^2\GCMHVNA>Q3Z?,57[5#]F+"OI\@XTR'+N'\FRNO32K5(^(V7YAB7E4<Q^
MK4_$7AS),EA5BYZ.5.EA(2E2C.G)0<ZBES<L7Y^)RVN\75Q#?[V;A4II/3]W
MT=K=6[-:IWMKJOH77/&7AGPKX8U+QAXCUO3M*\*:7IHUF^UNYG6'3;'2HK?[
M0]Z;I5*W,4D $H6,N91M10Q<!OYI?V"/'^G?%&Q_X+'?$;10(=!\;>%?&FM:
M%;QKFT;3KSPU\8IM(O;;T^W:/!+,#_=)'(S7W5X#_P"",?P?T:[T=/B1\<_C
MM\:OASX<O%O-&^%/BKQ9;VW@:Y$$RSPP:OIVC):"_ABV?9KJ%7A6> O'O7?Q
M]3_#+]@'X/\ PDNOVGV\*ZWXU2R_:LL=0TKQAIAF\+Q6?A/3+W2/$&CPP> 9
M;?P?'=6BVUIXCG8#7KKQ+:B6&*2[M;F(/!-T8#,.">%<LXIR[!YO5SS%9GA.
M&94J_P#8]3*Z6#_L;.,#F,Z$J=6K*I4E*&%E/VK2IQ<8486;BH1BL%FF.J8-
M5.6-.G_::EKK+GRNK&'EK-J*5[W=V]V>&?\ !%,!OV"/!,9XW^+O'ZY/3YO$
MLHY/_P!:N$_X+Q#9^PAJFQBK'XJ^ Y X?8RLTNN8(D_@*X#!^-I^;M7Z#_LN
M_LT>#/V3/A%I7P8^'NM>*=>\.:/JU_JEI>^-[O2[_5Q<:Y>^?<P^=HNBZ#:?
M8UD?$82Q)13*"S[P$SOVQOV4/ G[9'PANO@]\0]<\6^'O#=UK6EZ\^I>$;G1
M;'6_,T>9IUM[:ZUBSO1;QN<AG6)2,JY+JB8\O#<3Y72\6\-Q?6B_J,.)<)G6
M/;B_:/+*<JV.G%4[\S_VGE2UNUKHKVZ5AFLGP^$=^:&7Y;%KIS+#/[FM;^:/
MY_?VG/@/\)9/^"BGPCU#]JFUN],^ W[2WP9^'&G^'?%F@ZU_PC%IX=\9>%?
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M'C%=*U3PRSZLNFF%BBV#PMK8+,5^?=LCR%<DKZP_9Z_9Q^#_ .S#X#MOAO\
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MC1H-:OO ,FH:MKVD>([W7X]*U73;RV;2/"NK:5()% U5V5V7[+DA!7+,1\I
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MJU&.(I5O>;2<?K=.E4=X>]3;2NSZ/NEA2"[EP[L%\[9%&)'+JK/&B(P;>[$
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:+HQC&+>*G'D@ZLIJ<G&$>2"E&$7)0YY?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>adap-20200121.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.1d -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +K85w7xRiXgen8uNbXAsWaKMqbPtzp5xqekhuWh+bSmabycg500K7yYsMYiW4fcF -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:adap="http://adaptimmune.com/20200121" elementFormDefault="qualified" targetNamespace="http://adaptimmune.com/20200121">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://adaptimmune.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="adap-20200121_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="adap-20200121_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
    <import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>adap-20200121_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.1d -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>adap-20200121_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.1d -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://adaptimmune.com/role/Cover" xlink:href="adap-20200121.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://adaptimmune.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M\+L(6Z_-SOQCX[/@T,.ONQB^ %!+ P04    " #:BS90F5R<(Q &  "<)P
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MB.3X\7MF/2;/U'R;LUUTG\*],YM79O51ID7RL&4FQ&%$T 6"S(C$U)X%*"I
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M6([-Z#C1HI\:[63N]LO_4$L#!!0    ( -J+-E#G:X*&C (  '4&   4
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M)J$)<IQHNS"BL2P$$8WR1BUX:S2?-:PS%L/35B#E2SC"K\T5]]B0F/.Q#L=
M@HK5]*M>S'A<T0G\1[;(?:"]OXF66'$Q^&'PJ]&S_VTP",\.&C'._MAL]3T[
MMU9.[Z5HM8*XEM\63&XL6&1\K4,ZX\2KYPLWI?( .$HNX%!41^2[X_8,(ZZW
M:6QNU9S^AYK_]CZWH,%Q>13MK_Z_O,M_HI@MW7-HT:L&W5!2#D*BT(O&3M0U
M1'GAA<SIE_#PRJL^V?O4TR,O_0-^Q>_GUM#P0>)S6/$<S.EN?PHO3?*P99TW
MBISN]F>HQ:#>S@7WOT3Q U!+ P04    " #;BS90, /WOC<!   B @  #P
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M1TKM05\-_\GR"U!+ 0(4 Q0    ( -J+-E ?(\\#P    !,"   +
M      "  0    !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( -J+-E GZ(<.@@
M +$    0              "  >D   !D;V-0<F]P<R]A<' N>&UL4$L! A0#
M%     @ VHLV4 A:F%?N    *P(  !$              ( !F0$  &1O8U!R
M;W!S+V-O<F4N>&UL4$L! A0#%     @ VHLV4)E<G",0!@  G"<  !,
M         ( !M@(  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " #:
MBS90]A ;3ZD"  #Y"P  &               @ 'W"   >&PO=V]R:W-H965T
M<R]S:&5E=#$N>&UL4$L! A0#%     @ VHLV4.=K@H:, @  =08  !0
M         ( !U@L  'AL+W-H87)E9%-T<FEN9W,N>&UL4$L! A0#%     @
MVXLV4+JA.8K7 0  ,@8   T              ( !E X  'AL+W-T>6QE<RYX
M;6Q02P$"% ,4    " #;BS90, /WOC<!   B @  #P              @ &6
M$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ VXLV4/_ )@B]    A0(
M !H              ( !^A$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L! A0#%     @ VXLV4 N/V ,A 0  5P0  !,              ( ![Q(
J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      H "@"  @  010

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>13
<FILENAME>0001104659-20-005985-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-20-005985-xbrl.zip
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M(T/OZ\%((\_NV\"70 =PC X5[B6 +<PN+D\*'C,IYFASG*:#]_,L)_ \$SM
M\3+Z#H$9Z8%D<'6%SR8X/OY(MV"35^@1X\J$3-@J 7M&;N ,)^=X/JU:O@=9
MH>,"EQ24& XF&!P*&J%.3[RK*S#S_D&N(NXG%29V8&@L,=FG"9!!-U5$'&Z/
M&>,#HMQZ7#R=P]4+3[O@?K].ODRB79+A\1)2+I?S<KF\N;F]'ML>*336L5#/
M/3]N4$'HLC%&#\.U 97"G-45J83"E:K<],7,V6>\IJ PE*)P!BC-(BB(Z]NV
MP8G$X@"?;(&!?+SP]P^1< .89T<[(3,<$591/0\")& $,AA#5SS^W],5'<Q.
M@M@"+8#OTPS/4P5-=>X1HH=3"1^ >>"CA3@TYJJ.;L=W:J*3=><3]-6'H21.
M&..*"M V2B",'!H3U!9(<L26#68MD)]1/.-TX%@#D[0Q3!>>'B**T]-+@&A0
M3D6@[P9$9##3(""(:>$"!K7XY,UHIIJ,'/F$)$I04:3&)P#='0<H<5:/>4PV
M@<4AYP6GN[H!37CP'PT6@^N-L $V5T9)B20X@RG(1J)@/F&:O*DC_"M58/I:
M9@DZ/8G[<Q+HG90$^H('&2U\;(3[MBGR^SB/>&XLA;EQ?)[EB9Z&J1 _U0$V
MQ#!XIZ9I^:;*LPTQG\;V:@2&&4T[0IT#.!"!N+SBY4V M*;3]!B:8,+0^><)
M! 7,O6P]2NU<E@0-!@G14[;_<TFU&CA ^" '#3:@.Y^>@N29ASL.RS;'U17A
M+G_A99[%ZI#R1QWR#>N0?W#)L9KB,8^B-9E.."V)C" TOM^QTIBKXT.;8B/X
MS<Z8O%XWR"_S\RHMG>>S,G9)A4$;)##9N[U2MG,EMFW].!F'R=@ZH.KU.[(6
MVZ)6*FR++:^4B(?8>GVY5)&J9:W\P(927BKTO'ZD;/R9$P ,2P2U,#;/U2&3
MV"O2V<_R*!6D^/;A!;:#_A!)675,C<_@TTL#BBAM*,P;8$XY<Z5 E VR*O?\
MR6*QTCV9J-S?9E;N"Q$3ER/D]/V$KQ%!O.F22$J7ZN9B4MU,4[0?UZD%L5\L
MF'1^R'$>)^7R3Q5D<UP(G%T]6$O4?&-9_?K_L(RKU<6XC/G56PAY4?R7/!V\
M#C+-"<<O16M#_\-BE!<4H_Q&8EP(_TPQRJEB?-_8]#U^_D2UE$J5[Z>G:0%2
M7L00;IN*50/^L%?^&*XU7#S0M*#8&JS8M?G[@PB^0(AHP<-3U[,>@K6<0W-2
M87QF#-=-$5)^<Z=03I8AW@GA(I6@\D<EZ TK0>^N%'.>@_IF#\0)HR7^8IHW
MW/(E3F!^E%#F_7R44#Y**!\EE#\A</HHH7S(\:.$\CO+^*.$\J>(\:.$,NOG
MSU2&C\+%KUFXJ/SFA8N/&L54)M=I?SIOW-Q>MSKO\U3H]SJ@-L'7X+E3DX=Q
M''Q!MA-LGUGPB03)\Q$3SU7 /=.:;XR(2GV79TTZ/VF&+\H"G'A6 *C$DT)B
M;Z[">M3HAH<#^$Y8T6"#[Y?S3<]:7>$ J>_U+$?_QK1WV1CSZSU/:?S.GJFG
MFN"4 %#P3/5^KCS[W5#D5?/5;*0SJ)!?.3$F$66^]9![*YS*:E/Q1?+I+_.A
M'(QJ09=9HUC,QZ>=TX_C*KI%?/C*(W681SXS$\A^W7M1$NR9J-ILEB;?8I/R
M!IOY32I_S1L%?R/ZQ '^+&#EN="6QX_Y>CF'%/Z$IBQMF-.W&6[;1<<)PP&5
MG//ND\DY./,AA%/N:49HLKE++G@]TJV14^IZOTZD,C^(>"4;>.>B8FDCSEA(
M3XQZDCD=!I1S;<67%NV2]B'_\%#:.7C@CP,19U<Y(;P?.QX>/6FED\%3XZQW
M7WW<'AYLG2IG2M'?[EBW%VK[^;(E;Q\?G7S9/N]<O'3;Q?X7Z;$T/&@=C[[9
MZM.P=?#LG;>E,WOPY?JJ\EDYM^G%?Z^:WW9Z5N>E<Z&=2L>#LYWF:=7:^MN]
ME[8&U;/1S:75OVM9G7+QQ?RL>>ZMW?AF*</[@Z?SJ]NMF]+5C?QE>+13O;\Y
M^_*W9IE'_Y5.CBX/S*^&\72[/?Q:K YN6SLCZ72T93<O1M*7JX[>.KT?R?_7
MOK^^.7SRM[]>W8VDYPMF-QOWVD'G^,EW[KK]8T^2SIJCH7MORM?;5:W8.-AT
M-X]/KO;W!4O^'U!+ P04    " #;BS90<#\_N[F\   GBP0 %    '1M,C T
M,3DS9#-?97@Q+3$N:'1M[+UK<]M(LC;XG1'\#]C9?2>D"-@MR9>^N-<1\J5[
MO*_;]OIR9N<C2((2VB3  4#)FE^_>:W* @H49<MM:\03<:8MD@ *55E9>7GR
MR5__\?Z/EX_'HU__\?SX&?PWP?_[]?V+]R^?/_[U!_XO?/N#?/WKD]?/_I6\
M>_^OE\__[[_-J[+])3D\6+7)^V*9-\FK_#QY6RVS,N4/TN1=7A?SO\&%<.D;
MO6Z9U2=%^4MR\+?'?R\GS>K1KS^\Z?RDS3^U=[)%<0(_JXN3T_918J[Z];?7
MK][;4=QIBO_D/!3X]LGCYY].BTG1)H=W#W_]X0F\"%[PN/^8+4:R[4N: <)/
M#QXE]A6F>=GF=6?@](.VSLIF7M7+7Y+U:I77TZS)Z16.9]FJ+9;+=9F/1^]/
M\SI;Y>NVF#;):C'=^%+7.N*_9%KVLF2UGBR*:;(HED6;SY)IM5QEY452U2=9
M"6L[2];E+*_'H_8T3Q;9>9-4\^1Y>;+(REF"___/;)$W^_\-DW%TF!X<'.#_
M)\=+N&J:E<FS?%4U19O5%\F[TZS.F_^&%WV;K^!-X(^B/($U3(Y/3NK\)&MS
M6-O_AO<[/'KH5O)U/2O*_Z[E^_7#XP^OGCU_^\^W+]Z_>/5[<OS[V^?/_WC^
MZOVO/WRX85KI;X^?@=C-?DG^GZQ<XRH=':7)T<'1P34^(1QR>--)58-RN]-6
MJU^2)XML^C$YA(N::E','B7RY:1JVVH9^?Y:)I;.V*\L.'_A,]S=_X\[=Y+?
MBGP!:_LF.\D?P2W^O<[+*1H+R9T[8O#\^NS%_X0F :_%X='*&1YN 1[B9YL7
M!0;0-S%6P;O_^@,\,_+X%8SRSJ3.LX]W)CG8!3#0;'&>731N'#2RAY&!X6BO
M^F0S/S_@!/&<W,BEOZJ-=8F!M3.N=L;5#7[1G7'U;5YO4BUFU_6D(?/JZS_Y
MKSBCOYJM]5<</7][_+0ZSTO2CD]9G:;)RY=/K_$!#W[^.7F9?X+]VU:P?\_R
M<IU?V^WI?Q_\=/<!VA$T704< 7BK._SIWQ[CC?Y5U1_3Y-6_X $'1T?7^_2#
MNP^*LOMP^O!OC[,F<0HL:XLSU%H)GDY-?@8']6(\^H GUGD-YUE]?1O>C^LK
M",S+;%; SU%B?H?76N3+O/SEJSD8U[R+_EPW;3&_Z"R73)6QI!)K2(U'8$FE
MR;;V1[+1_$CV\.N_+V;_7E>/9,O]O::_]E.X93DOZF63%"U,,1QU.+OM>'1>
MM*=)?*LF>^YF\+7>BGZ69]-3E;@*_J?F 8JX)66VA#$79?)N>IK/UHL\.4[@
M1WE;)7O3:K'(IRBRBXN4+2IYC)785!Z7G)\6\"CX:)DTI]EB <9^4\&MIXOU
M+$]PDLR3DV8]@65HUSB)L$7PF7#PS?&K55V=%3,9%@Z@*ED@#@_&(_QA-8=I
M B,8'EDM94H*F*LI6PA-4H<;;@]NU*QA<--LE4V+%B;-O$RX._TZT'S#-RL8
M0H+S4>SC9>-1T33K#/PNFM\&%C297- -94GH<_Q[M:ZGIV"@Z_?!M.EP10TL
M^+*R:I,_JP+V% Q2EDW&@&]2KI<3N'@\@J^&C3Z]4,>CTG'\[%WCWX\D S[R
MLX7#>9B4L*<J-4,:NF&:K+(Z.<L6:YBU507K^.C@[L'!(>P*7$K\33KTT(Y%
MXX2SR5M<0YAC(WV\SDX$<4;V"I[WY 1<G[8SU2"5U9=,;;5"Z4IF>3.MBTE$
MY([V)OL)RQS*@%M1E&\00!H"S$V+-[R7'CY@*RZ;S0J\1[; "6[NHBI),G2!
MFZR8)=9RAZ\#=?"BA"OA.AC%&EZG,#,&SY]XH9K)5(3G![VI'URB8\,G^/'1
M4V$'_BFB?<E4)'86[&!?TS7C462PL-:RJ6'7@1Z9H6(S^L3N0'_Y754F.&$H
MB!WI\;+JWM_,U'C4>VKP&+J%/N);G"[;I(C<#;YL.)TGXWS2JI\7(!P@1CFJ
M6%!B-(U.E<R<*AF/ZGR:%ZLV%,_C9V^[ HGJ$&X#<HEJD>0ITQOY\RN985@R
M^2.[2 X/T4H^?(!/)G%=5K!9S:Y.DZ>PGI.L_ C'SJN[QW=35.I^;,&(O/;S
MJDT5\"GX$;@IYC6<$W"LYR3L^%_9$O@Z.A6H,6B*Y(7PL,PEFA!Y(+BA\FKZ
MW+O7+5+?E?2H7J<9:5J8X@:F*&M[ZA<48EW!%-%D+[./N;>:JOD<G@GS+-/O
MMRXN<%.!JLD:^J9C,L]@IN$WL[.BR28+U*4M&5F%L9!".>TN#E@.<.M)#J9"
M_@D>2W8'B,DL7\ #ZGSVK5;O6A^R3;#X:!<L_OK!XK]D\;<Y<NS6Q1TP+^!4
M%&>BNP5A.SS_!,9%>4+7+$$1XNG?\5;D8W_2@P&8+^9P-)\435MG9#& @FAY
M5ZHE]5L%CL&[._?XK[U7U=WQZ-Z]>W>.[MU[\.!'\GO.6#FPZ1PJ#&=J@^:8
MYG6;H4GOAIZ*FZ%7OS/?>'_,O.KQ%*VB\>CPYWOWZ' !-ZA$E\.^*WZ)O^R?
M*_5Z(?,%+[U>T"LWZ+<LUXL3.N?\X1&])>@W=YV[/:P*N5 ;I]-IL5D^78 ]
M QX>S!%[!]XVEC6ZF[Q#MR=^*WIOF$Z4##P3X?G+/"L;=I4&'F^FBDYOL#"K
MIKWCQT#?XD\;G@,\<"N^)3VDLU(YHUMH,L%\@_LUX@KXZ^&,,=?C5;-JNN9G
MP-VJ>E75F1B$=0X"@WJ.KP8IL5<'1LH+>"70'3 %7D#!E%4)]7+C%DV7WS^>
M/.KSHN$3"M>=3**,[>Y63&:>Y_@HWJ+/??_>P1.;N(B)B7.HW!6A7!8-OWS-
MH]"W;T)7URSJ.UW41VITJ^,-DG *3C5LQ]0?\1MOX6( H%:J=6N7 :U!>NNK
M"-=XM+5T9<[=M8;=O  ;!4,I\!3:ZZP],&C051 2M\"+.6X!"P@7-C 3-8[$
MO#QZ)'XP:-'JB^OZ#KQ9-Y;044?X-2P6?HJS)!82R! 8-]GJ%.S/^?[>T3Y^
MZ%9_TTZ*;:)0!C?N(Y@D$6?[,:W)%^ZOY,NV%[G[G[F_[B;/,> !9B7&[LBG
M!'FG%5DWR;IACQ<6OA2GUQV1QFIE:7@W>/!<13%][ER-1S!9*3G8UJ,>V/V9
MRF[\Q9W#_08.KU6+H1(RK=E&QFDP1O(%[ZX"3'QG7Z=!T(>\2WC2"D>'5Z*Y
M 6.8%Q@+,?,-@\DH1M/?##CN*4S>C&)L;A5(.36D"7$=>%V/[F-D(B)+PXJ3
M+G$N6W)<7@QM6C*5(L+T$,,A%((;?&31#(<AS$V2S=H4)C"5]2#AA@'!E/&,
M8YP5;-FMM#*K-8W$DGMUZ1@X9M5=-Y1WUJ\HH*1DQZ/YNBX+,%IF22081RH7
M=M<6FZNGF;?<6QBJN*[-E5QE;YE%?=/;4>,1/ ?'@:YPHSLG,1L'%\6-O-')
MBR]'RJ=A= ^S0/@1N,"D.RWQDV:]6BU8L"FR>N&.2G"V3BJ*E^KQYXT9*S33
M:G4AF\(MGW$3[)3C.?0<IZ^NRF(Z'CW+VBSY/</5(0D^!K&Z: H^K-[F;5WD
M9R!HS46#:Z4;]OFSWX_??K7HRI<$[/Z"1)0_DT*YN;X\V[>;AU[2=*LQ2&0'
MQ+B88A1H/,)'J))C\_+'7^X=),=W_[B;)IKTQ6"B>#C@C/9PD;PW,$E&V3$R
M(#()*\V&,CMA>.KZ1//S)N;[69S?\Y)SVL^*9KJHFC4HTC?9]&-VTEDGG,P7
M&&>M$[DF^0"'Q&\PZ<D_4?^#.O(:+7=!V8QTV:HNT)!GA>D%@MXJY:3($AR'
M!$/8H) &;#YR;6!KS5#?%A,*"9+*.\N;MJJ;C8]QHE"4>!:RNA9M"18T)D4T
MH_KDSJ$DM%CG>^<"[GV2H]CM)$@EB(4"#L^X)/2E2*XK6)CF>-FY7&:.2&=2
M81X!K!K6K.(<W$LVV'+@?(6.]SWO=WL#11U?P@5D8CB[P0V,2@>U%QO5P0,9
M%4>I+K%J#Q[HJ/8WV=8J\IC+KO-_KXO:Q2P&#W;R^X+L#*5DG6-15QDXG*?5
MN;M[1N_:YFCQ(90"MDWK(X8#WJ[.[MYL?^^G?1@@>N:T.<#4KBE[N^V(4]01
M,$@8)?@QX-9P HC-YTMM%SN0!S@0F(!\FI$-RR&%K$#9DU0IITW["0T8@B:9
MU<2E^9E5\"6_S7Q!X0!G9Z--SR8VY>81VROV-AC9;' OV#W?=B;@MW"_^>#L
MA?8\J*A,A= L^-_K!M>MH90@^&5-?+I.KM%$^V_18EN<;8/GXL#OW2XKRI8#
ML>AAG<B#W%F&B]]6E(MSZ!%_LNV)L7.:E7XC__KB\:0JT5F?Y;_^\.)QDCL+
M/G&;_#)-:J/=3^!NH,GA=L89@)F'6[V#6SF-19'H("&-_L,D)Y\$!E_,BPY(
MZ<F=(SE2=S*W5=+OWJ.$P1K-+S@4 78\2OX',3U_64ZPC\\-LWL'D4=0%N^2
M*EGSXOK*CY+W%ROXQ7&=38KIH^05.,,\+:\J?-FC( 6H5^$WIE[BOSU9>6-%
MOJ-F7PH:\VNH63PZ04M>XJR,1R8"]%^EDJ[PY'?/G[Y_\?I5<GBWOU_GV;)8
M7/QRV:-[>YO?YJK_BV7^O(L_/+:^>E4V L.M$4U88(7%A\>W++2TE^U_Z_6Y
MVAJ^N&0-.U$:M%TX?*UA&X<:Y"O/^4H*N9*E;0+6/I\X'F&"3V"/Z6"H(7FZ
MJ!K4'105L*[<)%]4YXS"QD$\XXJEY)DF4_J_Y4PNA9XX*3@>=<='MM*\6L#/
MFUL;"@2G["9(L-5!L: ^K;:-<I$R"B1WF>><ZU;WC3,@FE0!<=)L1B0+=G<\
M>F[@_QL&L2G5[E+(##T!ESXW2?#(4Q.PL,#-6"5D%XY'S1I>L/2):KVVS)OF
MDK$IBGF[H5$9 (4)HQG3LN(183SP3.#N%/P-AB?3.IQN201#8&R%[N,9;H[7
M3/,<[]R0 ^^S+HB.=*FATPRQ.W1YZ6HB\-<U_$A&AGZ\A',Z7GGRL:S.P94_
MR:ET!"9NM<#$6"A',,+Q"(M5%H5&"DBSH%2!3YCL%?3*^P*5#8,(-'0/:3<1
MS_\N4^>SQF!VV'CTA5LL301LHU 6](/#_4*W:GGQ)$WG?B G5@QL$J1DH_@(
M@9ALSJ6GB9,A3($N%C"!<$LL6) '-@9;&*BL;HA5X^>QQVS$:O32G3J[;CHI
M8&CSG;'9I1D\5T1D/(QXZ<LFT7?M8P,^^V7=E>9]'61Y*-\^'@TFW(O&AR/Q
MY;&(2BH",/S2@G6ST-OZ\ _5T!#UP!+CNECVMBH47 3ONB%V;&6-\KEIDG^:
MYBLGF;"E*$>3UW)O,.;\[,#)]GZG9 C%Z_ /X]$ 6DOJ,0:11Q+6O3K"("*%
MA%;-Z887:!5D@56 !X;9:_2C<Q@%?H$RPZ 6/."VV7UDLQ>4.8-/+F0WCD=;
M;L=(<-[!G!D(C/OR_B8<\'V+ ];9&(_B.&!?"*<':*!4Z5[1!\10P3OA?XSI
MIN_;W/>&_O$49 S$TF; V:I_E1<2<Q^T=DLQ$>-V06 +")Y!-EG@@M+>8RQU
MU^5,-7W%Y7B2R=(S0#[ :->Z;.MU;E'\8![ZXV].F-HZJ5AEI_0/?R/\BZ":
M='WOPDXBBGXT<\@MS/7E4S!U4 5I!1&^I!M,XWZ+L3G88XL\0R/Y;G+L-E\7
M)8+6?TESL7?,Y:0:R>LC%;CL],D^K07(8G%6S-;P2PD!;A%LI-1E&:*()=/O
M5=3P %(')'#_\I/K"ZJONDI@EO26*1E<);\(M"BDP#:NALLE+I"F0A=B6M1P
M;&&]V!0+-%D3"N3:G0K+;$8K%*ZFW3'&_.GODJBUAU7?FIWGDTWO "=7G2%Y
MTKZ60."LH.G<L[_QPBNEC0E=NF%?,C"OOR^_RH)'MB7E!/^Z!4^BZXTG=VS!
M RMG")+^A48.G=N7[/V.I=,U98;4=\P*(CU \+(A\RT8/.V&#2:1@$X)&;#,
MT/ 250,FE4<3&70M_1E"E!C#OF%^-JG&7NPC/J99,9/$B5AN^(<(,AY-5Y'D
M817U>0>)R/_&DV1G=&V35+Y_B_/']W;YXQLLW>_)10QR2JB67&I(ZE H7H),
M-1)$88 \*;85.J*JF?3 $I75<)F*"Z4.G!=[74.&-#/:+OM7U\/]N\7-HGTR
MMG"LZ.E3B<UZ)64^>#8@^U"%H9@+/D44R6?/D%[!AT:9I6C/IM/:T[I:GYQ&
M4--)_@G_;& >-9TAVOCNY;43=+B5% OPXVHJ,S17S$"'4X76" >SBQ.<2#0
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MA#R(PR72H5B2:]I$MK*>-QYOV0F2+C!6F'(7V,H[TH;VD8*#E4W S]-XY"F
M]':K[,*7><T1_JN\/GC4*WW/'*S<B6]8+@VRP]HCBBF&!F8WOG&-V;E]20IQ
MUVMM;ET[;B$7H4"KML;D))BD)P@?0/ND%G,6HY-4IX<:L77O:C'63=)WBO30
M%H,VR,&:?.G&\,X7ILC\H*89$S3[/L,!O3R)5R+[TI1V>?1\YX+A_O!R]<[@
M0)7\_>IDPRHCFE,$KE</J3';(.HWY&"D PV002FX3I(9:V?Z<U*PB^0:+>,
M@K9O.T$B0?H>)6FS#+F#J2]*D:^(,"YVDF..B@M/0LDA10T_CTI0Z++FF&J=
MYAI(ZJ;VJ?B&NV. FO\SGW(1!\7%Y<)B ><S%;U@X_AZO6JGA(!J$/U2XK_A
M.#&Q+<X%Z'&O)X+V4=  "MTUZ*B">4*N%(&_I[!O"NRHH, D,1LD.*5W$[B2
M1_T\(GP\H][I+>5 -JIZP"QP9\A,E@=^]UJSD.^<5>1RC%*U&(=+4++7=U6,
M2T3*OC,]7&T*EH*X$2?@HX;Z(&) "_.E9;9DOD!YB3J7\BUF1]+[(@-AN_!V
MDTRG;P)A83IR&/<&[),:?1'6;VAJR4&'X;BJ]V&>1QF/:?GBV0^WK&6]S#I@
M@0S-@YUF1<WZO=3VV!1JH$Y)DKKVFF,;]"K5=F*BX*?:NRZ&%U)Y&BY>+AD:
M]J@(0Z7:)--NZ9>QO_83A3UG(S 0V =3_VK3G3INB9)#"9I!D'=YB^,&7:3(
M'-4#$;5"?B$H+' ,_0:W3E0;3K 42\EQH3/QN2Z?8_@-73[_N&TT"'YAX(#^
M5!'&LFT5R>>FD9F'RJJP;?6>ZF%=,)=4P46NA;"+"LZTU+4!A;_37J"]OA?E
MU5=A@72]I15VJLI[VWJ4"W3)7*+[96 ?$2T[LES[S42()G_ND](B/15JDDUL
M$![5%[L/_A?V:Q?;%:&#WZ2\.-/4)4\F$!2CV81!.8(+TW=GD@BGK'F+?HWX
MR6Z/;94U^/$69PT>[K(&-UBZX03Y7@(+@?T[:7(QO/Y'X^KPV&?Y/%LO' ^6
ML +U&9!5,Y<![#9,Q6*?TN/](')/@0,JZ@%/E[KA3"[NL._.R6<P'%F#>T<?
MBU2$)(B@PGC#&0]3[2Q!T[$E"?H=WJT^4[N2AN<@=F!\9=XSGE9G>9GQD>'
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MV JA7BJ"^!Y[=!(.(E;P;"_<HKZ!-5Z)7C9C"?"=F5M# N0P2T%!.6BY51
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M/Y']7A>\=ZM21%=3+MQ/QRDH22.P5Q8V/9*=XO:7[ZM1E+KG03AA.1=YQI;
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MGV1:'B^(I1EX;A55TNS9AP2E*+'LC@B]-7I[9317;\UW;R_?'X\T+FYUB2<
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MHDTE,X1 ^U]\#DW+909[OZ;LEIUQ-["_PA-$^-^98=1Z@R;XK+#'QMT.GM.
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M<_$XZIYJ&MH. NMY#8N*3^] Z!5^+B.JM!7VM")D+SQ/AP''O><."F2@FDH
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M!D[1@>Q.S;VLJ4-$X?!;B(9IO5]?)QQTM:CZ@Q.FAL5P^Z+M[#FPJ\O;.2$
M.TW-KI5[@(V/62>-S@WAP*0M=KMM+9*L6,&'8:Q ^_-+.*G P1,2@$ Q+1!9
MQ=!BB(AB%+H1LP)<A;!T%^(5ZSU@'^6:2,4Y;P-%!LYGE?F:.0=[DV]#)<WL
M)_B*Z@&ID80L!(DHX/H_D"4@QMF"*=I#<Q3=>7H<F8B*J![?FL\^@Y]N/5K(
M3-2S?3E(^6PG@@R"$L9)9M/5.EZ]\ND*W@6I*WIY41HWW$ZI +&WS5!+V+'%
M8.#$2\;20!'.XH0@J*C+BFWM:W[T,$7 '=L/TO/%]'\VOG^NX=F?7O,\T..F
M2GANOK"$Y_9*ZS7=^5+/S"<]-"<<E$SFHX^AGN&"+IT9%$P.D%8"^:J14%DX
M-.2[/AIKW81.0KR_(N$@SND B9)T<%>SCE&HR?+UQ(:;U9$MVM4YL;4[UXOZ
MXO6"<RI)Y1N-<!XNOJ(9(U)(J7NI%WEZQ?S8XOWH\NWX<E%,YZ>**\S4S),\
MH[1P[=*ZT[%#H08*.JK6<NGMHIM4K[>8&VN:Q.SO3GP%&<\^_-9LM#;+M,(L
MI&Y""&8FERU-+&)DVJ01YSV8:4U?HJC7X/O$1$B,@;T@2HELD;[WOQPOD:\T
M&V8O*,^NY&PI[])$76B41F$H)X\L'O;R>!)@MR'+S$4:#"]K2<&,YXD>':9N
M5)3=D$\D1:Z#-AD'B95RZ@><YZ&/O8X@!+BJ;\$V<_1S_OR[1]WB9\%/ON4O
M@VZ077ZP0GH4[?PLJ;?]F*#*X7*/N&K9[LI\M9/K]R71&*8<=E ;Q]Z@M6D^
M\#3A*51N0&CL.O90NU]+&X41Y"9O8N_&/6P")@NV'^9F.]1N#8N]&"V[-+R*
MPFM68)@7XMRPJDO(:SE]>3_@U2JI;%\_CGS8./[\9/2P4Z9E402.R$R(LXF!
M$8:P<B(<G*%$@K2^0W1I)1QL/KL<G*"2VRV^\FUKCYA.B)AVZ4R8E$O'* BX
MDU[V8\33LF3H%V$*JOR+3IA0_[;!;(JI_+ZQQG^E0 R(;QH4796V]W6Z!)%W
M?3JG4HJ@)JFS]4T<8)GM6@QB%E+-\'G_\&1;-YZ[B[AMYOH GFD8BN,$3=E(
M*!IX>&Z9"H57KY"1J</TW#Z\.WBY64BV-5'&I99:]DN)'<0E"SO8+HI4$4PQ
M.*:L0<LG2^R%'7PZ3[H<Q;H@GD&TR4,D+J6(&$V3XU DYWE 8:EJ&0^\1BPP
M:CKO>[MPC"E#L^70IA$?*XB+IDGG,')\:27S?5-W1;!XEAC<M<I1_:443^2"
MA/&\\A/CB>-*P&[T'!S+J-F8SC0R^LZMUZ \3]#74X-Y?^(")@K=?E2W>W0Y
MF;5_FHWZ#335](K[8)/SFGPQ/2U)]5&$M[B(KH3Q1I.@-QL$#$CO@?5BJ/$3
MU'ZP(CU0;KF^D<4M%W@8.J/R5Y^56B_ &#41]@Z#$8UN[PK_7:(D1(_T3Q1K
MT,;64K"\]/,J6B8W<OS;+XN"(:VFXN D4IAB$)T:#6AFQ,G$J>[#40RO0*2J
M> 7H2?"'4EH5LA:$&I[R Z0SL7@HKX1]JJD"FT_6#O#X'N]WD">JZ<LO @PP
M=4.,D?20N27#TR():,1<R6=Q#C4;L")P/3,/.>3,@1U)-W1"MP_AD*#P05)3
M4]=LC#]]T/16Z<^E:'D:_Y7SF/B)%A5;4GA5\<\ZC=IL=&!L\$ONJ^6YBM"B
ME_.,X$;1(+\,49-T\!C&NJ6",60H$*4RLK@)B]PZ=#DU$^@24ZS1I4RN4"JR
MK&.(C(>+NE?&FM6(-7L>(&29DK*L)&:93))5)3$N(T.592:W V>G4SI!EDG*
M.YQ+N7D+67DAF*VK*.D[^1H]?=K=GV@&/?UA_)3)E*W)R91'(@5\^F1*^S69
M,O]FY (D4\87,#0;LZM@8!]2/'%]DF-ID#IR2:L[=(%P3IZ'^376 9=?B0XM
M*DUEQ"Y=%"H?DH>*):C>DD4-+T6IG+PW1<;7 9CB]-+*)E()I.L(\_X9O'^&
MI8O+7"- 'I\SI)S<63Q9;)?4A(PMUTW7]=3&F*UP@+..8#==QYP"$D?S6@P+
M^ZWYKV,&*%514A1A'B1&GO6)5<ZK3#!P(R::.V0NE5^!8<MK[J9>EY=FS)2Q
MS>7:];8)KR;RZ4_3Q]9)3Y<!JS;"U0?ZTA -)'3D6&K J!^ /R=%ODYQKM.N
MA-=257K$I426#::6'DO\H^R2TTN6:/B.=&G?9VL*AUI=_'957UW;L-5LH$&N
M&R;0"4[3\"KID*5)[YCGN@9>-B5H2.=]Y0'* 0";.LUO#(&",]-QZG]V<((8
M%AQL\I$S^;H4V;YS=8WLV)^ZOW?S[6$2$.&>ZS;[TB4FP;]37>V_0P_7")2B
M&\2:#F Z2,L6N;@J)"]FYB96-S4;-6%6\C'DV]BN$F:Y2H<,T1W)I;6)I&;<
M"LHY0)J)*M0L^$?P1 J:OP A".T&+ G6T227WM]7_L\M!H>-@>,&" <T<3.A
M(-"^&0X1=1*^;1-D'ASLX&F.T0^[J>>"E"JZ86%Z%7&DB=X$O,G:K?-V\M;A
M(4RS=SC57/-8KO\U8@<**\:6/,U=84<Q:H=3#GY.M955(XPI/\[)).G!L[F?
M<<S6O1+E9Z*Z. DC6TW1NR[:B?3H)?BUW2=2+V/:.5 @JNU?=>%$W"].6/3&
M? _'52679"OV&(17%(0D3JA1=/;UP7:%O8Y)HEB;"2!CD*TO"5Z)HN;\F+3S
MTNRI5+)M7W'N:'80/_,@S6,HS0U"K^^ #=0O$:N^?'*GA-7BK1AQC,(Q9JVR
MBVH\A(FM *QY=/I)LFDR;$LR;-5^@D1O&^T-9/'1HQL$W;"D@%5:53ZE8#7F
M7).N>2 2&-GW6U+!;Q#XD/'CW"<NO5M>_N"-&33-^3YV@*3>&(S7RILT&QLP
M+_=_#QGD^OI2EP;(&Z?D<(/3FN4)]G_A,F5%)C7XTF.M%C:6;NZ;MO<DN9&(
M-(]JBRB7QGA=9)/2RTL+9XT0J?@VC7L(MD2H8[CF+>@K!:<FI'47$\W4[#IT
MNHM&=:ODJ*)*+:19(JO1%.;3F%$9V27Z)*7"%1B,\= CE0XA#QB#"+4M$#9P
MA]I73GR_IJ]@YKC:<Z/43DT[-EF>"9P%"?6"7%.:L!>E T()&"4%1=!].[&'
M[@,+A&0GE9B('9?Q1I?4-Y&,X2[!S78!/@7#(N FPK*?F$UIC-)W@H+J2(0-
MK1^!1.(F"O+9\24_2C#\'B'PMS>072Y*"'Q]H4/@4TGI=%QTW_=WS[[\_0WQ
M>-]U5#?QF8YG7((O,FM=F<IK3>AOQS!]J3^W5LL7U!(43#I31<N;GE==BR@0
M$W3VT^DR/H)I7#E]F_,055FSH0]X2M9+C4^ 5EN>%J$5M<0#U%0C]P(^@1,3
M&>*ZK_(UI3(BNL@42&+I@"X[XL:R'QS?M=IAU<7H!<#AUP\#/" MHB6;9JF\
M!28N_FW("Q=0?-O3B^]XK\[JD;;3Q?BFKLB-;B]SS88(73PJ76:$BJ2,C,>)
MTJ41.?J47)$!=Z*T4PPP;8-V 1NANC=T!.9&"EL([7._+)WPT%<!?6@!79]>
M0*M-^QA&[%+L.%6Z= =$ETB:2#A5MSWG@.CG[/:JD9NV!A&7J]<KR8>65O+E
M6%R].FE=?5I1O;.]<9/D36.ROIMLLFXLBLFZL9@FZPVS^3"NU3@\WH<B,WI,
M/-Y'><@TH+__\)X!XN]]3VGD(IUJ:#06JI;&D,=O7C$<ABEF2!_R%)]P@//Q
M7DFN*(Y5;FIY\W%C5?(A4QWTU?O9A-$B+*?.'9^K>3;UPL_WZK9FM[S*!;&L
M)=/-*A7%V8M8^R<VS2=;YIPZ#99GL**_?_KX*<@B,,Q^__436?%J&2F3SKUQ
M7!$7#H*(:_S1%+9;GIN-#8JK7V 20_"NL' PTEYI^#-PRKI#*B",2H%@>))I
MHVY[2[_OP\$]YHO(I;)LTIE4!<0VID[FF'NMT[VVS37FVYD;Z';ZP)PY,'?;
MI+O]7^=*NN'JJ^@_CNB?STCTP2RG6AI,]OR&&X %6_?V@P#D:=3)^R,-<2QR
MHE$%I*>B/U)QMYNW"S@\C))++B('[:AI)RVX483&1#KU?(1-,[I,P"E]Y"&\
M#)E[(4=M>W9'+0:7B]>S])F=I0BVH#%I6:.HBA"[RDX59UC51X'2,,U&/U(
M[E)?PR"XD;ZWDZP?B^:_ZKU*S_,ZCGC/&U,L#9% ,<ZUG)R&08HI)ECB/Q#D
M]U3AQ>S@"Y$Q$F*9;Y=^\ASZDQOD3Y6-AC^CC&H\\!KX6@4BN2)G##>>2/W<
M58B=<:9JA!M"DS[CD&.I!H9IKYGO 3G.)7>F&EW97I3B5!/Z3<-.B#W/OA=T
MP2"4)-Q5J/] ]S%_PJQ7%.L6"8I%ZW(.#DQS)^FJ=X83$6)/25_E]T;PELI
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MV4QN8WG5U*(C1G@/N])WC51#BE00OB(T@7#>P)")Z&CD"6Y1%/=2^(B'WFR
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MX*,<_EC?//\HA\:#*@]M3]4]_R3\;1I;Z/=O'X]5X<%Q<0X&;+-Q!'8(1?K
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MBKKVF\NE,);#F*XK,V\G*P5FHDK14K3EJ",IS%4F:^*$&%0A=PG8G@2#$!&
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MP6K70JYXHETS8:_-1F_66J8$ME;.IAEAY=1=:^5(\EX9FO?%/:W1$2"T*'O
MX1S094TIW2Z1NTSNKJ5TV[):MC,P *@:8:53XJ\60>;,T91K//?;BH,4TB++
MNSHX--']>,AW8*WTVAS&6XK;-,7]M@;%F9(#=*BDC'^W_U7[&G.#Z.0DM2[L
MS&V*$'Q92QJJG$N;#8?A*3-C:E2\!*V#( 9R(BV"[8 MMHH+#2FVV; G0X4'
M0T7)&(99X$W/+IC^;AF&H*+Y7CHP-1!Z,V/CDTV!:<5%3Y.)D1.F W;=EV]
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M='70=W#^[O)7<B)\?_?V!O[X?U!+ P04    " #;BS90^!W./Q ,  #)*@
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MM]_8VZ;&Z<HOZZ?8[=(J7^J)1K6P7@. Q)J=L$WO#$\OL&*/&KQ= 3'N\HJ
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M2.:D4KKLAC*.R;KC;LAJLKD4EF"84.9!NV5U)&[ 9:H+/(EX)V4P7&E%V*^
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MG;GS;QG+;*53I^S.\]W=;1J.GG6'H^'3/U&R<<42X6"<<TC&#I'&B:C17.E
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M6_O[?O>ZPS^H];^PY1_B_AM02P$"% ,4    " #;BS90YV1#U$4#  "8#
M$0              @ $     861A<"TR,#(P,#$R,2YX<V102P$"% ,4
M" #;BS90-@B*BOP*  #?AP  %0              @ %T P  861A<"TR,#(P
M,#$R,5]L86(N>&UL4$L! A0#%     @ VXLV4(<!'(U6!P  .ED  !4
M         ( !HPX  &%D87 M,C R,# Q,C%?<')E+GAM;%!+ 0(4 Q0    (
M -N+-E#,>PEF"1<   6'   1              "  2P6  !T;3(P-#$Y,RTS
M7SAK+FAT;5!+ 0(4 Q0    ( -N+-E!P/S^[N;P  ">+!  4
M  "  60M  !T;3(P-#$Y,V0S7V5X,2TQ+FAT;5!+ 0(4 Q0    ( -N+-E#-
M-[$=$1T  .^X   4              "  4_J  !T;3(P-#$Y,V0S7V5X-2TQ
M+FAT;5!+ 0(4 Q0    ( -N+-E#X'<X_$ P  ,DJ   5              "
M 9(' 0!T;3(P-#$Y,V0S7V5X.3DM,2YH=&U02P$"% ,4    " #;BS90_0+D
MUE$,  "/*P  %0              @ '5$P$ =&TR,#0Q.3-D,U]E>#DY+3(N
9:'1M4$L%!@     (  @ #@(  %D@ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>tm204193-3_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="adap-20200121.xsd" xlink:type="simple"/>
    <context id="From2020-01-20to2020-01-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001621227</identifier>
        </entity>
        <period>
            <startDate>2020-01-20</startDate>
            <endDate>2020-01-21</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2020-01-20to2020-01-21">0001621227</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2020-01-20to2020-01-21">false</dei:AmendmentFlag>
    <dei:EntityTaxIdentificationNumber contextRef="From2020-01-20to2020-01-21" id="xdx2ixbrl0014">00-0000000</dei:EntityTaxIdentificationNumber>
    <dei:DocumentType contextRef="From2020-01-20to2020-01-21">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2020-01-20to2020-01-21">2020-01-21</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2020-01-20to2020-01-21">ADAPTIMMUNE THERAPEUTICS PLC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2020-01-20to2020-01-21">X0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2020-01-20to2020-01-21">1-37368</dei:EntityFileNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2020-01-20to2020-01-21">60 Jubilee Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2020-01-20to2020-01-21">Milton Park</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2020-01-20to2020-01-21">Abingdon, Oxfordshire</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="From2020-01-20to2020-01-21">OX14 4RX</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="From2020-01-20to2020-01-21">GB</dei:EntityAddressCountry>
    <dei:CityAreaCode contextRef="From2020-01-20to2020-01-21">44</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2020-01-20to2020-01-21">1235 430000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2020-01-20to2020-01-21">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2020-01-20to2020-01-21">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2020-01-20to2020-01-21">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2020-01-20to2020-01-21">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2020-01-20to2020-01-21">American Depositary Shares, each representing 6 Ordinary Shares, par value &#xa3;0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2020-01-20to2020-01-21">ADAP</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2020-01-20to2020-01-21">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2020-01-20to2020-01-21">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.3.a.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>97</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm204193-3_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adaptimmune.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="tm204193-3_8k.htm">tm204193-3_8k.htm</File>
    <File>adap-20200121.xsd</File>
    <File>adap-20200121_lab.xml</File>
    <File>adap-20200121_pre.xml</File>
    <File>tm204193d3_ex1-1.htm</File>
    <File>tm204193d3_ex5-1.htm</File>
    <File>tm204193d3_ex99-1.htm</File>
    <File>tm204193d3_ex99-2.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tm204193-3_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "tm204193-3_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "adap-20200121_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "adap-20200121_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "adap-20200121.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 97,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "adap",
   "nsuri": "http://adaptimmune.com/20200121",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm204193-3_8k.htm",
      "contextRef": "From2020-01-20to2020-01-21",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://adaptimmune.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm204193-3_8k.htm",
      "contextRef": "From2020-01-20to2020-01-21",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The start date of the period covered in the document, in CCYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://adaptimmune.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r10": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r11": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r12": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r13": {
   "Name": "Forms 10-K, 20-F, 40-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d-1"
  },
  "r14": {
   "Name": "Forms 20-F, 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220 and 240",
   "Subsection": "f"
  },
  "r15": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6631164240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jan. 21, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan. 21,  2020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-37368<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ADAPTIMMUNE THERAPEUTICS PLC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001621227<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">00-0000000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">X0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">60 Jubilee Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Milton Park<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Abingdon, Oxfordshire<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">GB<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">OX14 4RX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">1235 430000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">American Depositary Shares, each representing 6 Ordinary Shares, par value &#163;0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ADAP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
